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Summary 
Mesenchymal stem cells (MSCs) are unspecialized cells with the capability to differentiate into various 
cell entities. They also secrete many biologically active factors with regenerative potential, making 
them a potentially suitable option for the treatment of chronic liver diseases. However, the chronically 
damaged liver is susceptible to the formation of hepatocellular carcinoma (HCC), whose potential 
interaction with therapeutically applied exogenous MSCs is unknown. In this context, the family of 
proteinase-activated receptors (PARs) deserves special attention, which occupies a promoting role in 
the progression of HCC, cirrhosis and cholangiocarcinoma through activation in different cell entities 
of the liver parenchyma. PARs are currently insufficiently characterized in MSCs. Hence, we 
hypothesized that PARs may also exert a biologically relevant role in MSCs, as well in the potential 
interaction with HCC initiation and progression. 
 
For assessing the role of the PAR family in MSCs, we employed primary human adipose tissue-derived 
MSCs (AT-MSCs). Our results indicated that PAR1 is the predominantly expressed PAR subtype in 
AT-MSCs, which exerted a strong increase in the intracellular free Ca2+ concentration upon stimulation 
with thrombin or the subtype-specific PAR1-activating peptide (PAR1-AP) TFLLRN-NH2. Activation of 
other PAR subtypes caused only a comparatively weak (PAR2) or no Ca2+ response (PAR4). Hence, we 
focused the additional characterization on PAR1. We initially verified its presence on the plasma 
membrane of AT-MSCs via the freeze-fracture replica immunolabeling technique. Furthermore, PAR1 
activation in AT-MSCs caused no effects on the cells’ proliferation rate, but significantly reduced their 
rate of migration across a collagen-coated porous polycarbonate membrane. Moreover, we identified 
a large number of biologically active proteins in conditioned media of AT-MSCs, among them 
interleukin (IL)-6, IL-8 and monocyte chemotactic protein 1 (MCP-1). PAR1 activation led to an elevated 
expression and secretion of these cytokines. The PAR1 antagonist Atopaxar, the Ca2+ chelator BAPTA-
AM and the protein kinase C (PKC) inhibitor BIM-1 reduced the secretion of IL-8 and IL-6, thus implying 
PAR1 specificity and dependency on the Ca2+/PKC pathway of the observed expression and secretion 
events. 
  
The MSCs’ secretory activity is likely to affect adjacent cells, e.g. aberrant hepatocytes in the HCC 
microenvironment, during potential cellular therapy. We assessed the biologic relevance of such cell 
interactions in vivo using a xenotransplantation mouse model. To this end, we subcutaneously co-
injected AT-MSCs and cells from the HCC cell line Hep3B into immunocompromised mice. Hep3B cells 
and AT-MSCs together caused a strong formation of tumors with typical histologic HCC characteristics, 
while Hep3B cells alone only occasionally caused tumors of significantly smaller size and AT-MSCs 
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alone caused no tumors. To track down the stem cells in the tumors, we employed green fluorescent 
protein (GFP)-labeled AT-MSCs in this tumor model, but we were not able to detect GFP in the formed 
Hep3B tumors. These results implied that the AT-MSC-derived promoting effect on the Hep3B cells’ 
growth affected initial tumor developmental stages.  
Furthermore, the shRNA-mediated stable knockdown of PAR1 in AT-MSCs had no significant impact on 
the observed tumor formation by the co-injection of Hep3B cells and AT-MSCs. Therefore, the 
potentially PAR1-triggered signaling in AT-MSCs did not seem to have an influence on the tumor 
formation in the employed mouse model. 
 
In conclusion, we could demonstrate that the PAR family is expressed in AT-MSCs and that PAR1 has a 
significant impact on the biology of these stem cells via affecting their migratory behavior and by 
regulating the expression and secretion of proteins with potentially tumor-promoting effects. 
Furthermore, the in vivo interaction of AT-MSCs with HCC cells seems to favor HCC tumor growth in 
the subcutaneous mouse model studied. However, additional experimental efforts will aid to verify 
and assess the importance of these in vivo findings for the MSC-based therapy of HCC.   
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Zusammenfassung 
Mesenchymale Stammzellen (MSCs) sind unspezialisierte Zellen mit der Fähigkeit, sich in verschiedene 
Zelltypen differenzieren zu können. Zudem sezernieren sie viele biologisch aktive Faktoren mit 
regenerativem Potential, welche sie potenziell für die Behandlung von Lebererkrankungen geeignet 
erscheinen lassen. Die chronisch geschädigte Leber ist jedoch anfällig für die Entwicklung des 
hepatozellulären Karzinoms (HCC). Welchen Einfluss eventuell applizierte exogene MSCs auf die 
Entwicklung eines HCC haben könnten, ist bislang ungeklärt. In diesem Zusammenhang könnte die 
Familie der Proteinase-aktivierbaren Rezeptoren (PARs) von besonderer Bedeutung sein. Frühere 
Arbeiten haben gezeigt, dass die Aktivierung von PARs in verschiedenen Zellarten des 
Leberparenchyms stattfindet und eine fördernde Rolle in der Entwicklung des HCCs, der Zirrhose und 
des Cholangiokarzinoms einnimmt. Daher vermuteten wir, dass die in MSCs unzureichend 
charakterisierten PARs ebenfalls eine Rolle sowohl für die biologischen Eigenschaften dieser Zellen 
selbst als auch für die potentielle Interaktion mit der HCC Initiation und Progression haben könnten. 
 
Diese Fragestellungen wurden an primären MSCs, die aus humanem Fettgewebe isoliert wurden 
(AT-MSCs), untersucht. Unsere Ergebnisse zur PAR-Expression in diesen Zellen deuteten darauf hin, 
dass PAR1 der prädominant exprimierte PAR-Subtyp in den AT-MSCs ist. Die PAR1-Aktivierung mit 
Thrombin oder dem subtyp-spezifischen PAR1-aktivierenden Peptid (PAR1-AP) TFLLRN-NH2 führte zu 
einer starken Erhöhung der intrazellulären freien Ca2+-Konzentration, während die Stimulation anderer 
PAR-Subtypen nur eine schwache (PAR2) oder keine (PAR4) Ca2+-Antwort erzeugten. Aus diesem Grund 
fokussierten wir unsere weiteren Untersuchungen auf PAR1 und verifizierten zunächst dessen 
Expression auf der Plasmamembran mittels Elektronenmikroskopie von PAR1-immunmarkierten 
Gefrierbruch-Replikas von AT-MSCs. Die PAR1-Aktivierung in AT-MSCs hatte keinen Einfluss auf die 
Proliferationsrate der Zellen, führte jedoch zu einer signifikant reduzierten Migration der AT-MSCs 
durch eine Kollagen-beschichtete poröse Polycarbonat-Membran. Zudem identifizierten wir eine 
Vielzahl an biologisch aktiven Proteinen im Kulturüberstand der AT-MSCs, darunter Interleukin (IL)-6, 
IL-8 und Monozyten-chemotaktisches Protein 1 (MCP-1). Die PAR1-Aktivierung führte zu einer 
erhöhten Expression und Sekretion dieser Zytokine. Der Einsatz des PAR1-Antagonisten Atopaxar, des 
Ca2+-Chelators BAPTA-AM und des Protein Kinase C (PKC)-Inhibitors BIM-1 reduzierte die Sekretion von 
IL-8 und IL-6, was eine PAR1-Spezifität und Abhängigkeit vom Ca2+/PKC-Signalweg für die beobachteten 
Expressions- und Sekretionsereignisse impliziert. 
Die sekretorische Aktivität der MSCs könnte, im Zuge der potentiellen zellulären Therapie von 
Lebererkrankungen, Auswirkungen auf benachbarte Zellen, wie z.B. entartete Hepatozyten in der HCC-
Mikroumgebung, haben. Die Möglichkeit einer solchen Zellinteraktion prüften wir in einem in vivo 
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Xenotransplantations-Mausmodell. AT-MSCs und Zellen der HCC-Zelllinie Hep3B wurden dazu 
gemeinsam subkutan in immundefiziente Mäuse injiziert. Die Hep3B-Zellen und AT-MSCs zusammen 
führten zu einer starken Tumorbildung mit typischen histologischen HCC-Charakteristiken. Hep3B-
Zellen alleine bildeten nur gelegentlich Tumore mit deutlich geringerer Größe. Die alleinige Injektion 
von AT-MSCs bewirkte keine Tumorbildung. Um die Stammzellen in den Tumoren aufzuspüren, setzten 
wir grün fluoreszierendes Protein (GFP)-markierte AT-MSCs in diesem Tumormodel ein, jedoch 
konnten wir kein GFP in den gebildeten Hep3B-Tumoren detektieren. Dieser Befund impliziert, dass 
der stimulierende Effekt der AT-MSCs auf das Wachstum der Hep3B-Zellen während der initialen 
Tumorentwicklungsstadien auftrat. 
Weiterhin hatte der stabile Knockdown von PAR1 mittels shRNA in AT-MSCs keinen signifikanten Effekt 
auf die beobachtete Tumorbildung bei Koinjektion von Hep3B-Zellen und AT-MSCs. Daher schienen 
potenziell durch PAR1-ausgelöste Signalwege in AT-MSCs keinen Einfluss auf die Tumorformation in 
dem angewendeten Mausmodel gehabt zu haben.  
 
Zusammenfassend konnten wir zeigen, dass die PAR-Familie in AT-MSCs exprimiert wird und dass PAR1 
von Bedeutung für die Biologie dieser Stammzellen ist. PAR1 hat einen Einfluss auf das 
Migrationsverhalten und auf die Regulation der Expression und Sekretion von potentiell 
tumorfördernden Proteinen. Weiterhin scheint in dem untersuchten Mausmodel die in vivo 
Interaktion von AT-MSCs und HCC-Zellen das HCC-Tumorwachstum zu fördern. Um die Wichtigkeit 
dieser in vivo Daten für die Behandlung des HCC mit MSCs beurteilen zu können, werden jedoch 
weitere experimentelle Bemühungen als Verifikation benötigt.  
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1 Introduction 
Mesenchymal stem cells (MSCs) are emerging players in clinical research for the treatment and 
curation of tissue diseases, which fail to heal through natural mechanisms. Especially liver diseases can 
cause chronic damage and inflammation to the liver parenchyma, which potentially progress to 
cirrhosis and/or hepatocellular carcinoma (HCC). While conventional treatments of late stage liver 
diseases battle with relapse of HCC, the treatments with MSCs have recently shown promising curative 
effects. Notably, tremendous beneficial effects were observed with respect to the curation of liver 
failure and cirrhosis in vivo in animal models. However, the impact of MSCs on HCC and tumorous 
tissue in general remains controversial. HCC is one of the prevalent carcinomas and leading tumor-
related causes of death worldwide. Several malignant features of HCC cells have been shown to be 
promoted by the guanine nucleotide-binding protein (G protein)-coupled receptor family of 
proteinase-activated receptors (PARs). PARs have also been linked to the promotion of liver fibrosis 
and cholangiocarcinoma through their activation in hepatic stellate cells or cholangiocytes of the liver 
parenchyma. Therefore, PARs might promote liver diseases through the activation of other cell entities 
as well. The external addition of large quantities of MSCs as means of cell-based therapy would add 
another cell population into the liver, with an insufficiently assessed biological relevance of the PAR 
family and impact on HCC. (Adams et al. 2011; Farazi & DePinho 2006; Hass & Otte 2012; Nakanuma 
et al. 2010). 
1.1 Hepatocellular carcinoma  
Hepatocellular carcinoma (HCC) is the major primary carcinoma event in liver tissue and comprises up 
to 90 % of all cases of primary liver cancer. Although precise numbers about the worldwide 
epidemiology of HCC are rather inconsistent between the references, it is clear that HCC ranks as the 
fifth or sixth most common cancer in the world. Especially Southeast Asia and sub-Saharan countries 
are affected, and HCC is the second or third most cancer-related cause of death. HCC especially occurs 
in patients above 40 years, with incidence peaking at the age of 70. Moreover, men are affected 2.4 
times more often than women. (El-Serag 2011; European Association for the Study of the Liver & 
European Organisation for Research and Treatment of Cancer 2012; Farazi & DePinho 2006). 
1.1.1 Causes for HCC 
HCC has various underlying causes, which contribute to liver and hepatocyte aberrations. The liver is a 
major site for the storage of nutrients, a station for cleansing the body from harmful substances, and 
a general place of metabolite turnover and production. Hence, it is exposed to a variety of external 
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and internal influences that may cause sudden or slow changes in tissue integrity. Major influences for 
the onset of liver diseases include the following: 
(1) Viral infections: Hepatitis B and C virus (HBV, HCV), Epstein-Barr virus, cytomegalovirus and 
adenovirus. 30-50 % of HBV-caused deaths are due to HCC, 2.5 % of HCV patients develop HCC. 
(Adams & Hubscher 2006; Farazi & DePinho 2006; Rehermann & Nascimbeni 2005). 
(2) Steatohepatitis and alcohol: Excessive accumulation of cholesterols and triglycerides as a 
result of the metabolic syndrome (non-alcoholic steatohepatitis) or prolonged heavy alcohol 
intake (alcoholic liver disease). Additionally, the breakdown of alcohol in the liver leads to 
shortages of the oxygen and energy supply, and eventually damage of mitochondria and 
hepatocytes. (Ahmed 2015; Cunningham & Van Horn 2003; O’Shea, Dasarathy, & McCullough 
2009). 
(3) Obstructed bile and blood flow. 
(4) Inherited diseases: Haemochromatosis and Wilson’s disease express metabolic changes 
leading to a toxic accumulation of excess hepatic iron or copper, respectively. (Ulvik 2015; Wu 
et al. 2015). 
(5) Chemical compounds: drugs, food additives, herbal compounds, aflatoxin B1-contaminated 
food or high dosages of vitamin A can cause liver intoxication and mutagenic events. (Chen et 
al. 2015a; Lopez & Hendrickson 2014). 
(6) Cirrhosis: Scarring of liver tissue as an advanced stage of liver diseases, characterized by 
massive deposition of extracellular matrix (fibrosis) by activated hepatic stellate cells into the 
liver lobules, which leads to hardening and loss of function of the liver. (Tsochatzis, Bosch, & 
Burroughs 2014). 
 
While HBV infections make up the major risk factors for liver diseases in countries with limited access 
to socialized medicine, developed countries largely face problems of drug and alcohol abuse and 
diseases linked to obesity. All causes may potentially lead to more severe liver disease stages with 
chronic inflammation, cirrhosis and HCC. (El-Serag 2011; Farazi & DePinho 2006). 
1.1.2 Characteristics of HCC 
The variety of HCC risk factors creates the basis for a phenotypic and large molecular heterogeneity 
among cases of HCC. Genomic analyses revealed that a set of 48 genes was frequently mutated in 
advanced stage HCCs. These genomic alterations are acquired through the chronic pro-inflammatory 
state in the diseased liver, accompanied by a constant demise of hepatocytes, necrosis, and 
hyperproliferation of adjacent cells. It was estimated that in a liver parenchyma with chronic hepatitis 
1-3 % of hepatocytes die per day, in contrast to 0.01 % in healthy liver tissue. The liver is capable of 
growing to its full mass within five to ten days when two third of it is removed. However, the 
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permanent loss of hepatocytes during chronic inflammation may overcome the liver’s self-
regeneration potential, and may lead to genomic aberrations and eventually organ failure.  
The high cellular turnover in the diseased liver favors the selection of pro-oncogenic genomic lesions 
in hepatocytes or progenitor cells. These genomic alterations can occur during replication errors, 
oxidative stress, and integration of the HBV genome or DNA intercalation of mutagenic aflatoxin B1. 
Major common events during HCC formation include the activation of telomerase activity, promotion 
of Wingless Int-1 (Wnt), mitogen-activated protein kinase (MAPK) and Janus kinase-signal transducer 
and activator of transcription (JAK-STAT) pathways, alterations of cell-cycle genes and inactivation of 
the tumor suppressor p53. (Aravalli 2010; Farazi & DePinho 2006; Marquardt, Andersen, & 
Thorgeirsson 2015; Taub 2004). 
The progression of HCC is promoted by a large variety of autocrine and paracrine stimuli. Recent 
reports frequently described the involvement of receptors like epidermal growth factor receptor 
(EGFR), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor 
(VEGFR), hepatocyte growth factor (HGF) receptor (Met) and PARs in the promotion of HCC 
proliferation, invasion and migration. Especially PARs seem to play a central role in liver diseases since 
their implications in fibrosis, HCC and cancer were demonstrated by our and other research groups 
previously (for detailed information refer to paragraph 1.3.3, page 14). Cytokines like VEGF, HGF, 
monocyte chemotactic protein 1 (MCP-1), Interleukin (IL) 6 and IL-8 were also described in various 
publications to promote HCC through autocrine and paracrine mechanisms. The PAR family, as well as 
IL-6, IL-8 and MCP-1, were integral elements of this study and will be introduced in detail in paragraph 
1.3 (page 10) and 1.2.3 (page 7), respectively. (Farazi & DePinho 2006; Marquardt, Andersen, & 
Thorgeirsson 2015). 
The interplay of these molecular events in the liver causes the formation of a highly vascularized HCC, 
which forms single solid tumors with little or no tumor stroma during early stages. Advanced and 
terminal stages are characterized by an aggressive tumor state with multifocal lesions, vascular 
invasion and the formation of metastases. (European Association for the Study of the Liver & European 
Organisation for Research and Treatment of Cancer 2012; Schlachterman et al. 2015). 
1.1.3 Diagnosis and treatment of HCC 
The diagnosis of HCC is usually achieved through regular surveillance of high-risk patient groups with 
underlying pronounced hepatitis, non-alcoholic steatohepatitis, alcoholic liver disease or cirrhosis, or 
until HCC reveals itself. However, HCC may often not be perceived in early stages since it bears no 
pathognomonic symptoms and is prone to false diagnosis. Diagnosis tools include ultra-sonographic, 
computed tomographic and magnetic resonance imaging. In addition, percutaneous liver biopsies can 
be gathered to verify the diagnosis. Serum markers like alpha-fetoprotein (AFP) are upregulated in HCC 
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patients, but lack high specificity and may only serve as a hint for diagnosis. (Attwa & El-Etreby 2015; 
Schlachterman et al. 2015). 
 
About one-third of HCC patients are diagnosed in early stages and face good prognosis. Early stages 
comprise single tumor sites with up to three nodules and are eligible for resection, ablation with high 
frequencies or ethanol, or liver transplantation. The choice of treatment highly depends on the 
location of the lesion, cirrhotic background, and organ donor availability. Another 20 % of patients are 
diagnosed in intermediate stages with multiple lesions and are treated with transarterial 
chemoembolization (TACE), in which HCC tissue is flushed with cytotoxic agents like doxorubicin. HCC 
tissue is mainly supplied by hepatic arteries, which allows embolization of affected areas while the 
main supply of the remaining tissue is still achieved via the portal vein. The remaining 50 % of patients 
face a poor prognosis and are diagnosed with advanced stages of HCC including metastasis. These 
patients are treated with TACE, radioembolization with Yttrium90 loaded beads, radiation therapy or 
molecular approaches with specific monoclonal antibodies to block VEGFR, PDGFR, angiopoietin 
receptor 2 (Tie2) and others that drive vascularization of HCC. The multi-kinase inhibitor sorafenib is 
currently the only chemotherapeutic drug to increase the survival rate of advanced stage HCC patients. 
(Attwa & El-Etreby 2015; Chan & Yeo 2012; European Association for the Study of the Liver & European 
Organisation for Research and Treatment of Cancer 2012; Schlachterman et al. 2015; Xiu et al. 2015). 
 
Despite the wide range of treatment techniques, the median overall survival rate amounts to five years 
for early stage HCC patients, less than two years for advanced stage HCC patients and few months for 
terminal stage HCC patients. Even after transplantation, resection or ablation therapy, the supposed 
healthy tissue is still able to bring back the disease yet again and with stronger impact. The responsible 
mechanisms are uncertain. Metastasis below thresholds of detection sensitivity or residing cancer 
stem cells may cause recurrence and formation of new lesions, and mediate resistance to 
chemotherapy.  
In recent years, medical research explored novel treatment techniques for the curation of liver 
diseases, with a focus on the treatment with stem cells and derived techniques. The opportunities and 
risks of the employment of this cell-based approach will be elucidated in paragraph 1.2. (Aravalli 2010; 
Bayo et al. 2013; European Association for the Study of the Liver & European Organisation for Research 
and Treatment of Cancer 2012; Romano et al. 2015; Schlachterman et al. 2015).  
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1.2 Mesenchymal stem cells in the HCC microenvironment  
Stem cells are unspecialized cells, which fulfill essential roles in embryogenesis, tissue homeostasis, 
repair and regeneration. In recent years, particularly mesenchymal stem cells have become an 
attractive target for medical research to transfer their unique properties on the treatment and curation 
of chronic wounds and fibrosis, as in the case of liver diseases. (Bayo et al. 2013; Hass & Otte 2012; 
Liang et al. 2014). 
1.2.1 Stem cell entities and common characteristics 
The term stem cells comprises a variety of fibroblast-like shaped cell entities of different origins, which 
possess the feature of ’stemness’. It describes the capability to undergo an indefinite or vast amount 
of cell divisions and yet keeping an undifferentiated state by continuous self-renewal, and the ability 
to specialize into a variety of tissues. 
Today, stem cells of many different origins are known and applied in medical research and therapy. 
Embryonal stem cells (ESCs) form the inner mass of the blastocyst during embryogenesis. They are 
pluripotent and thus able to differentiate into any cell type of the three germ layers. In contrast, adult 
stem cells reside in small quantities in stem cell niches inside tissues or organs in order to maintain 
tissue homeostasis, regulation of inflammation, and wound repair. Adult stem cells are not pluripotent, 
but still multipotent, which means they are able to differentiate into a limited range of different tissues 
like connective tissue (mesenchymal stem cells, MSCs), hematopoietic cells (hematopoietic stem cells), 
neural cells (neural stem cells), skin and hair (epidermal stem cells), or epithelial tissues of the 
gastrointestinal tract (epithelial stem cells). (Martello & Smith 2014; National Institutes of Health 2015; 
Zipori 2004). 
MSCs were initially isolated from bone marrow and termed colony forming units-fibroblasts in 1976. 
Apart from the bone marrow niche, researchers were able to isolate MSCs from perivascular niches in 
the periphery, e.g. adipose tissue, placenta, umbilical cord, muscles, lungs and others. The presence of 
a putative human liver stem cell is still under discussion, but stem- or progenitor-like cells were found 
in liver parenchyma of several other species. (Aravalli 2010; Bayo et al. 2013; Christ & Pelz 2013; 
Friedenstein, Gorskaja, & Kulagina 1976; Ma et al. 2014).  
 
Finally, apart from naturally occurring stem cells, researchers were able to show that many 
differentiated adult cells, which are usually non-proliferative, could be reprogrammed to regain 
stemness characteristics. These so-called induced pluripotent stem cells (iPSC) are generated by the 
insertion and overexpression of a combination of few specific genes that can cause adult cells to regain 
pluripotency and proliferative capability. (Aravalli 2010; Malik & Rao 2013). 
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As pointed out in paragraph 1.1.2, the reprogramming of adult cells may also occur naturally through 
the selective pressure of a diseased tissue microenvironment. Cells that accumulate inheritable genetic 
aberrations may undergo malignant transformation and form so-called cancer stem cells (CSCs). They 
have been described for several types of cancer and are currently being considered as a source of 
tumor initiation, recurrence and metastasis. (Aravalli 2010; Garnier et al. 2010; Kreso & Dick 2014). 
ESCs and iPSCs may offer unlimited possibilities and elaborate tools to support clinical therapy of many 
diseases, but they bear burdens of ethical issues, a high risk to form stem cell tumors (teratomas) and 
issues of xenotransplant rejection when applied in cell-based therapies. However, MSCs might fulfill 
the requirements for safe employment in such therapies since they can be relatively easily acquired 
from the human body without major procedures and show fewer problems with histocompatibility. 
While bone marrow-derived MSCs (BM-MSCs) still play a major role in research to unveil signaling and 
cellular actions on in vitro and in vivo models, adipose tissue-derived MSCs (AT-MSCs) may be an, even 
more, valuable resource since adipose tissue harbors more stem cells than bone marrow and is easily 
accessible. One gram of adipose tissue harbors around 5,000 to 200,000 MSCs, which is approx. 1,000- 
to 10,000-fold more than an equal amount of bone marrow tissue. Hence, the employment of MSCs 
from patient’s adipose tissues, which can be propagated ex vivo and injected back into the patient’s 
diseased tissues and organs, is a valuable tool for autologous MSC-guided therapies. (Baer & Geiger 
2012; Ma et al. 2014). 
 
The variety of sources for MSCs and the lack of a unique MSC-marker or surface protein gave rise to a 
panel of minimal criteria for defining MSCs in vitro, set up by the International Society for Cellular 
Therapy. In general, MSCs must (1) show plastic adherence in vitro, (2) express a set of stem cell surface 
markers and lack the expression of hematopoietic markers, and (3) show the ability to differentiate 
into osteoblasts, adipocytes and chondroblasts under standard conditions. These criteria clearly 
discriminate BM-MSCs from hematopoietic stem cells, which are both present in the bone marrow. 
Functionally, MSCs are also able to differentiate into various specialized cell entities including 
hepatocytes, which makes them an attractive tool for cell-based therapy of liver diseases. (Dominici et 
al. 2006; Stock et al. 2010). 
1.2.2 MSCs as therapeutic approach for the treatment of HCC 
The employment of MSCs in therapeutic approaches to cure various diseases is based on the findings 
that they can support survival, regeneration and repopulation of damaged tissue through:  
(1) mitochondrial transfer to or cell fusion with damaged cells. 
(2) the release of microvesicles and exosomes filled with RNA, miRNA and proteins; and the 
secretion of biologically active proteins, which will be introduced in closer detail in paragraph 
1.2.3. 
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(3) transdifferentiation into various cell entities of the ectodermal, mesodermal and endodermal 
lineage. (Liang et al. 2014). 
 
Therefore, MSCs open up many possibilities for the treatment of liver diseases. Applications include 
the transplantation of (genetically engineered) MSCs, MSC-derived differentiated target tissue or 
progenitor cells, or the injection of MSC-conditioned media at the sites of interest in order to cure the 
damaged tissue. 
Reports about the systemic administration of labeled MSCs into mice revealed that the cells 
accumulated within lungs and liver after injection, but relocated to locations of injury, inflammation 
and cancer within the following one to three days, a process called ‘homing.' Though the engraftment 
of MSCs into diseased tissue was quantified to have an efficiency of less than 0.01 %, the local injection 
into the tissue of interest had 3.5 % efficiency. These numbers may seem small, but even the 
administration of conditioned MSC media caused protective effects on liver tissue in a radiation model 
in rats. (Chen et al. 2015b; Reagan & Kaplan 2011; Rustad & Gurtner 2012). 
 
The transplantation of MSCs or MSC-derived hepatic progenitor cells into the liver was successfully 
applied in a model of chemically induced acute liver failure in mice. Kuo et al. could demonstrate that 
intraspleenically or intravenously injected MSCs were able to engraft into the host liver and help liver 
survival by regeneration of the affected damaged tissue, probably due to anti-oxidative, anti-apoptotic 
and paracrine properties of the injected cells. Furthermore, they showed that MSCs were more 
effective than the MSC-derived hepatic progenitor cells.  
However, studies focusing on the interaction of MSCs and tumor cells indicated that MSCs could 
promote tumorigenic microenvironments as well. Studeny et al. and Niess et al. demonstrated that 
systemically injected MSCs were able to home to melanoma or HCC tumor models and contribute to 
tumor formation in vivo in mouse experiments. In a second step, they took advantage of the tumor-
specific homing and employed genetically engineered MSCs. Despite the demonstrated tumor-
promotion by MSCs, the coupling of MSCs with the expression of anti-proliferative proteins and drugs 
at the sites of tumor-incorporation resulted in an overall reduction of the tumor sizes. (Bayo et al. 
2013; Kuo et al. 2008; Niess et al. 2011; Studeny et al. 2002).  
1.2.3 Paracrine activity of MSCs and the potential impact on HCC 
Current reviews pointed out that the paracrine activity of MSCs might be the major factor in causing 
the regenerative impact of MSCs on diseased tissue in vivo. MSCs are known to secrete a cocktail of 
immunoregulatory, anti-apoptotic, pro-angiogenic and growth-promoting factors. Although 
comprehensive data on potential differences among populations of MSCs from different origins are 
currently lacking, BM- and AT-MSCs share approx. 91 % homology concerning transcriptome data 
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conducted by Jansen et al. This similarity seems to translate into the factors that are being secreted by 
MSCs since a study from Hsiao et al. found a similar secretion of several biologically active factors for 
both BM- and AT-MSCs. Some of those factors included VEGF, IL-6, IL-8, HGF and MCP-1. They are 
prominent players in physiological and pathological conditions and may present pivotal targets for the 
assessment of the experimental interplay of MSCs and HCC in order to understand MSCs impact for 
cell-based therapies. Their features and relevance for the HCC are briefly outlined below. (Bayo et al. 
2013; Hsiao et al. 2012; Jansen et al. 2009; Liang et al. 2014; Yagi & Kitagawa 2013).  
 
VEGF 
Vascular endothelial growth factor (VEGF) is a major stimulus for endothelial cells to cause 
physiological and pathological angiogenesis and an increase in vascular permeability. Moreover, it was 
found to play crucial roles in the onset and development of cancer in general. VEGF is described to 
promote growth and survival of cancer cells and to cause epithelial to mesenchymal transition, i.e. 
promotion of dedifferentiation, migration and invasion. 
VEGF has been shown to be secreted by HCC cells at elevated levels compared to other chronic liver 
diseases. Excessive amounts of VEGF in the liver may promote the connection of HCC to the highly 
oxygenated blood supply from hepatic arteries and cause cirrhosis-promoting sinusoidal 
capillarization. (Goel & Mercurio 2013; Iavarone et al. 2007; Yang & Poon 2008).    
 
HGF 
Hepatocyte growth factor (HGF) is important for epithelial, neuronal and organ development, latter 
especially for liver and placenta, and targets multiple cell types throughout the organism. HGF is 
expressed by mesenchymal cells in general and is a chemoattractant for MSCs. 
The impact of HGF on the liver comprises mitogenic, motogenic and survival stimuli on hepatocytes, 
by potently enhancing chemoattraction and migration, evasion of apoptosis/necrosis, thus reducing 
inflammation, induction of apoptosis of fibrosis-causing myofibroblasts and breakdown of extracellular 
matrix. (Forte et al. 2006; Nakamura et al. 2011; Neuss et al. 2004). 
 
MCP-1 
Monocyte chemotactic protein 1 (MCP-1) is a chemoattractant for monocytes, memory T cells and 
natural killer cells. It is expressed by endothelial cells, fibroblasts, smooth muscle cells, epithelial cells 
and others, but mainly by monocytes/macrophages. MCP-1 is also secreted by cancer cells and tumor-
associated macrophages and was found to correlate with the progression of breast carcinoma and 
poor prognosis. Patients with HCC also show significantly upregulated serum amounts of MCP-1 
compared to chronic HBV patients without HCC, thus making MCP-1 an additional serum marker for 
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improved diagnosis. Moreover, myofibroblast-derived MCP-1 was found to increase migration and 
invasion of HCC cells. (Dagouassat et al. 2010; Deshmane et al. 2009; Wang et al. 2013). 
 
IL-8 
Interleukin 8 (IL-8) is a chemoattractant and activator for neutrophil granulocytes. Apart from 
neutrophils, its receptors are especially expressed in endothelial cells and macrophages. IL-8-activated 
macrophages secrete growth factors. The activation of endothelial cells favors chemotaxis, survival, 
and proliferation in order to promote angiogenesis and wound healing. However, cancer cells were 
also found to express IL-8 and its receptors, thus additionally stimulating the tumor microenvironment 
in an autocrine and paracrine manner. Patients with HCC were found to possess significantly increased 
serum levels of IL-8, 17.6 pg/ml versus 1 pg/ml in healthy patients, which correlated with tumor size. 
Also, IL-8 stimulates the proliferation and survival of cancer cells. Chemotherapy was found to increase 
the secretion of IL-8 from cancer cells. (Ren et al. 2003; Waugh & Wilson 2008). 
 
IL-6 
Interleukin 6 (IL-6) mediates and contributes to a variety of different biologic actions, including B cell 
differentiation and T cell proliferation, stimulation of lymphocyte trafficking, elevation of lipolysis, and 
enhanced secretion of an iron metabolism-limiting compound by the liver. Moreover, it stimulates the 
secretion of acute phase proteins, fibrinogen and other factors by the liver and contributes to liver 
regeneration. Furthermore, it stimulates the secretion of IL-8, MCP-1 and other chemokines from 
various cell entities and is involved in angiogenesis via activation of VEGF. 
These multi-faceted effects might explain why IL-6 was found to play major roles in autoimmune and 
inflammatory diseases. Like many other factors, its elevated levels in patient sera were found to 
correlate with cirrhosis, cancer development and especially metastasis. Increased IL-6 expression rates 
were demonstrated in HCC cells compared to cirrhotic liver cells, which led to an autocrine stimulation 
of survival, proliferation and metastasis. Increased levels of IL-6 were also correlated with the 
progression from chronic hepatitis to HCC. On molecular level, HCC was demonstrated to show 
hypermethylation of IL-6 signaling suppressors SOCS (suppressors of cytokine signaling), making IL-6 a 
key player in the progression of HCC. Furthermore, elevated IL-6 serum levels were linked to obesity 
and a higher risk of developing HCC, which might explain the rise of HCC from steatohepatitis (see 
paragraph 1.1.1). Moreover, men are more frequently affected by HCC than women, which is thought 
to be due to the inhibitory effect of estrogens on IL-6-producing Kupffer cells, which are macrophages 
of the liver that reside in the sinusoids of the liver parenchyma. (Johnson et al. 2012; Mihara et al. 
2012). 
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1.3 Proteinase-activated receptors in the HCC microenvironment 
As pointed out in paragraph 1.1 and 1.2.3, the development of liver diseases, and HCC in particular, is 
a complex phenomenon with multiple involved causes, cells, biologically active proteins and signaling 
pathways. The proteinase-activated receptor (PAR) family, however, seems to be involved in the 
mediation of key mechanisms of liver diseases in general, since it has been demonstrated to contribute 
to the progression of cholangiocarcinoma, cirrhosis and especially HCC (refer to paragraph 1.3.3, page 
14). 
1.3.1 PAR family 
PARs are G protein-coupled receptors (GPCR), which share the common feature of seven 
transmembrane α-helices that are linked by extra- and intracellular loops, and the feature of 
transmitting extracellular signals onto intracellular-coupling G proteins. The PAR family comprises four 
members named in order of discovery, PAR1-4. The unique identity of PARs lies in their mode of 
activation. PARs comprise an extracellular N-terminal peptide chain that is prone to cleavage by 
proteinases from the serine and metalloproteinase families. They cleave at distinct positions of the N-
terminal peptide chain and cause the formation of a new N-terminus, which in turn serves as a 
‘tethered ligand’ and activates the receptor through binding at its second extracellular loop. 
Artificially generated peptide sequences, which have been raised according to the respective tethered 
ligand sequences of a specific PAR subtype, were found to activate PARs as well, with similar cellular 
responses as their corresponding proteinases. (Macfarlane et al. 2001; Ramachandran et al. 2012; Soh 
et al. 2010; Zhao, Metcalf, & Bunnett 2014). 
 
Proteinase- and activating peptide-guided receptor activation lead to binding and activation of 
heterotrimeric G proteins (subunits Gα, β, γ), which couple to the PAR’s intracellular situated C-
terminus. The activated receptor promotes the exchange of guanosine diphosphate (GDP) to 
guanosine triphosphate (GTP) in the active center of the Gα subunit, thus activating the G protein to 
trigger further distinct signaling cascades. PARs couple to Gαq, Gαi and Gα12/13, which are more or less 
frequently activated depending on the activating proteinase or activating peptide. Other directly 
coupling effectors include β-arrestin 1 and 2, which serve as another platform for the activation of 
downstream signaling. (DeFea et al. 2000; Gieseler et al. 2013; Lin & Trejo 2013; Ramachandran & 
Hollenberg 2008; Ramachandran et al. 2012; Soh et al. 2010; Zhao, Metcalf, & Bunnett 2014). 
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The major signaling cascades being activated by PARs comprise:  
(1) Gα12/13 → RhoGEFs → RhoA 
(2) Gαq → PLC-β → IP3/DAG → Ca2+, PKC, MAPKs, RTKs 
(3) Gαi → MAPK, inhibition of adenylyl cyclase 
(4) β-arrestins → ERK1/2, Rac1 
(5) Gβγ → PI3K, Rac1, GRKs, K+ channels, PLC-β, Src 
DAG - diacylglycerol; ERK1/2 - extracellular-signal regulated kinase 1/2; GRK - G protein-coupled receptor kinase; IP3 - inositol 
triphosphate; MAPK - mitogen-activated protein kinase; PI3K - phosphatidylinositide 3-kinase; PKC - protein kinase C; PLC-β - 
phosphoinositide phospholipase C β; Rac1 - Ras-related C3 botulinum toxin substrate 1; RhoA - Ras homolog gene family member A; 
RhoGEF - Ras homolog gene family member guanine nucleotide exchange factor; RTK - receptor tyrosine kinase; Src - sarcoma, proto-
oncogene tyrosine-protein kinase Src 
The cross-activation of receptor tyrosine kinases like EGFR, Met, VEGFR and PDGFR may cause further 
activation of MAPKs, PI3K, PLC-β and JAK-STAT signaling pathways. (Gieseler et al. 2013; Ramachandran 
& Hollenberg 2008; Regad 2015; Soh et al. 2010; Zhao, Metcalf, & Bunnett 2014). 
 
PAR knockout studies have revealed insights into their biological functions. Genetic inactivation of the 
PAR1 gene in mice caused mortality at embryonic day nine; however, half of the knockout mice seemed 
to develop normally, but with altered response to vascular injuries. PAR2 and PAR3 knockout mice 
developed normally without overt phenotypes, whereas PAR4 knockout mice had an impaired platelet 
function. (Hamilton, Cornelissen, & Coughlin 2004; O’Brien et al. 2000). 
A lack of strong phenotypes for PAR2-4 knockouts is likely related to a considerable functional 
redundancy of PARs as they are often expressed simultaneously. In general, the PAR family members 
are seen as sensors of wounds and contribute to the inflammation and healing processes during the 
different phases. Detailed analyses have revealed that they play roles in platelet aggregation and 
secretion (PAR1, 3, 4), vasoregulation (PAR1-4), inflammation, gastrointestinal tract, nociception 
(hyperalgesia, PAR2; analgesia, PAR1 + 4) and the central nervous system (PAR2). With respect to their 
involvement in diseases, the contribution to arthritis (PAR2) and tumor progression of various cancer 
entities (PAR1, 2) need to be mentioned. In addition to tissue distribution, the subcellular locations like 
lipid rafts or caveolae, availability of interacting proteinases, receptor homo/heterodimerization and 
cross-activation of other receptor entities like receptor tyrosine kinases were found to be relevant for 
PAR signal transduction. (Adams et al. 2011; Ramachandran & Hollenberg 2008; Ramachandran et al. 
2012; Zhao, Metcalf, & Bunnett 2014). 
 
The attenuation of PAR signaling is of general medical interest, e.g. to limit activation of platelets and 
hence the formation of blots clots, which can cause thromboembolism after effects like ischemic stroke 
or myocardial infarction. However, the blood coagulation is of systemic importance, and blocking core 
aspects of it requires well-balanced and -established antagonists. In general, PAR signaling may be 
1 Introduction 
12 
limited by blocking PAR-activating proteinases, proteinase cleavage sites of PARs, or the intracellular 
C-terminus to prevent binding of effectors. Moreover, antagonists that interact with the receptor at 
the second extracellular loop provide promising features. (Ramachandran et al. 2012). 
1.3.2 PAR1 – the prototypical PAR  
PAR1 was discovered in 1991 by the Coughlin group and has become the prototypical subtype of the 
PAR family since then. However, it differs in several features from PAR2-4, which will be briefly outlined 
along the following characterization of PAR1. (Vu et al. 1991; Zhao, Metcalf, & Bunnett 2014). 
 
PAR1, 3, 4 are activated with the highest efficacy by thrombin, and PAR2 by trypsin. Though thrombin is 
not able to cleave PAR2, trypsin can cleave and activate PAR1 and PAR3 with low efficiency, and PAR4 
with approximately similar potential as thrombin. Thrombin possesses an anion-binding exosite that 
enables transient binding to the negatively 
charged region of the PAR1 N-terminus (amino 
acids D51-F56), which leads to conformational 
changes of thrombin and greatly enhances its 
ability to cleave at PAR1’s R41/S42 of about 25-
fold. PAR3 offers a shorter thrombin-binding 
region as PAR1, but with similar dose-
responses to thrombin as PAR1. PAR4 offers no 
such binding site for thrombin, thus causing 
the requirement of higher thrombin 
concentrations for PAR4 activation. (Coughlin & 
Camerer 2003; Macfarlane et al. 2001; Zhao, 
Metcalf, & Bunnett 2014). 
 
The activation via the newly formed N-
terminus can be mimicked by artificial 
peptides. These selective peptide agonists 
activate the receptor without cleavage. As 
illustrated in Figure 1-1, the subtype-specific 
PAR1 activating peptide TFLLRN-NH2 is based 
on the receptor’s tethered ligand sequence SFLLRN. In general, slight modifications of the peptide’s 
amino acid sequence or the addition of chemical moieties may improve the efficacy. (Macfarlane et al. 
2001; Zhao, Metcalf, & Bunnett 2014). 
 
 
Figure 1-1: Basic concept of PAR1 signaling and research tools 
Serine proteinases like thrombin are able to cleave the N-terminal PAR1 
peptide chain and thereby revealing a newly formed tethered ligand 
that activates the receptor. Artificial subtype-specific agonist peptides 
mimic this tethered ligand and trigger characteristic signaling of 
respective proteinases. Atopaxar is an antagonist that blocks PAR1 
activation.  
A major common PAR-activated pathway is the Gαq mediated 
activation of phospholipase C β (PLC-β), thus leading to generation of 
diacylglycerol (DAG) and inositol triphosphate (IP3), which causes an 
increase in the free intracellular Ca2+ concentration. 
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Major activators of PAR1 are thrombin, activated factor X (FXa) and plasmin, which cleave at the same 
site and cause activation of Gαq, Gα12/13 and β-arrestin 1-mediated signaling pathways. Activated 
protein C (APC), matrix metalloproteinase (MMP) 1 and 13, neutrophil elastase and neutrophil 
proteinase 3 cleave PAR1 at distinct positions of the N-terminus, which causes different preferential 
contribution of the in paragraph 1.3.1 mentioned signaling pathways. (Ramachandran & Hollenberg 
2008; Soh et al. 2010; Zhao, Metcalf, & Bunnett 2014). 
 
The PAR1 signaling is terminated via rapid phosphorylation of the intracellular C-terminus by G protein-
coupled receptor kinases (GRKs), protein kinase A (PKA) or PKC, thus inhibiting further coupling of G 
proteins. Although β-arrestins play a major role in PAR2 signaling and desensitization, β-arrestin 1 
seems to contribute to PAR1’s signaling, but only little to its desensitization. The receptor is then 
internalized via clathrin and dynamin-dependent processes. PAR1 is rapidly replenished on the plasma 
membrane through intracellular PAR1 reservoirs. Unlike PAR2, PAR1 was demonstrated to cycle 
constitutively between the plasma membrane and endosomal vesicles, thus establishing intracellular 
reservoirs. Ubiquitinylation of the PAR1 C-terminus seems to contribute to PAR1’s subcellular 
distribution and prevents its phosphorylation and thus desensitization. (Gieseler et al. 2013; Soh et al. 
2010; Zhao, Metcalf, & Bunnett 2014). 
 
PAR1 was shown to form heterodimers with all other subtypes, which alters and enhances the triggered 
signaling of the involved subtypes. Intriguingly, the heterodimerization with PAR3, the subtype that is 
least known about and does not seem to create intracellular signals on its own, enhances the activation 
of PAR1 and PAR4 by thrombin and reduces their agonism via the Gαq pathway. Moreover, PAR3 seems 
to compensate the lack of PAR1 in murine platelets. Human platelets express PAR1 and PAR4. In murine 
platelets, however, only PAR4 and PAR3 are found. (Gieseler et al. 2013; Ramachandran & Hollenberg 
2008; Soh et al. 2010; Zhao, Metcalf, & Bunnett 2014). 
 
PAR1’s role in the activation of human platelets and accompanied pathologic events gave rise to 
extensive research on finding specific antagonists. The PAR1 antagonists Vorapaxar and Atopaxar 
completed clinical trials phase III and phase II respectively and revealed to be beneficial for the 
treatment of cardiovascular diseases and the inhibition of platelet aggregation. However, they also 
caused increased possibilities of moderate and severe bleeding and intracranial bleeding events 
(Vorapaxar) or hepatic abnormalities (Atopaxar). While the attribution of the utility and the complex 
in vivo interactions and side effects is ongoing, these antagonists already provide useful tools for in 
vitro research purposes. (Al-Khafaji et al. 2015; Cui et al. 2012; Moschonas, Goudevenos, & Tselepis 
2015; Ramachandran 2012; Tello-Montoliu et al. 2011). 
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Atopaxar is a commercially available PAR1 antagonist that was developed by the Japanese 
pharmaceutical company Eisai Co., Ltd. It has shown to attenuate PAR1 activation via thrombin and 
specific PAR1-APs in a concentration-dependent manner. Hence, it presumably interferes with the 
second extracellular loop (Figure 1-1), which is supposed to facilitate ligand binding and receptor 
activation. (Al-Khafaji et al. 2015; Cui et al. 2012; Matsuoka et al. 2004; Serebruany et al. 2009; Tello-
Montoliu et al. 2011; Wurster & May 2012). 
1.3.3 The role of PAR activation in liver diseases 
The disruption of the vascular endothelial barrier, as it occurs during the course of e.g. fibrosis, cirrhosis 
and cancerous liver diseases, causes the activation of various potentially PAR-activating proteinases of 
the blood coagulation cascade. These comprise activated factor VII (FVIIa; activates PAR2), FXa (PAR1-4), 
thrombin (PAR1,3,4), APC (PAR1,3), and plasmin (PAR1), which are mainly produced by the liver. Tumor 
microenvironments have been reported to show an enhanced and less limited activation of the blood 
coagulation cascade, thus leading to increased concentrations of thrombin and presumably 
prerequisite FVIIa and FXa. HCC tissue and cell lines were demonstrated to express and secrete 
elevated amounts of thrombin, which correlated with HCC metastasis and recurrence in affected 
patients and with metastatic features of established HCC cell lines. In the context of liver diseases, it 
is, therefore, likely that PARs are activated throughout the affected liver parenchyma. (Coughlin 2000; 
Falanga 2011; Garnier et al. 2010; Licari & Kovacic 2009; Madhusudhan, Kerlin, & Isermann 2015; ten 
Cate & Falanga 2008; Xue et al. 2010; Zacharski, Hommann, & Kaufmann 2004). 
 
Recent publications of our group and other researchers could demonstrate that PARs are relevant for 
the progression of liver diseases: 
(1) Cholangiocarcinoma – intrahepatic cancer of the bile ducts – was demonstrated to be 
promoted in growth and migration via activation of PAR2 (Kaufmann et al. 2012; Nakanuma et 
al. 2010). 
(2) Liver fibrosis and cirrhosis: PAR1 and PAR2 were demonstrated to mediate activation of hepatic 
stellate cells, thus leading to enhanced proliferation, promotion of myofibroblast 
differentiation, and enhanced collagen secretion. Hepatic stellate cells reside in the 
perisinusoidal space of the liver lobules and are the major contributors to liver fibrosis. 
(Borensztajn et al. 2010; Duplantier et al. 2004; Fiorucci et al. 2004; Gaça, Zhou, & Benyon 
2002; Knight et al. 2012; Lu et al. 2014; Mercer & Chambers 2013). 
(3) HCC: PAR2 has been demonstrated to promote the invasiveness of HCC cells involving the 
cross-activation of the HGF receptor Met while PAR1 and PAR4 promoted migration of HCC cells 
via cross-activation of Met and PDGFR (Kaufmann et al. 2007, 2009; Mußbach et al. 2014). 
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Hence, it seems that PARs play a pivotal role in the development and progression of liver diseases via 
stimuli arising from the different cell entities of the liver parenchyma. In conclusion, regarding the in 
paragraph 1.2.2 (page 6) presented emerging cell-based techniques to cure liver diseases, PARs may 
also get activated in exogenously employed stem cells and hepatic precursor cells.  
1.4 Hypothesis and objective 
MSCs are considered as a valuable resource for the treatment of diseases associated with chronic 
tissue damage, as it occurs in liver fibrosis and cirrhosis. The biological properties of MSCs are still 
incompletely understood. The administration of MSCs as means of cellular therapy of liver diseases 
would add large quantities of a multifaceted and multipotent cell entity to diseased 
microenvironments. The consequences of the arising cell interactions are likewise insufficiently 
understood. To obtain better insights into these processes, the assessment of the role of PARs in MSCs 
appears of great interest. On the one hand, PAR expression has been detected in MSCs and is likely to 
affect their functions, but a detailed characterization of the different PAR subtypes and their biologic 
impact on the MSCs and surrounding cell entities is currently lacking. On the other hand, MSCs have 
shown beneficial effects on chronically inflamed liver tissues in experimental mouse models. Exposure 
of MSCs to an inflamed microenvironment is likely to activate resident PARs. Moreover, the interaction 
of MSCs and cancerous tissue remains controversial, and PAR activation may play a relevant role in it. 
Hence, we hypothesized that PARs may play a crucial role in MSCs, and assumingly alter their paracrine 
activity with an impact on the development of HCC. As illustrated in Figure 1-2, our goals were 
therefore to (1) characterize the PAR subtypes in MSCs, (2) to assess the biological relevance of PARs 
in MSCs, and (3) to assess the effect of MSCs on HCC cells in vitro, and in vivo in a xenotransplantation 
mouse model – with consideration of the impact of PARs. 
 
Figure 1-2: Hypothesis of the PAR-mediated impact of MSCs on the HCC microenvironment 
MSCs are currently under investigation for cell-based curation of chronic liver diseases. Tumor microenvironment- and inflammation-derived 
proteinases might activate PARs in MSCs. Our goal was to assess the presence and biological relevance of the different PAR subtypes in MSCs. 
Furthermore, we wanted to assess the impact of MSCs on HCC and whether MSCs’ PARs contribute to it. 
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2 Methods 
2.1 Basic cell maintenance 
The link between hepatocellular carcinoma (HCC), mesenchymal stem cells (MSCs) and proteinase-
activated receptors (PARs) was addressed with in vitro and in vivo assays. All assays were conducted 
using primary human MSCs and cells from the permanent HCC cell line Hep3B. All cells were cultured 
at standard conditions of 37 °C, 5 % CO2 and 95 % humidity. 
2.1.1 Isolation of MSCs from human adipose tissue 
All used MSCs were of human origin and derived from adipose tissue of several donors (Table 2-1). 
Thus, the cells are called adipose tissue-derived MSCs (AT-MSCs). All cell batches were gathered with 
donor’s consent at the University Hospital of Leipzig (Germany), approved by its Institutional Ethics 
Review Board. 
Isolation and characterization of the AT-MSCs were 
carried out by the laboratory of Dr. B. Christ from the 
Applied Molecular Hepatology Laboratory, 
Department of Visceral, Transplantation, Thoracic 
and Vascular Surgery, University Hospital Leipzig 
(Germany). The protocol is based on a collagenase 
digestion of the adipose tissue, followed by filtration 
through a nylon mesh, and the separation of the 
different cell populations with a Percoll® gradient 
centrifugation. The mononucleated cells were 
harvested from the interphase, washed and seeded 
on uncoated plastic flasks. Due to the MSCs’ 
characteristic of adhering to plastic surfaces, they 
remain in the flask while suspension cells can be 
washed away (Christ, Brückner, & Stock 2011). 
Purity and entity of the cells were verified using flow 
cytometry and in vitro differentiation into other lineages (Table 2-2) (Aurich et al. 2007; Christ & Pelz 
2013). The used protocols were similar to the published ones for bone marrow-derived MSCs (BM-
MSCs).  
Table 2-2: Analyzed characteristics of AT-MSCs 
Stem cell markers 
positive for:  
CD13, CD29, CD44, CD54, CD90, CD105, CD166 
Hematopoietic markers 
negative for:  
CD11c, CD14, CD34, CD45, glycophorin-A, HLA-DR 
Differentiation  
osteogenic, adipogenic, hepatogenic 
 
Table 2-1: Human AT-MSC batches 
Donor 
# 
Batch 
# 
Gender 
 
Date of 
birth 
Date of 
extraction 
1 0312 m 1947 2012 
2 0512 f 1986 2012 
3 0612 f 1933 2012 
4 0712 m 1978 2012 
5 0812 f 1973 2012 
6 0113 m 1954 2013 
7 0213 m 1962 2013 
8 0214 f 1965 2014 
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2.1.2 AT-MSC culture medium  
The AT-MSCs were cultured with a special 
growth medium called EM6F, supplemented 
with 15 % (v/v) fetal calf serum (FCS). EM6F 
was provided by Prof. B. Christ from the 
Applied Molecular Hepatology Laboratory, 
Department of Visceral, Transplantation, 
Thoracic and Vascular Surgery, University 
Hospital Leipzig (Germany) and is composed 
of the ingredients listed in Table 2-3. 
The resulting serum-containing full culture 
medium is termed in the following as 
‘EM6F15’. 
2.1.3 Initial seeding of cryopreserved AT-MSCs  
Prior to seeding, the culture flasks were coated with Dulbecco's Modified Eagle Medium 
(DMEM)/0.5 µg/ml fibronectin and left open under the sterile bench for 30-60 min to let the medium 
dry up in the flask. The cryopreserved AT-MSCs were rapidly thawed in a 37 °C water bath for a few 
seconds, transferred into 5 ml cold DMEM medium and centrifuged at 500 g for 5 min. Another 
washing step with cold DMEM was carried out to remove the dimethyl sulfoxide (DMSO). Finally, the 
cells were resuspended in EM6F15. Cells were seeded at a density of 400/cm².  
2.1.4 AT-MSC maintenance 
The culture medium was replaced every two to four days. One week after initial seeding, the cells were 
detached and seeded into designated dishes for the particular experiments. For that, the cells were 
washed twice with a warm phosphate-buffered saline (PBS) (Biochrom, cat. no. L 1825) and incubated 
with a warm 0.05 % trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco®, cat. no. 25300045) 
solution for 2 min. The detached cells were transferred into FCS-containing DMEM and centrifuged at 
500 g for 5 min. After another washing and centrifugation step, the cells were resuspended in EM6F, 
counted with a cell counting chamber (Neubauer) and seeded for further purposes. Remaining and 
unused cells were split into new culture flasks. 
All experiments were carried out with cells that were in culture no longer than one to three weeks 
(one to three passages). Cells for knockdown experiments (refer to paragraph 2.4.4, page 33) were in 
culture for three to four weeks due to the transduction protocols and expansion of the cells.    
Table 2-3: Composition of AT-MSC growth medium EM6F 
Ingredient Amount Provider 
DMEM 60 % (v/v) Sigma 
MCDB 40 % (v/v) Sigma 
apotransferrin 5 µg/ml Sigma 
selenous acid 5 ng/ml Sigma 
linoleic acid 5 µg/ml Sigma 
bovine insulin 5 µg/ml Sigma 
ascorbic acid 2-phosphate 100 µM Sigma 
dexamethasone 1 nM Sigma 
PDGF-BB 10 ng/ml Sigma 
EGF 10 ng/ml Sigma 
penicillin/streptomycin 100 U/ml / 100 µg/ml Invitrogen 
(Aurich et al. 2007) 
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2.1.5 AT-MSC starvation  
The AT-MSCs were starved before stimulation or migration experiments to synchronize cellular 
behaviors. Starvation was achieved by washing the cells twice with warm PBS and cultivating them in 
DMEM without additives for 24 h.   
2.1.6 Hep3B cell line 
The permanent cell line Hep3B derives from an eight-year-old patient with a correlation of hepatitis B 
virus (HBV) and primary HCC. It was established in the late 1970s, and although the HBV surface antigen 
is produced by the cell line, it yields no active virus particles, making it suitable for safety level 1. Hep3B 
cells grow in monolayers with an epithelial cell shape, resembling characteristics of liver parenchymal 
cells. When injected into severe combined immunodeficiency (SCID) mice, metastatic tumors arise 
(Aden et al. 1979; Knowles, Howe, & Aden 1980).  
The Hep3B cell line was obtained from the Leibniz Institute DSMZ (German Collection of 
Microorganisms and Cell Cultures, cat. no. ACC93). The Hep3B cells were cultured in Roswell Park 
Memorial Institute medium (RPMI) 1640 (Biochrom, cat. no. FG1235) with 10 % (v/v) FCS (Biowest, cat. 
no. S1810) and 1 % (v/v) penicillin-streptomycin (final: 100 U/ml / 100 µg/ml) (Corning, cat. no. 30-
002-CI), changing medium every two to three days. The cells adhere firmly to the flasks. Detaching 
them required washing with PBS and trypsin-EDTA, followed by 8-10 min incubation with fresh trypsin-
EDTA.  
The detached cells were transferred into FCS-containing RPMI and centrifuged at 500 g for 5 min. After 
another washing and centrifugation step, the cells were resuspended in RPMI, counted and seeded for 
further purposes. 
2.2 Detection of PARs in AT-MSCs 
2.2.1 mRNA expression analysis 
2.2.1.1 RNA extraction 
Total RNA was isolated from cells that covered a 3.5 cm dish with at least 60-80 % confluence. The 
procedure was carried out according to the manufacturer’s protocol of the NucleoSpin® RNA kit 
(Macherney-Nagel, cat. no. 740955). The basic principle is a lysis buffer that inactivates RNases before 
they can degrade the released RNA. Via a tube-based ionic exchange column, nucleic acids are bound 
and cleansed from other cell compounds with a washing step. Incubation with DNase degrades all DNA, 
which is then washed away. Finally, RNA is eluted with water, which dislodges the RNA from the 
column. 
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The RNA was eluted in 50 µl double-distilled water (ddH2O). The elution step was repeated by adding 
the eluate back on the column, in order to increase RNA yield. The RNA’s concentration and purity 
were determined using a NanoDrop™ spectrophotometer (ND-1000, Peqlab) and following the 
manufacturer’s instructions. 
2.2.1.2 cDNA synthesis 
The isolated RNA was transcribed into cDNA via the First 
Strand cDNA Synthesis Kit (Thermo Scientific, cat. no. K1612) 
on a Mastercycler® ep gradient (Eppendorf). For all 
experiments, Oligo(dT)18 primers were used to ensure 
transcription of mRNA. The sample set up and used programs 
were as presented in Table 2-4. 
 
The amounts of applied RNA were equal for all samples of their 
respective assays.  
 
 
 
 
2.2.1.3 Quantitative real-time PCR 
With the help of the SYBR Green fluorescent dye-based technique of quantitative real-time PCR (qPCR) 
(Bustin et al. 2009), specific sequences of given cDNAs are amplified with specific primers, along with 
a real-time determination of present DNA. SYBR Green intercalates during each elongation step into 
double stranded DNA and emits light when excited. The signal intensity of SYBR Green is proportional 
to the amount of double-stranded DNA in the sample.  
Analyses were conducted with the Maxima SYBR Green/ROX qPCR Master Mix (2x) (Thermo Scientific, 
cat. no. K0221) on a Mastercycler® ep realplex4 (Eppendorf). Used primers, sample and program setups 
are shown in Table 2-5 and Table 2-6. Predesigned qPCR primers (KiCqStart® SYBR® Green Primers) 
were obtained from Sigma. PAR subtype primer sequences were obtained from PrimerBank 
(http://pga.mgh.harvard.edu/primerbank) or personally designed with the help of the Primer-BLAST 
tool from the homepage of the National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast). The PAR subtype primer sequences were then 
synthesized by Sigma. 
 
Table 2-4: Protocol for cDNA synthesis 
Step 1:  
1 reaction = 11 µl [µl] 
RNA (500 ng) + H2O 10 
Oligo(dT)18 Primer 1 
 11 
→ 65 °C, 5 min  
  
Step 2:  
1 reaction = 9 µl [µl] 
5x Reaction Buffer 4 
RiboLock RNase Inhibitor 1 
dNTPs 2 
M-MuLV Reverse Transcriptase 2 
 9 
→ add 9 µl mix to every sample  
→ 37 °C, 60 min 
     70 °C, 5 min 
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Table 2-5: List of used primers for qPCR 
Gene/Target Sequence [5’ → 3’] TA [°C] 
Length of 
Amplicon Species Reference 
Reference Gene 
GAPDH F: ACCCACTCCTCCACCTTTGAC R: TCCACCACCCTGTTGCTGTAG 58 110 human Sigma 
PARs      
F2R/PAR1 
F: GCCATCGTTGTGTTCATCCTG 
R: GCTGATCTTAAAGGGGAGCAC 58 114 human 
PrimerBank 
ID: 166362739c2 
F2RL1/PAR2 
F: CTGTGGGTCTTTCTTTTCCGAA 
R: CAAGGGGAACCAGATGACAGA 58 102 human 
PrimerBank 
ID: 216548424c2 
F2RL2/PAR3 
F: CCTGCCCAAGCACACCTATG 
R: GGTGGTGATGTCTGGCTGAA 58 124 human personally designed 
F2RL3/PAR4 
F: CCTCTATGGTGCCTACGTGC 
R: GCACCTTGTCCCTGAACTCG 58 104 human personally designed 
Cytokines      
IL-8 F: TACTCCAAACCTTTCCACC R: CTCAGCCCTCTTCAAAAAC 55 174 human Sigma 
IL-6 F: GCAGAAAAAGGCAAAGAATC R: CTACATTTGCCGAAGAGC 55 178 human Sigma 
MCP-1 F: AGACTAACCCAGAAACATCC R: ATTGATTGCATCTGGCTG 53 143 human Sigma 
Table 2-6: Protocol for qPCR analyses 
1 reaction = 12 µl [µl]  qPCR profile temp., duration 
Maxima SYBR Green/ROX qPCR Master Mix (2X) 6  enzyme activation 95 °C, 10 min 
ddH2O 4.26  
40x 
denaturation 95 °C, 15 s 
primer forward (10 µM) 0.37  annealing TA, 30 s 
primer reverse (10 µM) 0.37  elongation 72 °C, 20 s 
cDNA 1   60 °C, 15 s 
 12  TM determination 60 → 99 °C, 10 min 
    99 °C, 15s 
   end 20 °C, 2 min 
 
Each analysis of a particular cDNA consisted of 
three technical replicates. Quantification cycle 
numbers (Cq) of each replicate were picked by 
applying the same threshold for the reference 
gene (GAPDH) and the genes of interest (GOI) 
in each experimental setup. The relative gene 
expression and fold changes were calculated 
with the presented equations on the right. 
 
Each replicate of Cq GOI was paired with a replicate of Cq GAPDH. The mean value and standard deviation 
(SD) were calculated from the corresponding relative expression or fold change, respectively. 
In order to compare the results for PAR subtype expressions, the applied primers were required to 
exert similar efficiencies in qPCRs. For analyzing the efficiencies of the PAR subtype primers, qPCRs 
 
 
Δ =   −  
 
ΔΔ =  ,    −  ,    
  !"##$% $&'# ()*+, = 2./0 
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with series of dilutions (10-1, 10-2, 10-3 and 10-4) from a mixture of cDNA were carried out for every pair 
of primers. The pooled cDNA of several different cell entities (AT-MSC, Hep3B, LX2, HEK293T, BV173, 
K562, Mv4-11 and Molm13) was provided in the efficiency analyses to counterbalance low expression 
and absence of expression of particular PAR subtypes. 
The obtained Cq values were plotted against the logarithmic scale of the dilutions, and a linear 
regression was applied.  
The qPCR’s efficiencies were calculated 
from the regression line’s properties: 
2.2.2 Ca2+ mobilization assay 
PARs canonically trigger an increase in the cytoplasmic free Ca2+ concentration, which can be detected 
with Ca2+-binding fluorophores like Fluo-4-acetoxymethyl ester (Fluo-4-AM) by laser scanning confocal 
microscopy. Hence, the functional presence of PARs in AT-MSCs can be verified by endogenous PAR-
activating enzymes and artificial synthesized PAR subtype-specific activating peptides (PAR-APs).  
 
AT-MSCs were seeded into 48-well plates (for overview images with 10x objective) or chambered cover 
glass slides with four wells (Nunc™, cat. no. 155383; for higher magnifications) in 500 µl EM6F15 
medium and cultured up to approx. 80-90 % confluence. The subsequent steps involved the reagents 
listed in Table 2-7 and Table 2-8.  
Table 2-7: Reagents for calcium assays  
Reagent Reagent/Amount Amount Provider (cat. no.) 
Fluo-4-AM Stock 1 g/l in DMSO 1:600 Molecular Probes (F-14201) 
HEPES-buffer, pH 7.4 NaCl 
KCl 
MgSO4*7H2O 
HEPES 
Glucose 
Na2HPO4 
 145 mM 
5 mM 
1 mM 
10 mM 
10 mM 
0.5 mM 
Roth (3957) 
Roth (6781) 
Merck (5886) 
Applichem (A1069) 
Merck (1.08337) 
Roth (K300.2) 
CaCl2-solution CaCl2 1.5 mM 1.5 mM Applichem (A4689) 
HEPES/CaCl2-buffer 
(H/Ca2+-B) 
add freshly: CaCl2-Solution 
into HEPES-Buffer 1:1,000 - 
 
Following a washing step with 500 µl 37 °C-warm 10 mM HEPES/1.5 µM CaCl2-buffer (H/Ca2+-B), the 
cells were incubated for 20 min with 1.5 µM Fluo-4-AM, which was diluted in H/Ca2+-B. After washing 
twice, 200 µl of H/Ca2+-B were loaded into the wells and kept at 37 °C prior to measurement.  
Agents known or expected to elevate the intracellular free Ca2+ concentration were diluted in 100 µl 
of H/Ca2+-B to reach the desired final concentration (Table 2-8) after adding it to the 200 µl in the 
chamber (1:3 dilution).  
8"12$%  = 10. 
;
<= 
112%2> = (8"12$%  − 1)×100 
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Further characterization of the agent-triggered increase in intracellular free Ca2+ concentrations was 
assayed with the PAR1 antagonist Atopaxar and the Ca2+ chelating BAPTA-AM (1,2-Bis(2-
aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester)). For relevant 
experiments, Atopaxar and BAPTA-AM were diluted into the buffers and were present during 
fluorescent dye staining and in the last remaining 200 µl of H/Ca2+-B. Thus, the incubation time was 
approx. 40 min before each assay. 
Table 2-8: Agents used for the investigation of PAR-mediated effects on intracellular calcium  
Agent Target Stock Final conc. Specific Activity / Sequence Provider (cat. no.) 
human 
α-Thrombin PAR1,3,4 10 NIH-U/µl 
0.5 - 2  
NIH-U/ml 
3045 ± 33 NIH U*/mg 
(mean of two batches) 
Enzyme Research 
Laboratories (HT 1002a) 
Trypsin PAR1,2,3,4 1 mM 10 nM - Sigma (T1426) 
PAR1-AP PAR1 10 mM 100 - 260 µM TFLLRN-NH2 Group of Dr. P. Henklein, 
Institute for Biochemistry 
(Charité), Berlin (Germany) 
PAR1-RP - 10 mM 100 µM RLLFT-NH2 
PAR2-AP PAR2 10 mM 10 µM 2-furoyl-LIGRLO-NH2 
PAR4-AP PAR4 10 mM 400 µM AYPGKF-NH2 
Atopaxar PAR1 1 mM 0.1 µM - Axon (2030) 
Ionomycin Ca2+ stores 1 mM 5 µM - Sigma (I9657) 
BAPTA-AM Ca2+ 10 mM 5 - 7.5 µM - Calbiochem (196419) 
BIM-1 PKC 10 mM 1 - 10 nM - Merck Millipore (203290) 
*1 NIH (National Institute of Health) unit (NIH-U) is approximately 1.1-1.3 international unit (Gaffney & Edgell 1995).  
 
The AT-MSCs’ intracellular free Ca2+ concentration was monitored and recorded with a confocal 
Axiovert 100M laser scanning microscope (Zeiss). The excitation by an argon ion laser at 488 nm 
wavelength caused Ca2+-bound Fluo-4-AM to emit light at 516 nm. An increase in Fluo-4-AM-
fluorescence was interpreted as an elevation of the intracellular free Ca2+ concentration. Every 
recording was concluded with a re-stimulation by Ionomycin in order to obtain a positive control. 
Ionomycin causes an elevation of intracellular free Ca2+ concentrations by stimulation of intracellular 
stores and translocation of extracellular Ca2+ (Morgan & Jacob 1994). For this purpose, 100 µl of an 
Ionomycin solution (10 µl of 1 mM Ionomycin diluted in 500 µl H/Ca2+-B) were added to the wells.  
2.2.3 Freeze-fracture replica immunolabeling assay of PAR1 
Freeze-fracture replica immunolabeling (FRIL) provides an elaborate technique to visualize cell 
structures and the distribution of proteins of interest. FRIL requires complex machines and qualified 
experimenters. Therefore, the detection of PAR1 on the MSC plasma membrane (donor #7) was 
conducted by the team of Dr. Martin Westermann in the Center for Electron Microscopy of the 
University Hospital of Jena (Germany). 
Small drops of resuspended MSCs were placed between two 0.1 mm thick copper carriers and rapidly 
frozen by plunging into a cup with liquid ethane/propane (1:1), which in turn was cooled by liquid 
nitrogen. The carrier sandwich was then mounted in the cooled (-150 °C, 10-6 Pa) freeze-fracture 
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machine (BAF400T, Balzers) and tensile fractured by the swift separation of both carriers from each 
other. The tensile fracturing causes the cells to split up, predominantly in the hydrophobic region of 
the membrane bilayer, thus generating an exoplasmic fracture face (EF) and a protoplasmic fracture 
face (PF). Afterward, the fracture faces were replicated by two electron beam guns that first vapor-
deposited a 2 nm thin platinum/carbon layer in a 35° angle onto the surface. The angle is required to 
create ‘shadows’ on cellular structures and thereby making them visible on microscopic images. 
Secondly, this layer was stabilized by a 15 nm thick carbon layer that was vapor-deposited from above 
(90°). In the next step, the major proportion of the biological material was dissolved in a cleaning 
solution (2.5 % (w/s) SDS, 10 mM Tris-HCl pH 7.5, 30 mM saccharose) overnight, which leaves a thin 
layer of macromolecules attached to the replica. The replicas were washed three times with PBS-buffer 
for 10 min each (75 mM NaCl, 12.5 mM NaH2PO4, 67 mM NaHPO4 pH 7.2) and blocked for 30 min with 
labeling buffer (1 % (w/v) BSA, 0.5 % (w/v) gelatin, 0.005 % (v/v) Tween in PBS). Remaining epitopes 
are suitable for detection by primary antibodies. For the assay, the PAR1-specific mouse monoclonal 
antibody WEDE15 (Beckman Coulter, cat. no. IM2085) was diluted 1:10 in labeling buffer and 
incubated on the replicas overnight at 4 °C. The replicas were washed again three times with labeling 
buffer. The primary antibody was detected by a 10 nm gold particles-labeled secondary antibody (anti-
mouse IgG, British Biocell International). The replicas were washed again with PBS-buffer and fixed 
with 0.5 % (v/v) glutaraldehyde for 10 min and finally washed in ddH2O. 
The replicas were mounted on copper grids and imaged in a transmission electron microscope (CEM 
902.A, Zeiss). The gold particles scatter the electron beam and are visible as black dots on the images, 
thereby indicating the location of PAR1. Further comprehensive details on freeze-fracture and FRIL are 
described in the reviews by Fujimoto and Severs (Fujimoto 1995; Severs 2007). 
2.3 Cellular effects of PAR1 activation on AT-MSCs 
2.3.1 Proliferation assay 
1,500 MSCs in 200 µl EM6F15 were seeded per well of micro-clear flat bottom 96-well plates (Greiner, 
cat. no. 655098) and incubated for 24 h, followed by washing twice with PBS and starvation in 100 µl 
DMEM for further 24 h. Afterward, the starvation medium was replaced with 100 µl of EM6F, including 
stimulating agents and particular concentrations of FCS. The plates were placed in an additional humid 
chamber in the incubator, to prevent evaporation at the rim of the plates, and incubated for up to 
three days. 
20 µl of CellTiter-Blue® reagent (Promega, cat. no. G8080) were added to each well, gently shaken and 
further incubated for up to 4 h. The contained dye resazurin is converted by living cells into the 
fluorescent resorufin that was detected at 540exitation nm/610emission nm wavelength with the Infinite® 
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F200 plate reader (Tecan). The recorded fluorescence is proportional to the number of living cells. All 
wells were seeded with the same number of cells at the start of the experiment. Therefore, 
fluorescence differences between particular stimulations are likely to represent a larger or smaller 
number of cells and were interpreted as higher or lower rate of proliferation. (Riss et al. 2004).  
2.3.2 Migration assay 
Migration assays were carried out in a Neuro Probe 48-well micro chemotaxis chamber with a 
migration area of 8 mm² per well and polycarbonate membranes with pores of 8 µm diameter (Neuro 
Probe, cat. no. AP48, PFB8).  
The membranes were handled with sterile forceps and incubated overnight in a 0.35 % (w/v) collagen 
solution (Sigma, cat. no. C3867; diluted in PBS), followed by washing with PBS for three to five times 
under a sterile bench. After the last washing step, they were air-dried for approx. 5 min.  
In the lower compartment, cell culture medium with attractants was added with a total volume of 
27 µl. A dry collagen-coated membrane was placed carefully on top of the filled bottom wells, facing 
the reflective side up. The rubber gasket and the upper chamber part were placed on top and tightened 
with the nuts. 2,000 cells in 51 µl EM6F were seeded into each well.  
At all times, the wells were checked for proper loading and that no air bubbles were trapped under 
the membrane. Moreover, loading of the upper chamber was done swiftly by getting close above the 
membrane without touching or poking it with the pipet tip and lifting the pipet while injecting the 
medium. In this way, air bubbles were less likely to be trapped in the upper chamber.  
The fully loaded chamber was placed in the incubator for 10-30 min to let it warm up. Afterward, an 
objective slide was placed on the chamber to serve as a lid and prevent evaporation. The migration 
was carried out for 16 h overnight. 
 
For analyzing the migration, the nuts were removed, and the upper chamber was lifted and turned 
upside down on a paper towel. Membrane and rubber gasket were stuck on the upper part. Hence, 
migrated cells were facing upside. The upper left corner of the membrane was cut off with scissors, 
and the whole membrane was placed into PBS and washed to remove remaining medium. Afterward, 
the membrane was fixed in -80 °C cold methanol for 1 h at room temperature. The reusable chamber 
components were immediately washed thoroughly with distilled water and tapped onto paper towels 
to remove excess water from the wells. They were placed into sterile plastic boxes and dried at 37 °C.  
Subsequently to fixation, the membranes were quickly air-dried in a few seconds, and placed into a 
0.5 % (w/v) crystal violet (Serva Electrophoresis, cat. no. 27335) solution for 20 min. The membranes 
were washed carefully with ddH2O until the rinsing water stayed clear from the violet dye. The wet 
membrane was placed, with migrated cells facing down, onto a 60 mm long cover slip. Non-migrated 
cells were wiped off with a wet cotton swab from the other side of the membrane. While leaving the 
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slide with the membrane to dry up, a few drops of immersion oil (Merck Millipore, cat. no. 
1046990001) were placed onto an object slide. The dry membrane was removed from the cover slip 
and placed on the object slide, with migrated cells facing up. Another two to three drops of oil were 
added, and the cover slip was put on top. Air bubbles in between the layers were removed by gently 
squeezing them out with forceps. Excess oil was removed over a few hours by placing the object slides 
between paper towels and putting a light box on top for constant pressure.  
The total number of migrated violet cells per well was counted manually under a light microscope. 
  
Every three experiments, the acrylic chamber parts were boiled in a 1 % (w/v) Terg-a-zyme® (Sigma, 
cat. no. Z273287) solution for 3 h at 60 °C; the rubber gaskets were boiled at 100 °C for 30 min. All 
parts were washed with sterile distilled water, dried and stored as described above. 
2.3.3 Immunoblotting 
The stimulation of cells results in the activation of intracellular signaling pathways that lead to 
alterations in cellular behaviors. One key factor of cellular signaling is the phosphorylation of cascades 
of proteins. The phosphorylation status can be assayed by SDS-PAGE-separated protein lysates, which 
have been transferred to protein-binding membranes for analyses. The detection is achieved by 
specific primary antibodies and light-emitting secondary constructs. 
2.3.3.1 Stimulation of AT-MSCs for immunoblot analyses  
AT-MSCs were seeded into 6-well plates, grown up to 70 % confluence, washed twice with PBS and 
starved in 1.5 ml DMEM for 24 h. The plates were placed on a heating plate (37 °C) and respective 
stimulating agents, which were pre-diluted into 500 µl of DMEM, were added to the wells. 
2.3.3.2 Protein determination assay 
The AT-MSCs in the 6-well plates were washed with PBS and lysed in 150 µl cold lysis buffer (Table 2-9) 
on ice. The protein content was determined with the Micro BCA™ Protein Assay Kit (Thermo Scientific, 
cat. no. 23235). 2 µl of each sample were diluted in 200 µl ddH2O, along with a lysis buffer and ddH2O 
control. 200 µl of bovine serum albumin (BSA) standards (10, 20, 40, 80 µg/ml) served as positive 
controls. The bicinchoninic acid (BCA) reagent was prepared according to the manufacturer’s 
instructions; 200 µl were added to each tube. After incubation at 37 °C for 2 h, each tube was 
distributed into two wells of a 96-well plate, and the absorption was measured at 570 nm. 
The absolute protein concentration was calculated via comparison to the linear regression of the BSA 
standards. 
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Table 2-9: Lysis buffer composition 
Ingredient Amount Provider (cat. no.) 
HEPES 50 mM, pH 7.4 AppliChem (A1069) 
NaCl 150 mM Roth (3957) 
EDTA 1 mM Roth (8043) 
EGTA 2 mM AppliChem (A0878) 
NP-40 alternative 1 % (v/v) Merck (492016) 
add freshly   
Sodium orthovanadate 1 mM, reactivate for 5 min at 95 °C Sigma (S6508) 
Aprotinin 16 µg/ml Sigma (A6297) 
Pefablock (AEBSF hydrochloride) 1 µg/ml AppliChem (A1421) 
Leupeptin hemisulfate 2 µg/ml AppliChem (A2183) 
Pepstatin A 2 µg/ml AppliChem (A2205) 
Phenylmethanesulfonyl fluoride (PMSF) 1 mM, add prior to use Sigma (P7626) 
 
2.3.3.3 SDS-PAGE 
The protein lysates were separated on vertical sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). The gels were prepared as listed in Table 2-10 and filled into Hoefer 
electrophoresis units equipped with 1 mm spacers.  
Table 2-10: Buffers used for SDS-PAGE 
 Ingredient Amount Provider (cat. no.) 
Separation gel 
(10 %) 
Acrylamide/bisacrylamide 30 %, Rotiphorese® Gel 30 33 % (v/v) Roth (3029) 
Separation gel buffer (2 M Tris pH 8.8) 19 % (v/v) AppliChem (A1086) 
SDS 20 % 0.5 % (v/v) Applichem (A3942) 
Ammonium persulfate (APS) 20 % 0.4 % (v/v) Serva Electrophoresis (13375) 
 N,N,N',N'-Tetramethyl-ethylenediamine (TEMED) 0.08 % (v/v) Serva Electrophoresis (35930) 
Stacking gel  
(4 %) 
Acrylamide/bisacrylamide 30 %, Rotiphorese® Gel 30 19.8 % (v/v) Roth (3029) 
Stacking gel buffer (0.5 M Tris pH 6.8) 25 % (v/v) AppliChem (A1086) 
SDS 20 % 0.5 % (v/v) Applichem (A3942) 
APS 20 % 0.6 % (v/v) Serva Electrophoresis (13375) 
N,N,N',N'-Tetramethyl-ethylenediamine (TEMED) 0.04 % (v/v) Serva Electrophoresis (35930) 
10x Running  Glycin 1.92 M Roth (3908) 
buffer pH 8.4 Tris 250 mM AppliChem (A1086) 
 SDS 20 % 1 % (v/v) Applichem (A3942) 
6x Loading Tris pH 6.8 62.5 mM AppliChem (A1086) 
buffer Glycerol 10 % (v/v) Roth (3783) 
 SDS 20 % 2 % (v/v) Applichem (A3942) 
 β-mercaptoethanol 5 % (v/v) Roth (4227) 
 Bromophenol blue a pinch Roth (A512) 
 
500 µl of the separation gel were mixed with additional APS and TEMED and immediately pipetted into 
the gel unit to seal all borders. The sealing gel polymerized within few seconds and the remaining 
separation gel was added and sealed with isopropanol (Roth, cat. no. 6752) to achieve a smooth upper 
border. The stacking gel was added upon hardening of the separation gel and removal of remaining 
isopropanol; a comb was inserted to form the lanes. After polymerization of the stacking gel, the comb 
was removed, and the whole system was assembled, flushed and filled with 1x running buffer.  
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20 µg of total protein from each lysate were mixed with loading buffer, boiled for 5 min at 95 °C and 
loaded onto respective lanes, along with a molecular weight marker (PageRuler™ Prestained Protein 
Ladder, Thermo Scientific, cat. no. 26616). The separation was conducted at constant 120 V. 
2.3.3.4 Immunoblotting 
The separated proteins were further blotted onto polyvinylidene fluoride (PVDF) membranes with 
pore sizes of 0.45 µm (Merck Millipore, cat. no. IPVH00010) using a semidry technique. 
Table 2-11: Buffers used for immunoblotting 
 Ingredient Amount Provider (cat. no.) 
Anode buffer Tris 300 mM AppliChem (A1086) 
 Methanol 20 % (v/v) Roth (3880) 
Cathode buffer Tris 25 mM AppliChem (A1086) 
 6-aminocapronic acid 40 mM Roth (3113) 
 Methanol 20 % (v/v) Roth (3880) 
 SDS (20 %) 0.05 % (v/v) Applichem (A3942) 
10x Tris-buffered 
saline/Tween 
(TBST) 
Tris 200 mM, pH 7.4 AppliChem (A1086) 
NaCl 1.5 M Roth (3957) 
Tween® 20 0.5 % (v/v) Serva Electrophoresis (37470) 
Ponceau solution Ponceau S 0,25 % (w/v) Sigma (P3504) 
 Acetic acid 5 % (v/v) Roth (3735) 
Blocking solution BSA in 1x TBST 5 % (w/v) PAA Laboratories (K41-001) 
Stripping buffer Tris pH 6.7 62.5 mM AppliChem (A1086) 
 β-mercaptoethanol 100 mM Roth (4227) 
 SDS (20 %) 2 % (v/v) Applichem (A3942) 
 
Three layers of anode buffer-soaked Whatman® cellulose filter paper were placed on the anode of a 
Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad). The PVDF membrane was activated for 10 s in 
methanol and placed on the papers. The polyacrylamide gel was calibrated for few minutes in cathode 
buffer and placed on top of the membrane, followed by three further layers of cathode buffer-soaked 
filter papers. The device was closed, and blotting was conducted at constant 2 mA/cm² for 1 h.  
Subsequently, the membranes were rinsed with water and incubated in Ponceau S solution for 5 min, 
which turns proteins red. The protein bands were made visible by rinsing one to two times with water 
to remove excess dye. The membranes were cut according to the intended usage of primary antibodies 
and further rinsed with water until the red dye was completely gone. The destaining of the membranes 
required frequent rinsing with fresh water over 5-10 min.  
The membranes were blocked with blocking solution at constant gentle shaking for 1 h.  
Following three washing steps with TBST over 30 min, the membranes were incubated with primary 
antibodies at constant gentle shaking and 4 °C overnight. The antibodies were diluted in 1 % (w/v) BSA 
in TBST. 
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Table 2-12: Antibodies used for Immunoblotting 
Antibody Dilution Provider (cat. no.) 
primary    
ATAP2 1:1,000 Santa Cruz Biotechnology (sc-13503) 
WEDE15 1:1,000 Beckman Coulter (IM2085) 
pERK 1/2 (p44/p42) mouse monoclonal antibody 1:1,000 Cell Signaling (9107) 
ERK 1 (K-23) rabbit polyclonal antibody 1:3,000 Santa Cruz Biotechnology (sc-94) 
secondary    
goat anti-mouse IgG-HRP 1:500 Santa Cruz Biotechnology (sc-2005) 
goat anti-rabbit IgG-HRP 1:2,000 Santa Cruz Biotechnology (sc-2004) 
 
The following day, the membranes were washed again with TBST for three times over 30 min and were 
incubated with horseradish peroxidase (HRP)-labeled secondary antibody, diluted in 1 % (w/v) BSA in 
TBST, for 50 min at RT. After another washing procedure, the membranes were placed on a dry glass 
plate and covered with Western Lightning® Plus-Enhanced Chemiluminescence Substrate (Perkin 
Elmer, cat. no. NEL105001EA) for 1 min. Afterward, excess solution was drained off. The membranes 
were covered with a transparent film, and the emission of light was detected with an LAS-4000 
(Fujifilm). The obtained images were converted into negatives for better display and visibility. 
2.3.4 Proteome Profiler™ antibody array 
To investigate the profile of secreted proteins of stimulated and unstimulated AT-MSCs, supernatants 
of growing AT-MSCs were applied on antibody-based proteome arrays from R&D Systems. The arrays 
consist of strips of nitrocellulose membranes with spotted duplicates of immobilized capture 
antibodies for specific sets of proteinases (cat. no. ARY021), cytokines (cat. no. ARY022) or proteins 
involved in angiogenesis (cat. no. ARY007). 
 
AT-MSCs were seeded into 6-well plates and cultivated up to a confluence of 50-70 %, starved for 24 h, 
and fresh EM6F medium was left on the cells for another 24 h for conditioning. The supernatants were 
collected and centrifuged to sediment cell debris.  
The following steps were conducted according to the manufacturer's protocol. In brief, the conditioned 
medium was mixed with a biotinylated detection antibody and incubated on the washed membranes 
overnight at 4 °C. The spotted antibodies on the membranes capture their respective target proteins 
in complex with the pre-bound biotinylated detection antibody. After washing, the membranes were 
incubated with a streptavidin-HRP-conjugate. Streptavidin binds to biotin, thus linking HRP to the 
detection antibody, which in turn is bound to the immobilized protein.  
After a further washing step, the membranes were placed on a dry glass plate and 1 ml Chemi Reagent 
Mix was added onto each membrane. The reagent was drained, and a transparent film was placed on 
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the membrane to prevent desiccation. The HRP converts the substrate in the reagent into a 
chemiluminescent signal, which was photographed using an LAS-4000 (Fujifilm). 
 
The resulting images were quantified using the Multi Gauge v3.0 software (Fujifilm). The calculated 
mean pixel densities of each particular protein were divided by the mean density of the positive 
controls from the respective membrane, to normalize possible differences between the membranes. 
On a subjective basis, the results were grouped according to their strength in respect to the positive 
controls (PC): “+++” of more than 75 % of PC; “++” of 25 to 75 % of PC; “+” of 5 to 25 % of PC; and “o” 
of 2 to 5 % of PC. Less than 2 % of PC were close to the background levels and considered as no 
secretion, “-.“  
2.3.5 Enzyme-linked immunosorbent assay 
To further address the AT-MSCs’ expression patterns as a response to PAR1 stimulation, the targets of 
the mRNA expression analysis were subjected to enzyme-linked immunosorbent assays (ELISAs) for 
proving mRNA expression into functional secreted protein. Therefore, the AT-MSCs were prepared as 
described in paragraph 2.3.4, and the supernatant medium was collected and frozen at -80 °C.  
RNA samples were gained and analyzed from the underlying cells according to paragraph 2.2.1 (page 
18). Additional wells with cells were used for protein determination according to paragraph 2.3.3.2 
(page 25). 
 
ELISAs for the detection of IL-8 and IL-6 were purchased from ImmunoTools (cat. no. 31670089, 
31670069) and conducted according to the manufacturer’s protocols.  
In brief, 96-well ELISA plates were coated with primary capture antibodies and incubated at 4 °C 
overnight. Excess medium was tapped out of the wells. The wells were blocked with blocking buffer 
for 2 h. Samples and a dilution series of a positive control were pipetted in duplicates into the wells. 
No washing steps were required between those steps. Incubation was carried out at 4 °C overnight. 
The following steps required three to five thorough washing steps and tapping out of the excess buffer 
in between. Stepwise, secondary antibody, HRP-streptavidin conjugate and substrate solution (Table 
2-13) were added and incubated. The HRP is turning a colorless substrate solution into a blue dye.  
The substrate conversion was stopped with sulfuric acid, which changed the color of the dye from blue 
to yellow. The amount of each colorimetric development was quantified with an Anthos Reader HT3 
(Anthos Mikrosysteme) at 450 nm wavelength. 
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Table 2-13: Substrate solution for ELISAs 
 Ingredient Amount Provider (cat. no.) 
Solution A 
5 ml 
prepare prior to experiment, store up 
to few days at 4 °C: 
  
 3,3′,5,5′-Tetramethylbenzidine (TMB) 12 mg Sigma (860336) 
 Acetone 0.5 ml Roth (KK40) 
 Ethanol 4.5 ml Roth (K928) 
 H2O2 (30 %) 10 µl Roth (9681) 
Solution B Citric acid 288 mg Roth (6490) 
50 ml ddH2O 50 ml - 
 Potassium hydroxide solution raise pH to 4.1 solid NaOH, Roth (9356) 
Substrate solution combine prior to use:   
 Solution A 0.5 ml - 
 Solution B 10 ml - 
 
2.4 Interaction of AT-MSCs and Hep3B cells in an in vivo xenograft mouse 
model 
The interaction of MSCs and tumor cells harbors a complex microenvironment with multiple 
components that may promote or inhibit tumor growth (Yagi & Kitagawa 2013). The interaction is 
presumably affected by surrounding and attracted cell types as well. In order to assess the potential 
interaction between MSCs and HCC cells, AT-MSCs were subcutaneously co-injected with cells from 
the HCC cell line Hep3B into the flank of mice from the CB17 SCID strain. Whether AT-MSCs’ PAR1 is 
contributing to tumor growth in the model was addressed using a stable PAR1 knockdown in the AT-
MSCs. The knockdown cells were then co-injected with Hep3B cells. Furthermore, the AT-MSCs’ fate 
in the tumor model was assayed in a batch with green fluorescent protein (GFP)-labeled AT-MSCs.     
2.4.1 CB17 SCID mouse strain 
The CB17 severe combined immunodeficient (SCID) mouse strain is an albino mouse that lacks 
functioning B and T cells, thereby making it suitable for implantation of cells from other organisms 
without rejection of the xenograft. Macrophages, natural killer cells and granulocytes remain 
unaffected by the deficiency (Charles River 2015). The mice were originally purchased from Charles 
River (strain code 236) and bred in a pathogen-free environment at the Service Unit Small Animal, 
Research Center Lobeda (FZL), University Hospital of Jena (Germany) at a constant 12 h light/dark 
cycle, and freely access to food and water. Handling and experiments were approved by respective 
authorities and followed governmental animal care regulations. Male mice with similar age and 
weights were used for all experiments.  
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2.4.2 Preparation and injection of AT-MSCs and Hep3B cells into CB17 SCID mice 
Before the mice experiments, all cells were cultured according to protocols mentioned earlier 
(paragraph 2.1, page 16). On the day of cell injection into the mice, the cells were detached from the 
flasks, washed with PBS and resuspended in small volumes of RPMI. 200 µl of RPMI were prepared 
with respective amounts of cells according to Table 2-14.   
The cells were kept at 37 °C in 1.5 ml tubes and flicked 
frequently to prevent agglutination and sedimentation of the 
cells while the mice were prepared. The resuspended cells were 
drawn up into a syringe and injected subcutaneously into the 
flank of mice that were anesthetized with diethyl ether. The mice were placed back into the cages and 
observed for tumor formation over the following 11-24 days.  
 
When tumor formation was sufficient, all mice were scanned with the X-ray computed tomography 
TomoScope® Synergy Twin (CT Imaging). For that, the mice were anesthetized by inhalation of 2 % 
(v/v) isoflurane in a closed plastic box and then placed into the tube of the tomograph with further 
isoflurane inhalation. The mice were scanned for 29 s at 65 kV between skull and tail to make sure to 
cover all possible locations of the tumors. Tumor formations were analyzed with the ImpactView 
software (CT Imaging). Deformations beneath the skin, the presumed tumors, were measured at their 
point of maximum height, length and width. Tumor volume was calculated as follows: 
 
 
 
3D reconstruction of the CT images was conducted by using Imalytics software (Philips). All CT 
measurements and analyses were carried out with the kind help of Y. Ozegowski from the Department 
of Radiology, University Hospital of Jena (Germany). 
 
After scanning all mice, they were sacrificed by cervical dislocation. The part of the skin with the tumor 
was cut off from the respective mouse, and a photo was shot to document angiogenesis. After the 
tumor was cut loose from the skin, it was placed onto graph paper, and another photo was shot. For 
further histochemical analysis, the tumors were put into 5 % (v/v) formalin, pH 7, to fix and preserve 
them for further processing. Mice showing no perceptible tumors were skinned and carefully checked 
for possibly overlooked formations of tumors. Tumors with GFP-labeled AT-MSCs were cut in half and 
separated onto a tube of formalin or Tissue-Tek® (Sakura, cat. no. 4583), respectively. 
All cell co-injections and removals of tumors were carried out with the kind help of Dr. B. Günther from 
the Service Unit Small Animal, Research Center Lobeda (FZL), University Hospital of Jena (Germany). 
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 Table 2-14: Number of cells for Injection 
Cell type Number of cells 
Hep3B 100,000 
AT-MSCs 500,000 
Hep3B + AT-MSCs 100,000 + 500,000 
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2.4.3 Histological tumor analysis 
The fixed tumors were placed into gaskets and washed with tap water, to remove the formalin, for 2 h. 
After that, the tissue was dehydrated by increasing amounts of ethanol (2x 70 % ethanol, 2x 96 % 
ethanol, 3x 100 % ethanol), followed by soaking in xylene (1x xylene-ethanol mixture, 2x xylene) to 
remove ethanol and serving as a solvent for paraffin embedding. All twelve washing steps lasted for 
1 h each, using the tissue processor TP1020 (Leica). Paraffin was heated up to 60 °C to turn it liquid. 
The tumors were thoroughly soaked in paraffin (2x) and cast into metal gaskets to form small paraffin 
blocks using the Embedding Center EG1160 (Leica). 
After hardening and cooling down of the blocks, thin tumor containing slices of 3-4 µm diameter were 
cut off using a microtome (Microm) and N35 microtome blades (Feather) and placed on objective slides 
for further immunohistochemical treatment.  
The prepared slides were stained with hematoxylin/eosin (HE) using the ST5020 Multistainer (Leica) 
for general staining of tumor tissue. Hematoxylin binds basophilic cellular structures, while eosine 
binds acidophilic structures (Chan 2014). The staining procedure comprised: washing in xylene (3x; 
3/2/1 min), decreasing ethanol concentrations (100/96/70 %; 80 s each), ddH2O (15 s), 2x hematoxylin 
(4 min each), rinsing water (5 min), eosin (4 min), increasing ethanol concentrations (70/96/2x 100 %; 
80 s each) and xylene (3x; 2/1 min). 
Furthermore, primary antibodies for detection of cytokeratins 5, 6, 8, 17 and 19 (Clone MNF116; Dako, 
cat. no. M0821), alpha-smooth muscle actin (α-SMA; Clone 1A4; Dako, cat. no M0851) and Ki-67 (Clone 
MIB-1, cat. no. M7240) were applied. The slides were prepared in the PT-Link (Dako) with preheated 
(84 °C) Target Retrieval Solution (Dako; high pH, cat. no. K8004, cytokeratin and α-SMA; low pH, cat. 
no. K8005, Ki-67) for 20 min at 97 °C and subsequently washed in Wash Buffer (Dako, cat. no K8007) 
for 5-10 min. The following steps were conducted by the Autostainer Link 48 (Dako) with the 
EnVision™FLEX, High pH (Link) kit (Dako, cat. no. K8000). Staining steps comprised: blocking of 
peroxidases (5 min), incubation with primary antibody (30 min), secondary antibody Mouse (LINKER) 
(Dako, cat. no. K8021), HRP (20 min), substrate working solution (10 min), hematoxylin (7 min), and 
final rinsing with ddH2O. Wash Buffer was applied between every incubation step. 
Finally, the slides were washed with ddH2O (2x), ethanol (2x 70 %, 2x 96 %, 2x 100 %) and xylene (4x), 
and covered with mounting medium (Dako, cat. no. CS703) and cover slips. 
 
The stained slides were scanned and digitally converted into virtual slides using the 
NanoZoomer 2.0-HT digital slide scanner (Hamamatsu) and its viewing platform NDP.view2. 
All histological assays and evaluations were carried out with support from E. Oswald from the 
Department of General, Visceral and Vascular Surgery (Experimental Transplantation Surgery) 
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University Hospital of Jena (Germany) and Dr. K. Katenkamp from the Institute of Pathology, University 
Hospital of Jena (Germany). 
2.4.4  Genetic modification of AT-MSCs 
The fate of the AT-MSCs and the impact of PAR1 in AT-MSCs on the tumor development in the AT-MSC-
Hep3B SCID mouse model was addressed with genetically modified AT-MSCs. To that end, we labeled 
a batch of AT-MSCs with GFP to track them inside the tumor mass. In another batch, the stable 
knockdown of PAR1 mRNA was achieved by post-transcriptional silencing of the PAR1 gene F2R with 
short hairpin RNA (shRNA). The protocol was carried out with commercially available bacterial stocks 
from Sigma that contain plasmids with a particular shRNA sequence, which targets PAR1 mRNA, and a 
puromycin resistance for the selection of successfully transduced cells (Table 2-15). 
Table 2-15: F2R MISSION® shRNA bacterial glycerol stocks used for PAR1 knockdown 
Provider: Sigma   
Product type: SHCLNG-NM_001992   
Species: human   
# TRC number Clone ID Sequence 
1 TCRN0000352793 NM_001992.3-1247s21c1 CCGGCCCACAAACGTCCTCCTGATTCTCGAGAATCAGGAGGACGTTTGTGGGTTTTTG 
2 TCRN0000352674 NM_001992.3-1270s21c1 CCGGGCATTACTCATTCCTTTCTCACTCGAGTGAGAAAGGAATGAGTAATGCTTTTTG 
3 TCRN0000342351 NM_001992.3-384s21c1 CCGGCCCGGTCATTTCTTCTCAGGACTCGAGTCCTGAGAAGAAATGACCGGGTTTTTG 
4 TCRN0000342352 NM_001992.3-1068s21c1 CCGGCCTACTACTTCTCAGCCTTCTCTCGAGAGAAGGCTGAGAAGTAGTAGGTTTTTG 
5 TCRN0000003688 NM_001992.x-2152s1c1 CCGGGACGGCAAGGTTTAAGTTATTCTCGAGAATAACTTAAACCTTGCCGTCTTTTT 
TRC = The RNAi Consortium 
 
Table 2-16: Material for plasmid purification, transfection and transduction 
 Ingredient Amount Provider (cat. no.) 
LB agar LB-medium 
Agar 
autoclave 
cool down to 50 °C 
ampicillin 
25 g/l 
15 g/l 
 
 
100 µg/ml 
Roth (X968) 
Applichem (A0949) 
 
 
Roth (K029) 
LB medium LB-medium 
autoclave, cool down 
ampicillin 
25 g/l 
 
100 µg/ml 
Roth (X968) 
 
Roth (K029) 
DNA plasmid purification NucleoBond® Xtra Midi - Macherey Nagel (740410.10) 
Polyethylenimine  Stock: 10 µg/µl 2.5 µg/µg DNA Sigma (408727) 
Polybrene 
(Hexadimethrine bromide) Stock: 0.8 mg/ml 1:100 Sigma (107689) 
Puromycin Stock: 2 mg/ml 1:1000 Sigma (P-8833) 
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2.4.4.1 Breeding of E. coli stocks / amplification of plasmids 
Ampicillin-containing LB agar plates were prepared by pouring the warm and liquid solution into sterile 
10 cm bacterial dishes, leaving them aside to cool down and harden. After that, ampicillin resistant 
bacterial stocks were plated onto the LB agar by scratching some cells out of the frozen stock with a 
pipet tip, and carefully wiping the tip over the plate. The plates were incubated at 37 °C for 
16 h/overnight. 
The following day, a single colony was picked and transferred into 200 ml LB medium with ampicillin 
in a 500 ml conical flask. The flask was loosely closed with an aluminum cap and shaken at 37 °C and 
about 180 rpm for 16 h. 
 
The purification of the plasmids from the Escherichia colis (E. coli) suspension was carried out following 
the protocol of the NucleoBond® Xtra Midi Kit (Macherey Nagel, cat. no. 740410). In short, the 
suspension was spun down in an Avanti™ J-20 XPI centrifuge (Beckman Coulter) and the cell pellet was 
resuspended in an RNase-containing buffer. Hence, possible interfering RNA is ‘removed’ from the 
purification. The suspended cells were lysed with an alkaline buffer containing denaturing SDS. Plasmid 
DNA was separated by a column filtration based on an ionic exchange resin that captures the negatively 
charged DNA. In the final step of this protocol, the plasmid DNA was eluted with ddH2O. Afterward, 
the DNA was precipitated with ethanol and isopropanol, washed again, and resuspended in ddH2O. 
The plasmid’s concentration and purity was determined using a NanoDrop™ spectrophotometer (ND-
1000, Peqlab) and following the manufacturer’s instructions.    
2.4.4.2 Transfection of HEK293T cells / lentivirus production 
Following the preparation of a sufficient amount of plasmid, HEK293T cells were transfected with 
plasmids that encode viral particles and the shRNA for knockdown or non-targeting control, 
respectively. HEK293T cells serve as a host to produce lentiviruses that in turn are able to transduce 
target cells with high efficiency. 
HEK293T cells derive from human embryogenic kidney (HEK) cells that were transformed with the 
simian virus 40 (SV40) large T antigen (Shein & Enders 1962), which drives continuous replication by 
primarily binding and inactivating the tumor suppressors retinoblastoma protein and p53 (Ali & 
DeCaprio 2001). 
HEK293T cells were kindly provided by Dr. Carol Stocking-Harbor from the Heinrich-Pette-Institute in 
Hamburg (Germany). The culture medium was DMEM with 10 % (v/v) FCS and 1 % (v/v) 
penicillin/streptomycin (termed DMEM10). 
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A minimum of one T160 flask of HEK293T cells was required per one 6-well plate of target cells. In the 
beginning, 2.5 Mio HEK293T cells were seeded in 20 ml DMEM10 in a T160 flask and left to grow for 
one and a half days for proper attachment. On the day of transfection, the plasmids (Table 2-17) were 
prepared as listed in Table 2-18. 
Table 2-17: Vectors used for transfection of HEK293T cells 
 Product Name / Description Provider 
non-taget (nt) control MISSION® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA  Sigma (SHC002) 
pMDL, pRSV, pVSV Lentiviral Packaging Plasmids provided by Dr. Carol Stocking-Harbor,  Heinrich-Pette-Institute, Hamburg (Germany) 
eGFP LeGO-iG2 Lentigo Vectors 
Table 2-18: Ratios of DNA for preparation of transfection 
For one T160 flask Tube 1 Tube 2 
DMEM 0.5 ml 0.5 ml 
Expression vector (nt/PAR1KD/eGFP) 20 µg - 
Viruscapsule pMDL 20 µg - 
 pRSV 10 µg - 
 pVSV 4 µg - 
Polyethylenimine (Sigma, cat. no. 40872) 
(PEI, 2.5 µg PEI per 1 µg DNA) 
- 135 µg 
 
Tube 1 and 2 (Table 2-18) were pipetted together, gently vortexed immediately and left at RT for 
30 min. 
Just before the end of the incubation time, the medium of the HEK293T cells was changed to FCS-free 
DMEM. HEK293T cells do not adhere firmly to the flask, and the transfection process reduces the 
adhesion additionally. Therefore, gentle conduction of all following steps was required to prevent loss 
of cells and diminished virus output. The mixture of plasmid DNA was added drop-wise to the medium 
in the flasks and incubated for another 6 h. Electrostatic attraction causes PEI and plasmid DNA to build 
up condensed particles with a cationic charge, which in turn bind to anionic surface molecules on the 
cells, thus favoring endocytosis of the particles. PEI alters the osmotic potential of the endosomes and 
swelling causes them to release the particles from the vesicles (Sonawane, Szoka, & Verkman 2003). 
Unused transfection material was washed away by replacing transfection medium with fresh 
DMEM10.  
The following days, the virus-containing medium was harvested at 24, 48 and 72 h, and fresh DMEM10 
was refilled into the flasks. The harvested medium was filtered through 0.2 µM syringe filters to 
remove cell debris. Filtered medium was frozen and stored at -80 °C. Prior to transduction, the virus-
containing medium was concentrated by factor 50-100 with an Amicon Ultra-15 Centrifugal Filter Unit 
with Ultracel-30 membrane (Merck Millipore, cat. no. UFC903) at 4,000 g. In general, target cells were 
tried to be prepared in sync to virus production to avoid freezing of viruses. 
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2.4.4.3 Lentiviral transduction of AT-MSCs 
About six days prior to transduction, 400 AT-MSCs/cm² were seeded into fibronectin-coated 6-well 
plates.  
The concentrated virus-containing medium of one T160 flask was added to the amount of fresh 
EM6F15, which was required for one whole 6-well plate, along with the cationic polymer polybrene 
(Stock: 0.8 mg/ml → 1:100). Polybrene enhances the transduction rate by aggregation of viruses and 
adsorption to target cells by neutralizing negatively charged cell surfaces (Davis, Morgan, & Yarmush 
2002; Davis et al. 2004). The AT-MSC culture medium was carefully replaced with the transduction 
medium mix. Afterward, the 6-well plates were placed in aerosol-tight trays of a swinging bucket rotor 
and centrifuged in a Heraeus Multifuge 1S (Thermo Scientific) at 500 g for 1 h. This procedure was 
carried out three times in a row with 8-16 h incubation in between (e.g. morning, evening, next 
morning). 
After a minimum time of 48 h post-transduction, the culture medium was changed to selection 
medium, containing 2 µg/ml puromycin. Previous tests for the selection efficiency showed that all 
AT-MSCs detach within 48 h at puromycin concentrations of more than 1 µg/ml. At the end of the 
selection, surviving cells were washed properly and given fresh medium. 
The cells were detached at confluences of approx. 50-70 %, and were passaged from initially a single 
well of a 6-well dish to a T75 flask and then further to one T160 flask. After a total duration of 3.5 to 4 
weeks in vitro, with two passages, the AT-MSCs were ready for in vivo experiments. The PAR1 
knockdown efficiency was assessed with small proportions of cells that were split at passage two and 
grown in a 6-well plate dish prior to mRNA extraction. The GFP labeling was evaluated with a 
fluorescence microscope. 
The co-injection tumor-assay set up for AT-MSC-nt, AT-MSC-PAR1KD and AT-MSC-GFP was the same 
as the one for wild type AT-MSCs described in paragraph 2.4.2 (page 31). 
2.5 Statistical analysis 
All data were tested for statistical significance by independent two-sample student’s t-tests assuming 
equal variances. Significances were indicated with stars (*) or circles (°) above the mean values with 
their respective standard deviation (SD) bars. Further details are given in the figure legends. 
Calculations were carried out in Microsoft Excel. 
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3 Results 
Mesenchymal stem cells (MSCs) are of keen interest to current medical research to cure tissue diseases 
with chronic inflammation, fibrosis or impaired regenerative capacities. Cancerous diseases like 
hepatocellular carcinoma (HCC) may benefit from the ameliorative effects of MSCs, too. The 
progression of HCC has been shown to benefit from the activation of proteinase-activated receptors 
(PARs) in tumor cells as well as surrounding cell entities of the tumor microenvironment. However, the 
biological role of PARs in MSCs and the impact of MSCs on the HCC microenvironment are currently 
insufficiently understood. Therefore, we conducted in vitro assays to characterize PARs in MSCs and 
assessed their impact on biological features of MSCs. Subsequently, we analyzed the significance for 
surrounding HCC cells in vivo in a xenotransplantation HCC tumor model. 
3.1 Characterization of PARs in AT-MSCs 
PARs have not been of particular interest to stem cell research so far, and comprehensive analyses are 
still lacking. Hence, in order to understand the importance of the PAR family in MSCs, it was necessary 
to analyze their presence, functionality and distribution inside the cells.  
3.1.1 PAR1 is the predominantly expressed PAR family member in AT-MSCs 
Addressing the presence and relative quantities of the PAR family in adipose tissue-derived (AT) MSCs 
required primer pairs of similar quality. Therefore, PAR subtype-specific primers were employed in 
qPCRs of a dilution series of a mixture of cDNA (1.5 µg/µl) from several cell types. The obtained 
 
Figure 3-1: Efficiency of primers used for PAR expression analyses 
(A) Primer efficiency test. Depiction of the quantification cycles (Cq) from qPCRs using dilutions of a cDNA mixture (1.5 µg/µl, pooled from 
various cell types) and PAR subtype-specific primers. Dots show the mean values of technical duplicates from one assay. (B) Attributes of 
the respective linear regressions from the primer efficiency test. GAPDH and PAR subtype primers fulfilled the efficiency requirements. R² 
= coefficient of determination 
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quantification cycles (Cq) for each dilution were fitted with a linear regression (Figure 3-1, A) and 
respective attributes were calculated (Figure 3-1, B) as described in paragraph 2.2.1.3 (page 20). 
The present DNA in a PCR is duplicated every cycle if it runs with 100 % efficiency (amplification 
rate = 2). Hence, the desired values of a standard PCR can be calculated (Figure 3-1, B). Any primer pair 
should have an efficiency of 90 to 110 %, with respective values of the coefficient of determination 
(R²) and slope. All of our applied primer pairs fulfilled the desired values for each attribute and 
demonstrated efficiencies between 92 and 101 % over the given range of concentrations of template 
cDNA. As further displayed in Figure 3-1 A, no amplification was monitored for PAR1 and PAR3 at cDNA 
concentrations below 1.5 ng/µl (10-3 dilution), and for PAR4 below 15 ng/µl (10-2 dilution). In general, 
the PAR4 gene transcript showed little presence in the pooled cDNA, since undiluted cDNA 
demonstrated Cq values above 30.  
 
We employed the PAR subtype primers in qPCRs with 
cDNA from AT-MSCs from eight different patients (see 
Table 2-1, page 16). The expression was assessed as a 
percentage of GAPDH expression and showed a 
significant overall dominance of PAR1 mRNA 
expression, compared to PAR2, PAR3 and PAR4 (Figure 
3-2, A). PAR3 was expressed in larger amounts than 
PAR2. PAR4 was barely detected. The expression of 
PAR1 varied strongly among the different donors. 
Hence, all single donor results were plotted again in 
relation to the PAR1 expression (Figure 3-2, B). The 
expression pattern remained similar and displayed 
that PAR1 was expressed in significantly larger 
amounts, of about five to ten times more, than PAR2 
PAR3 and PAR4. 
3.1.2 PAR activation causes an increase in [Ca2+]i in AT-MSCs 
PARs are capable of eliciting a distinct increase in the intracellular free Ca2+ concentration ([Ca2+]i) upon 
stimulation. The expression analyses of the PAR subtypes in AT-MSCs revealed the expression of PAR1, 
PAR2 and PAR3 while PAR4 was barely detected. Thus, the activation by canonical activating proteinases 
and PAR subtype-specific activating peptides (APs) provided additional feedback on presence and 
functionality of the particular PARs.  
The images displayed in Figure 3-3 show that stimulation of AT-MSCs with thrombin (Figure 3-3, B) and 
the PAR1-AP (Figure 3-3, E) resulted in a strong temporary increase in [Ca2+]i, comparable to the 
 
 
Figure 3-2: Expression levels of PARs in AT-MSCs 
The mRNA expression of the four PARs in AT-MSCs was 
analyzed in one batch of AT-MSC cDNA per donor. Bars 
represent mean values ± SD of technical qPCR triplicates, 
eight donors in total. (A) Box plot of relative expression 
levels as percentage of GAPDH expression. (B) Results of 
single donors relative to PAR1 expression.  
PAR1 was the predominantly expressed PAR subtype in the 
analyzed AT-MSCs. ***p-value ≤ 0.001; *p-value ≤ 0.05 
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response that was induced by Ionomycin, which triggers Ca2+ mobilization from intracellular stores and 
Ca2+ intake from surrounding buffer. The caused Ca2+ peak was triggered immediately after addition of 
the agents and went steadily down to the initial state within 70-100 s. Ionomycin’s effects were 
permanent and caused disruption of cellular integrity in the applied range of concentration since the 
Ca2+ peaks were usually constant, and leakage of cytoplasm into the buffer was occasionally observed. 
 
 
 
 
Figure 3-3: Intracellular Ca2+ response to stimulation of PARs in AT-MSCs 
AT-MSCs (donor #6) were cultured in 48-well dishes and labeled with the Ca2+-binding dye Fluo-4-AM. The treatments with agonists 
resulted in an increase in [Ca2+]i, which was seen as an increase in Fluo-4-AM-fluorescence and recorded by an inverted confocal laser 
scanning microscope. Each row represents the time course of a single well with representative images. The mean fluorescence ± SD of 
five representative cells (white circles) is depicted in the respective graph on the right, with marked time points of images (A-O) and 
treatments (labeled in white bars in pictures; time points marked with arrows in graphs). The displayed images are representative for 
one additional separate assay with donor #8.  
Stimulation of AT-MSCs with thrombin (1 NIH U/ml; A-C) and PAR1-AP (260 µM; D-F) resulted in a strong increase in [Ca2+]i, comparable 
to the positive control Ionomycin (5 µM). Trypsin (10 nM; G-I) and PAR2-AP (10 µM; J-L) triggered less, PAR4-AP (400 µM; M-O) triggered 
no signal.  
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Trypsin (Figure 3-3, H) caused a weaker Ca2+ response than thrombin, PAR1-AP or Ionomycin and cells 
did not react at once but rather kept flashing up after each other distributed over a long time. However, 
the main peak appeared within the first 50 s after stimulation. The PAR2-AP (Figure 3-3, K) activated 
single AT-MSCs. The Ca2+ response was about 40 s short and less strong than thrombin, PAR1-AP or 
Ionomycin. The intensity was similar to trypsin, but, all affected cells reacted at once. The PAR4-AP 
(Figure 3-3, N) was unable to induce an intracellular free Ca2+ signal in the AT-MSCs. Therefore, we 
subsequently applied the PAR1-AP as a positive control, in order to verify the ability of the cells to 
respond with a membrane receptor-mediated Ca2+ signal. 
Due to the lack of specific tools for the analysis of PAR3, only PAR1, PAR2 and PAR4 were portrayed in 
further assays. PAR3-derived activating peptides were found to activate PAR1 and PAR2, and currently, 
no subtype-specific PAR3-AP is known (Hansen, Saifeddine, & Hollenberg 2004; Zhao, Metcalf, & 
Bunnett 2014). 
Thrombin and PAR1-AP caused an increase in [Ca2+]i in AT-MSCs. However, thrombin canonically 
cleaves and activates PAR1, PAR3 and PAR4. Therefore, in the next experimental step both agents were 
sequentially combined in order to (1) deplete the amount of PAR1 on the plasma membrane by 
activation with PAR1-AP, and (2) to see if an additional stimulation via PAR3 or PAR4 is possible in a 
follow-up stimulation with thrombin (Figure 3-4). Moreover, Experiments with the reverse PAR1-
peptide RLLFT (PAR1-RP), validated as a negative control for PAR1-AP (Kaufmann & Hollenberg 2012), 
were performed. 
 
 
Figure 3-4: Subsequent stimulation of AT-MSCs with PAR1-AP and thrombin  
AT-MSCs (donor #1) were cultured in 48-well dishes and labeled with the Ca2+-binding dye Fluo-4-AM. The treatments with agonists resulted 
in an increase in [Ca2+]i, which was seen as an increase in Fluo-4-AM-fluorescence and recorded by an inverted confocal laser scanning 
microscope. Each row represents the time course of a single well from one assay with representative images. The mean fluorescence ± SD of 
five representative cells (white circles) is depicted in the respective graph on the right, with marked time points of images (A-H) and 
treatments (labeled in white bars in pictures; time points marked with arrows in graphs). 
(A-D) Stimulation of AT-MSCs with PAR1-AP (100 µM) resulted in a strong increase in [Ca2+]i, comparable to the positive control Ionomycin 
(5 µM) while subsequent treatment with thrombin (1 NIH U/ml) had almost no effect. (E-H) The stimulation of AT-MSCs with the reverse 
peptide PAR1-RP (100 µM), which served as negative control, showed no effect on the cells while the subsequent treatment with thrombin 
(1 NIH U/ml) resulted in a strong increase in [Ca2+]i, comparable to the positive control Ionomycin.  
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As shown in Figure 3-4, PAR1-AP led to an increase in [Ca2+]i in AT-MSCs, comparable to Ionomycin (D), 
while PAR1-RP had no effect (B + F). Subsequent treatment with thrombin showed that if PAR1 was 
already stimulated with PAR1-AP, no further stimulation was induced by thrombin in the cells (C). 
Following the PAR1-RP application, thrombin was able to cause a strong Ca2+ signal (G). These results 
indicated that PAR1 might be the sole PAR subtype in AT-MSCs to respond to thrombin via Ca2+ signals. 
3.1.3 PAR1 antagonist Atopaxar inhibits PAR1-mediated [Ca2+]i increase in AT-MSCs 
Additional Ca2+ assays were carried out with the PAR1 antagonist Atopaxar, in order to test its efficacy 
and to verify that the observed Ca2+ mobilization by PAR1 agonists was specific to the PAR1 stimulation.  
As shown in Figure 3-5, thrombin and PAR1-AP were able to increase rapidly the [Ca2+]i, comparable to 
Ionomycin. Preceded incubation of the AT-MSCs with the PAR1 antagonist Atopaxar caused a 
concentration-dependent reduction of the thrombin or PAR1-AP-triggered [Ca2+]i increase. The 
concentration of 0.1 and 0.5 µM Atopaxar sufficiently inhibited thrombin’s actions on a majority or 
almost all of the AT-MSCs. The results for the stimulation with PAR1-AP were similar. Hence, the other 
thrombin receptors PAR3 and PAR4 did not seem to contribute to the Ca2+ elevation that was triggered 
by thrombin.  
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Figure 3-5: PAR1 antagonist Atopaxar reduces Ca2+ mobilization in AT-MSCs upon PAR1 activation with thrombin or 
PAR1-AP 
AT-MSCs (donor #8) were cultured in 48-well dishes and labeled with the Ca2+-binding dye Fluo-4-AM. Treatments with thrombin (time 
point marked with arrows in diagrams) resulted in an increase in [Ca2+]i, visualized by an inverted confocal laser scanning microscope as 
an increase in Fluo-4-AM fluorescence. Each row represents a single well with the mean ± SD time course of five representative cells 
(white circles) depicted in each diagram, along with marked time points of pictures for the measured areas (A-X). Images of two 
representative assays are shown. 
The pre-treatment of AT-MSCs with increasing concentrations of Atopaxar resulted in a concentration-dependent blocking of the 
thrombin- (A-L) and PAR1-AP-induced (M-X) Ca2+ increase in AT-MSCs.  
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3.1.4 Effect of the Ca2+ chelator BAPTA-AM on AT-MSCs 
PAR1 was shown to exert a strong increase in the free cytosolic Ca2+ concentration in AT-MSCs upon 
stimulation with thrombin and PAR1-AP (see Figure 3-3, Figure 3-4 and Figure 3-5). The Ca2+ signal may 
result in further downstream signaling and biologic effects on the cells. In order to intercept the Ca2+ 
signal, we depleted the intracellular free Ca2+ with the selective Ca2+-chelating agent BAPTA-AM (1,2-
Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester)). In the following 
initial assays, we assessed its efficacy on depleting intracellular free Ca2+.  
3.1.4.1 Ca2+ chelator BAPTA-AM reduces PAR1-triggered [Ca2+]i increase in AT-MSCs 
As shown in Figure 3-6, thrombin and PAR1-AP were able to trigger a rapid increase in [Ca2+]i, 
comparable to Ionomycin. In the presence of the Ca2+ chelator BAPTA-AM, the Ca2+ response in the AT-
MSCs was reduced for both thrombin and PAR1-AP stimulation. At a concentration of 2.5 µM BAPTA-
AM the response was already diminished by approximately half, and at 5 µM almost no remaining 
reaction was visible. BAPTA-AM also attenuated the increase in [Ca2+]i triggered by Ionomycin. 
However, the Ca2+ influx seemed to saturate the chelator at the employed concentrations, and the 
maximum fluorescence was still achieved after approx. 100-150 s. 
These results show that BAPTA-AM is able to reduce and even abrogate the effects of PAR1 activation 
on intracellular free Ca2+ elevation. 
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Figure 3-6: Intracellular Ca2+ response to PAR stimulation in AT-MSCs in presence of the Ca2+ chelator BAPTA-AM 
AT-MSCs (donor #6) were cultured in 48-well dishes and labeled with the Ca2+-binding dye Fluo-4-AM. Treatments with thrombin and 
PAR1-AP (time point marked with arrows in diagrams) resulted in an increase in [Ca2+]i, visualized by an inverted confocal laser scanning 
microscope as an increase in Fluo-4-AM fluorescence. Each row represents a single well from one assay with the mean ± SD time course 
of five representative cells (white circles) depicted in each diagram, along with marked time points of pictures for the measured areas 
(A-R). 
Stimulation of AT-MSCs with thrombin (1 NIH U/ml) and PAR1-AP (260 µM) resulted in a strong [Ca2+]i increase, comparable to positive 
control Ionomycin (5 µM). Pre-treatment of AT-MSCs with increasing concentrations of the Ca2+ chelator BAPTA-AM resulted in a 
concentration-dependent suppression of (A-I) thrombin- and (J-R) PAR1-AP-induced Ca2+ increase in MSCs. The influence of BAPTA-AM 
caused Ionomycin to require more time to raise the [Ca2+]i to levels as without BAPTA-AM.  
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3.1.4.2 AT-MSCs remain viable in prolonged presence of BAPTA-AM 
The abrogation of the PAR1-mediated [Ca2+]i elevation by BAPTA-AM was shown in paragraph 3.1.4.1. 
However, incubation times of 24 h were intended for upcoming assays, and the strong impact of 
BAPTA-AM might exert negative effects on general Ca2+ homeostasis and AT-MSC viability over longer 
periods. Therefore, AT-MSCs were treated with several concentrations of BAPTA-AM and incubated 
for 24 h. 
 
As shown in Figure 3-7, a BAPTA-AM concentration of 10 µM altered the morphology of multiple 
AT-MSCs. We observed structural changes that resembled a multitude of internal compartments or 
vacuoles. The application of trypan blue revealed that these altered cells remained viable by showing 
no uptake of the dye. Dead cells would take up the dye and appear dark blue. The assayed cells 
appeared transparent and similar to the background, hence remaining viable. At lower BAPTA-AM 
concentrations, only a few single altered cells were found. Therefore, 2.5-7.5 µM BAPTA-AM were 
considered suitable for the application in long-term assays.   
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Figure 3-7: Ca2+ chelator BAPTA-AM causes multiple internal changes in AT-MSCs’ morphology at a concentration of 10 µM  
AT-MSCs (donor #6) were cultured in 6-well plates and incubated with increasing concentrations of the Ca2+ chelator BAPTA-AM for 24 h. 
Cell viability was determined by trypan blue staining. Dead cells accumulate the dark blue stain (not present in the pictures) while living cells 
appear transparent and similar to the background as is the case in the displayed pictures. The figure displays representative images of one 
assay. 
AT-MSCs showed morphological changes after incubation with 10 µM BAPTA-AM while staying viable. The alterations resembled vacuoles 
(indicated by black arrows, highlighted in black boxes). Between 2.5 and 7.5 µM BAPTA-AM only single altered AT-MSCs were found. 
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3.1.5 PAR1 is located on the plasma membrane of AT-MSCs 
The expression analyses of paragraph 3.1.1 revealed that PAR1 was the predominantly expressed PAR 
subtype in the analyzed AT-MSCs. Furthermore, the PAR1-activating agonists thrombin and PAR1-AP 
exerted a strong Ca2+ elevation inside the cells as pointed out in paragraph 3.1.2. Therefore, we focused 
further PAR analysis in AT-MSCs on PAR1.  
 
The presence of PAR1 in AT-MSCs on protein level was verified by immunoblotting and electron-
microscopic images of immunolabeled freeze-fracture replicas using PAR1-specific antibodies.  
We employed two different PAR1-specific antibodies on AT-MSC lysates, ATAP2 (Santa Cruz 
Biotechnology) and WEDE15 (Beckman Coulter). PAR1 has a molecular weight of 47 kDa or 66 kDa, 
respectively, depending on its degree of glycosylation. The glycosylation alters movement behavior 
during SDS-PAGE and may cause smear bands if heavily glycosylated. As shown in Figure 3-8, ATAP2 
highlighted multiple bands, including a faint one at approx. 47 kDa and three stronger bands at approx. 
37, 43 and 66 kDa. WEDE15 highlighted bands at the same molecular weights, but the ones at 43 and 
47 kDa appeared more prominent in respect to the other faint bands. Therefore, WEDE15 marked PAR1 
at expected molecular weights more prominently and with less strong bands at unexpected weights 
than ATAP2. WEDE15 is also able to detect both cleaved and the intact receptor and has been used 
extensively by other researchers over the past two decades. Hence, we used WEDE15 for the detection 
of PAR1 on AT-MSC plasma membranes.    
 
 
 
The distribution of PAR1 on AT-MSC plasma membranes was visualized on freeze-fracture replicas of 
AT-MSCs. This technique provides cross sections of frozen cells, which primarily fracture between 
bilipid membranes. Replicas of the protoplasmic and exoplasmic facing membrane structures are 
recreated to strengthen the biologic material for cell structure visualization. Membrane proteins may 
then be detected by the application of primary antibodies and gold particle-labeled secondary 
antibodies. The gold particles cause black dots on electron microscopic images of the replicas (detailed 
information in paragraph 2.2.3, page 22). 
Figure 3-8: Test of PAR1-specific antibodies ATAP2 and WEDE15 on AT-MSC lysates 
AT-MSCs (donor #1) were seeded into 6-well-plates, grown to approx. 70 % confluence and 
then lysed. 20 µg of AT-MSC protein lysates were separated by SDS-PAGE and blotted onto 
protein-binding PVDF membranes. PAR1 was detected with the specific primary antibodies 
ATAP2 (Santa Cruz Biotechnology) or WEDE15 (Beckman Coulter), HRP-labeled secondary 
antibody and a chemiluminescent detection. The immunoblots (negative images shown) 
depict PAR1 immunoblots of AT-MSC lysates from one assay.  
The PAR1 antibodies ATAP2 and WEDE15 detected several bands on immunoblots of AT-MSC 
lysates (donor #1). Unglycosylated PAR1 has a molecular weight of about 47 kDa. Glycosylated 
(glyc.) PAR1 has a molecular weight of about 66 kDa. Note that ATAP2 seemed to recognize 
less PAR1 at 47 kDa than WEDE15, while WEDE15 detected less glyc. PAR1 at 66 kDa than 
ATAP2 (negative images shown), both in relation to respective co-appearing bands. 
3 Results 
49 
We applied the PAR1-specific antibody WEDE15 on AT-MSC freeze-fracture replicas. As presented in 
Figure 3-9, multiple black dots were found on the exoplasmic fracture face of AT-MSC replicas, which 
were treated with WEDE15 and a gold-labeled secondary antibody (A), while no black dots were found 
on negative control replicas, which were treated with the same secondary antibody, but without 
WEDE15 (B). Therefore, the black dots represented the distribution of presumed PAR1 on the plasma 
membrane of AT-MSCs. Note that single as well as closely co-localized dots were found on the images.   
 
Figure 3-9: PAR1-immunolabeled freeze-fracture replica of the exoplasmic fracture face (EF) of AT-MSCs 
Localization of PAR1 on AT-MSCs (donor #7) was visualized by electron microscopic images of freeze-fracture replicas on the exoplasmic 
fracture face (EF). Replicas were treated with the PAR1-specific antibody WEDE15 (Beckman Coulter) and a gold-labeled secondary antibody, 
which were detected as black dots on the images. Intramembrane proteins are visible as small particulate structures. Shown are 
representative images of one assay. (A) PAR1 was labeled on the AT-MSC plasma membrane as single particles (arrows) and clusters (circles). 
(B) Negative Control. Representative image of replicas treated without primary antibody WEDE15. 
 
3.2 PAR1 signaling in MSCs – AT-MSCs show high basal ERK phosphorylation 
PAR1 was detected on the plasma membrane of AT-MSCs. Moreover, it was found to be presumably 
the major expressed PAR family member that will respond to activation in AT-MSCs. In order to unravel 
PAR1 downstream effectors and possible signaling pathways, we conducted immunoblot assays and 
focused on the extracellular-signal-regulated kinase (ERK) due to strong initial signals. 
 
The mitogen-activated protein kinase (MAPK) pathway was addressed by the analysis of the ERK 
phosphorylation status in immunoblot-based assays with stimulation by thrombin or PAR1-AP of 
starved AT-MSCs. Though multiple experiments were carried out with two batches of AT-MSCs (donors 
#1 and 6) with attempts to optimize conditions for stimulation, including time, concentration, HEPES-
buffering of medium and the use of heated plates during stimulation, no consistent pattern and 
correlation of the strong ERK signal with the stimulation could be obtained. The immunoblots in Figure 
3-10 display representative results of different experiments for the ERK phosphorylation status in 
AT-MSCs from donor #6. 
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Though a strong ERK phosphorylation in cells stimulated with thrombin or PAR1-AP was observed in 
frequent cases, negative controls frequently presented the same amount of ERK phosphorylation. This 
raised the question if the examined AT-MSCs possessed a high basal ERK phosphorylation or if they 
were particularly sensitive to stimuli from the outside, which might have caused the observed 
inconsistency. 
 
 
 
 
 
In another approach, the AT-MSCs were pre-incubated with two different inhibitors of the upstream-
located MAPK/ERK kinase (MEK). As seen in Figure 3-10 B, the MEK-inhibitors were able to attenuate 
the pERK level in comparison to unstimulated control, even though PAR1-AP was present. At the same 
time, the pERK level in the PAR1-AP stimulated positive control was relatively low and with the lowest 
concentration of the inhibitors even somewhat higher.  
 
Taken together, the AT-MSCs may possess elevated pERK levels in general, with seemingly unstable 
consistency. Although the involvement of the MAPK signaling in mediating the biologic effects of PAR1 
activation seems likely, we could not conclusively resolve the effect of PAR1 stimulation on ERK 
activation. 
3.3 Biological effects of PAR1 activation on AT-MSCs 
The general ability of PAR1 to activate multiple intracellular effectors and influence other pathways via 
cross-activation of other signaling pathways may have a significant influence on MSC growth and 
migration. In addition, PAR1 signaling comprises actin rearrangements via coupling to Gα12/13, which 
Figure 3-10: AT-MSCs show inconsistent ERK 
phosphorylation upon PAR1 stimulation, probably due to 
high basal pERK levels 
The immunoblots (negative images shown) depict ERK-
immunoblots of AT-MSC lysates from three representative assays 
(A) or one assay (B), respectively. AT-MSCs (donor #6) were seeded 
into 6-well plates, grown to approx. 70 % confluence, starved for 
24 h, and stimulated with several concentrations of thrombin and 
PAR1-AP. Inhibitors were incubated for 1 h prior to stimulation. 
20 µg of AT-MSC protein lysates were separated by SDS-PAGE and 
blotted onto protein-binding PVDF membranes. ERK and pERK were 
detected with specific primary antibodies, horseradish peroxidase 
(HRP)-labeled secondary antibodies and a chemiluminescent 
detection technique. 
No clear correlation between stimulation with several 
concentrations of thrombin and PAR1-AP, and the level of ERK 
phosphorylation was observed. Note that untreated controls vary 
between a low and high phosphorylation status of ERK. Hence, 
making it unclear whether the PAR1 stimulation caused the 
observed pERK levels in stimulated samples (A+B). The pre-
treatment with two different agents to inhibit upstream-located 
MEK decreased pERK levels in presence of PAR1-AP. Therefore, the 
influence of PAR1-AP did not seem to purposely affect pERK levels.  
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Figure 3-11: Stimulation of PAR1 reduces 
the migration rate of AT-MSCs 
The migration assay was carried out in a 
Neuroprobe 48-well micro chemotaxis chamber 
using collagen-coated polycarbonate membranes 
with 8 μM-sized pores. 2,000 starved AT-MSCs 
(donor #6) were seeded into each well. After 16 h 
of migration in EM6F medium, non-migrated cells 
were wiped off the membrane and remaining 
cells were stained with crystal violet and counted. 
Bars show mean values ± SD of five separate 
assays. 
The presence of thrombin or PAR1-AP 
significantly reduced the rate of migration of AT-
MSCs. Positive control with FCS was carried out 
only once due to massive migration compared to 
control without FCS. (A) Absolute number of 
migrated cells; (B) combined single assays 
relative to their respective control. ***p-value ≤ 
0.001 versus untreated control. 
might directly affect the MSCs’ ability to migrate (Ramachandran et al. 2012; Siehler 2009). Therefore, 
we investigated the impact of PAR1 stimulation on MSC proliferation and migration. 
3.3.1 PAR1 mediates reduced migration of AT-MSCs 
MSCs have been shown to exert impressive capacities of migrating to tumors and other inflamed 
tissues (Bayo et al. 2013). Those pathologic microenvironments are enriched with thrombin and other 
PAR-activating proteinases (ten Cate & Falanga 2008). Therefore, it was of great interest to assess the 
migration of MSCs under the presence of PAR1-activating thrombin and PAR1-AP. 
The migration assays were carried out in a Neuroprobe chemotaxis system. 2,000 starved AT-MSCs 
were seeded into small wells that were separated from the bottom wells by a collagen-coated 
polycarbonate membrane with 8 µm-sized pores. The bottom wells contained culture medium with 
fetal calf serum (FCS), thrombin or PAR1-AP. As seen in Figure 3-11 A, about one-fourth of initially 
seeded cells were migrating across the membrane in control culture medium. FCS enhanced the 
number of migrated cells by a large amount and reached the limit of proper single cell counting. In the 
presence of thrombin and PAR1-AP, the number of migrated cells decreased. However, the number of 
migrating cells differed between each assay. Hence, data were plotted again with every single assay 
with respect to control (Figure 3-11 B) and showed a significant reduction of the relative migration 
rates of thrombin and PAR1-AP stimulated AT-MSCs of approx. 20-40 %. 
 
 
 
 
 
3.3.2 PAR1 mediates no significant enhancement of AT-MSCs’ proliferation 
The analysis of MSC proliferation was approached with viability assays in 96-well microtiter plates. 
Viable cells are able to convert the non-fluorescent substrate resazurin into the fluorescent dye 
resorufin, which can be detected by plate readers. The higher the fluorescence, the more cells are 
present per well, which can be interpreted as presumed higher rate of proliferation. 
3 Results 
52 
PAR1’s impact on the AT-MSCs’ proliferation was approached with multiple different experimental 
setups. Figure 3-12 displays a representative assay with a time- and FCS-dependent assessment of 
AT-MSCs’ proliferation rate in the presence of thrombin or PAR1-AP. 
 
 
 
Three 96-well microtiter plates were initially seeded with equal amounts of AT-MSCs and were 
incubated for up to 76 h post-stimulation. As seen in the figure, a similar resorufin fluorescence was 
recorded for all wells of the first plate measured at 0 h, representing that the AT-MSCs were seeded 
uniformly over the whole plate. The second plate, which was analyzed 35 h post-stimulation, showed 
approximately twice as much fluorescence as at 0 h for cells without FCS. This amount seemed to 
reduce in a concentration-dependent manner with increasing concentrations of FCS. AT-MSCs growing 
in the presence of 15 % FCS showed a minor increase in fluorescence, compared to respective wells on 
the ‘0 h plate’. The third plate, which was analyzed 76 h post-stimulation, showed a minor increase in 
fluorescence for cells without FCS and an apparently concentration-dependent major increase in 
fluorescence for AT-MSCs in the presence of increasing concentrations of FCS, compared to respective 
wells on the ’35 h plate’. Overall, there was no or only a minor impact of thrombin or PAR1-AP on the 
fluorescence, especially with 15 % FCS after 76 h. Otherwise, the standard deviations of the PAR1-
stimulation quadruplicates were greater than the difference of the enhanced fluorescence in respect 
to controls. The other experiments (not shown) included thrombin concentrations up to 5 NIH U/ml 
and PAR1-AP concentrations up to 500 µM, but with no significant enhancement of the AT-MSCs’ 
proliferation. 
3.4 Protein secretion activity of AT-MSCs and impact of PAR1 
Current trends in medical therapy deem MSCs as potential mediators to cure chronic wounds, by the 
limitation of inflammation and the promotion of regeneration and self-renewal. While differentiation 
and incorporation into diseased tissue provides one aspect of their potential, the literature stresses 
their paracrine activity by secreting a plethora of immunomodulatory proteins and growth factors. This 
cocktail of active paracrine agents might have unforeseeable effects on especially cancerous diseases. 
Figure 3-12: PAR1 stimulation has no significant effect on 
AT-MSC proliferation 
1,500 AT-MSCs (donor #6) were seeded into 96-well plates, leaving 
them 24 h to attach, followed by starvation in DMEM for 24 h. The 
medium was replaced with EM6F containing PAR1 agonists and 
various FCS concentrations. After 0, 35 and 76 h, the cell viability was 
measured by applying the Promega CellTiter-Blue® Cell Viability 
Assay. Viable cells convert the dye resazurin into fluorescent 
resorufin and thereby giving feedback on cell proliferation. The graph 
shows data of one experiment with mean values ± SD of technical 
quadruplicates. This experiment was representative for five in total. 
Stimulation of AT-MSCs with thrombin or PAR1-AP over up to 76 h, 
along with the presence of increasing concentrations of FCS, showed 
no significant enhancement of AT-MSC proliferation at any given 
conditions.  
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Since the literature is pointing out a tumor-inhibiting as well as a tumor-promoting impact of MSCs, 
the assessment of their influence on the designated disease, tissue entity and involved cell types 
becomes an essential key component of basic research, in order to understand and limit potential side 
effects. (Maxson et al. 2012; Zhang & Wang 2013).    
Therefore, the following sections were dedicated to identifying the secreted proteins of the applied 
AT-MSCs with proteome arrays. Furthermore, if MSCs would be inoculated into diseased tissues, they 
would presumably encounter several potential PAR1-activating proteinases. Hence, in the subsequent 
step, our goal was to verify the proteins that were influenced by PAR1 activation as detected by the 
array analyses, via enzyme-linked immunosorbent assays (ELISAs) and mRNA expression analyses.  
3.4.1 General overview of proteins secreted by AT-MSCs  
The analysis of proteins that were secreted by AT-MSCs was carried out by conditioning basic culture 
medium by starved AT-MSCs for 24 h. The conditioned medium was then employed in three different 
proteome arrays, which comprised the detection of sets of cytokines, proteinases and angiogenesis-
related proteins. This profiling approach delivered a broad overview of proteins that were secreted by 
AT-MSCs under serum-free standard growth conditions over 24 h. The arrays consisted of specific 
protein-capturing antibodies that were spotted in duplicates on membranes. The capture antibody-
protein complex was in turn recognized by HRP-labeled detection antibodies. The final signal was 
quantified and ranked according to their signal intensity with respect to positive controls. Although 
the signal intensity is dependent on the quality of each single antibody population, the results were 
also grouped into strong (+++), medium (++), few (+) and weak (o) secretion, which covered signals 
that were distinct from insignificant/background levels (-). 
 
Two separate batches of conditioned medium from AT-MSCs (donor #7) were analyzed. One was 
employed on the angiogenesis-related proteins array, the other batch on the proteinases and 
cytokines arrays. The total results are presented in Table 3-1, and prominent secreted proteins are 
shown in Figure 3-13. Altogether, the arrays are capable of analyzing more than 160 proteins and 
approx. one-third of them were secreted by AT-MSCs in noteworthy amounts of more than 5 % of the 
mean positive controls. In general, a variety of extracellular matrix-related proteins (tissue inhibitor of 
matrix metalloproteinases (TIMPs), thrombospondin 1 (TSP-1), Serpin E1) and proteinases (matrix 
metalloproteinases (MMPs), cathepsins) were secreted along with a set of growth factors (angiogenin 
(Ang), angiopoietins (Ang-1), hepatocyte growth factor (HGF)) and immunoregulatory proteins 
(pentraxin 3, interleukin 8 (IL-8), IL-6, monocyte chemotactic protein (MCP-1)).  
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Table 3-1: Proteins secreted by AT-MSCs into supernatant growth medium over 24 h 
Angiogenesis-related proteins (Proteome Profiler™ Human Angiogenesis Array) 
+++ IGFBP-3, Pentraxin 3, Serpin E1, TIMP-1, TSP-1 
++ Serpin F1 
+ Activin A, Angiogenin, Angiopoietin-1, Angiopoietin-2, EG-VEGF, Endostatin/Collagen XVIII, Endothelin-1, IGFBP-1, 
MMP-9, Platelet factor 4 (PF4), TIMP-4, uPA, VEGF 
o ADAMTS-1, Angiostatin/Plasminogen, Artemin, Coagulation Factor III, CXCL16, Endoglin, FGF acidic, FGF basic, 
FGF-7, GM-CSF, HB-EGF, HGF, IGFBP-2, IL-8, LAP (TGF-beta1), MCP-1, MIP-1alpha, MMP-8, NRG1-beta1, PD-ECGF, 
PDGF-AA, Persephin, PIGF, Prolactin, Serpin B5, TSP-2 
- Amphiregulin, DPPIV, EGF, FGF-4, GDNF, IL-1beta, Leptin, PDGF-bb, Vasohibin, VEGF-C 
Proteinases (Proteome Profiler™ Human Protease Array Kit) 
+++ - 
++ Cathepsin B, Cathepsin X/Z/P, MMP-1, MMP-2, MMP-3 
+ ADAMTS1, Cathepsin A, Cathepsin C, Cathepsin D, Cathepsin V, DPPIV/CD26, MMP-13, Proprotein, Convertase 9 
o ADAMTS13, Cathepsin L, Cathepsin S, Kallikrein 3/PSA, Kallikrein 7, Kallikrein 10, Kallikrein 13, MMP-7, MMP-8, 
MMP-9, Neprilysin/CD10, Presenilin-1, uPA/Urokinase 
- ADAM8, ADAM9, Cathepsin E, Kallikrein 5, Kallikrein 6, Kallikrein 11, MMP-12, Proteinase 3 
Cytokines (Proteome Profiler™ Human XL Cytokine Array Kit) 
+++ Serpin E1 
++ Chitinase 3-like 1, DKK-1, ENA-78, MCP-1, Pentraxin-3 
+ Angiogenin, Angiopoietin-1, Complement Factor D, EMMPRIN, Endoglin, FGF-19, GDF-15, HGF, IGFBP-3, IL-11, 
IL17A, IL-6, IL-8, MIF, Osteopontin, SDF-1alpha, TSP-1, uPAR, VEGF 
o Adiponectin, Aggrecan, Angiopoietin-2, BDNF, CD14, CD30, CD40 Ligand, C-reactive Protein, Cystatin C, EGF, FGF 
basic, FGF-7, Flt-3 Ligand, GM-CSF, GRO-alpha, ICAM-1, IFN-gamma, IL-1alpha, IL-1beta, IL-2, IL-3, IL-10, IL-12 p70, 
IL-22, IL-24, IL-27, IL-32alpha/beta/gamma, I-TAC, Kallikrein 3, Lipocalin-2, M-CSF, MMP-9, Myeloperoxidase, 
PDGF-AA, RANTES, RBP4, Relaxin-2, Resistin, SHBG, TARC, TFF3, Vitamin D BP 
- BAFF, C5/C5a, Cripto-1, DPPIV, FAS Ligand, G-CSF, GH, IGFBP-2, IL-1ra, IL-4, IL-5, IL-13, IL-15, IL-16, IL-18 Bpa, IL-
19, IL-23, IL-31, IL-33, IL-34, IP-10, Leptin, LIF, MCP-3, MIG, MIP 1alpha/MIP-1beta, MIP-3alpha, MIP-3beta, PDGF-
AB/BB, PF4, RAGE, ST2, TfR, TGF-alpha, TNF-alpha 
“+++” > 75 % of positive control (PC); “++” 25-75 % of PC; “+” 5-25 % of PC; “o” 2-5 % of PC; “-“ < 2 % of PC/background  
 
Due to the large number of identified proteins, only a few were investigated more thoroughly in further 
experiments. 
3.4.2 PAR1 activation affects protein secretion by AT-MSCs  
We detected a plethora of different cytokines, chemokines, proteinases and other proteins in the 
supernatant of conditioned growth medium of AT-MSCs (Table 3-1, Figure 3-13). For the purpose of 
identifying the secreted proteins that might be affected by stimulation of PAR1, we additionally 
characterized conditioned growth medium of thrombin- or PAR1-AP-stimulated AT-MSCs. As presented 
in Figure 3-14, the arrays showed duplicates of signals for detected protein targets (Figure 3-14, A), 
which were quantified and assessed for the impact of PAR1 stimulation (Figure 3-14 B). We focused 
our efforts on the proteins that were described in the literature to exert crucial impacts on 
angiogenesis, proliferation and immunoregulation, and might, therefore, be of paramount clinical 
relevance of the MSC-mediated treatment of HCC.  
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Figure 3-14: Overview of cytokines 
and growth factors secreted by 
AT-MSCs under the influence of PAR1 
activation over 24 h 
AT-MSCs were seeded (donor #6) into 6-
well plates, grown to a confluence of 
approx. 50 %, starved for 24 h, and fresh 
FCS-free medium was conditioned over the 
following 24 h. The medium was applied on 
a Proteome Profiler™ Human XL Cytokine 
Array. The immunoblot-based array (A, 
negative images shown) was quantified, 
and obtained pixel densities were plotted in 
respect to positive controls (B). The chart 
displays one assay with mean values of 
technical duplicates from selected proteins 
(1-7) in conditioned medium from AT-MSCs 
of one donor. 
The AT-MSCs secreted a variety of cytokines 
that showed influences by the presence of 
thrombin and PAR1-AP. We focused on the 
ones with potential tumor-promoting 
features. Especially, the secretion of IL-6, 
IL-8 and MCP-1 seemed to be influenced by 
PAR1-stimulation. 
 
 
Figure 3-13: AT-MSCs secrete various proteins with potential effects on tumor microenvironments 
AT-MSCs (donor #6) were seeded into 6-well plates, grown to a confluence of approx. 50 %, starved for 24 h, and fresh FCS-free medium was 
conditioned for the following 24 h. The medium was applied on Proteome Profiler™ Arrays for the analysis of angiogenesis-related proteins, 
proteases and cytokines. The duplicate spots for each detection of the immunoblot-based arrays were quantified, and the obtained mean 
pixel densities were plotted with respect to positive controls in order of decreasing intensity. Some proteins were present on two of the 
three arrays, but were listed separately. The chart displays the major secreted proteins detected in two separate conditioned medium 
preparations from one donor. The results were grouped according to the signal intensity with respect to positive control (PC): “+++” more 
than 75 % of PC; “++” 25 till 75 % of PC; “+” 5 till 25 % of PC; proteins with lower secretion not shown. Highlighted in black bars are proteins 
of further interest, which are potential tumor promoters and partially showed influences by PAR1 stimulation (shown in Figure 3-14). 
The analyzed AT-MSCs secreted a variety of extracellular matrix proteins, proteases, growth factors and immunoregulatory proteins, in 
general, a set of proteins that can potentially promote tumor environments by enhanced angiogenesis and growth. Among the proteins that 
were present on two of the three arrays (e.g. serpin E1, VEGF, angiogenin), quantitative rather than qualitative differences were observed 
between the two batches of conditioned medium from one donor.  
 
 
 
Among those presented proteins in Figure 3-14, the spots for the detection of IL-6, IL-8 and MCP-1 
caused stronger signals when incubated with supernatants from PAR1-stimulated AT-MSCs than with 
conditioned medium from untreated AT-MSCs. Therefore, the impact of PAR1 on the secretion of these 
cytokines by AT-MSCs was further verified by qPCRs and ELISAs. 
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3.4.3 PAR1 mediates increase in IL-8, IL-6 and MCP-1 expression in AT-MSCs 
The activation of PAR1 in AT-MSCs indicated the enhancement of the basal secretion of IL-6, IL-8 and 
MCP-1 (Figure 3-14). These events might be due to the upregulation of the expression of their 
respective mRNAs. Therefore, we performed mRNA expression analyses of IL-6, IL-8 and MCP-1 mRNA 
in AT-MSCs, which were treated with increasing concentrations of thrombin and PAR1-AP for 24 h. 
Furthermore, we assessed the impact of the PAR1 antagonist Atopaxar on their mRNA expression. The 
cells were pre-incubated with Atopaxar for 40 min, and it was present throughout the 24 h of 
stimulation. The results are presented in Figure 3-15. 
 
 
 
The treatment with thrombin caused a significant upregulation of IL-6, IL-8 and MCP-1 mRNA, with no 
apparent dose-dependence for the used concentration range. IL-6 mRNA expression was enhanced up 
to 20-fold, IL-8 mRNA up to five-fold, and MCP-1 mRNA up to seven-fold. No increase in expression by 
treatment with 2 NIH U/ml thrombin was observed with prior Atopaxar incubation.  
In some cases, PAR1-AP stimulated a significant two- to threefold increase in the IL-6, IL-8 and MCP-1 
mRNA expression. No increase in expression was observed for MCP-1 and IL-6 mRNA for the 
stimulation with 260 µM PAR1-AP and prior treatment of 0.1 µM Atopaxar. However, in the cases of 
pre-treatment with 0.1 µM Atopaxar for IL-8, and pre-treatment with 1 µM Atopaxar for MCP-1 and 
IL-8, a mean upregulation of mRNA expression was observed. This might hint at off-target effects at 
Figure 3-15: Effect of 24 h PAR1 
activation on the fold change of IL-6, 
IL-8 and MCP-1 mRNA expression in 
AT-MSCs  
AT-MSCs (donors #3 and 7) were 
stimulated with thrombin and PAR1-AP for 
24 h, followed by qPCR of IL-6, IL-8 and 
MCP-1 mRNA. Bars depict mean values ± 
SD of technical qPCR triplicates from two 
to seven separate experiments.  
Stimulation of PAR1 with thrombin or 
PAR1-AP in AT-MSCs caused a significant 
upregulation of IL-6, IL-8 and MCP-1 gene 
expression. Pre-treatment with the PAR1 
antagonist Atopaxar seemed to prevent 
the observed mRNA upregulation in 
frequent cases, especially for 0.1 µM 
Atopaxar. ***/°°°p-value ≤ 0.001, **/°°p-
value ≤ 0.01, *p-value ≤ 0.05 versus 
untreated control (stars) or respective 
samples without antagonist (circles). 
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higher Atopaxar concentrations. Since 0.1 µM Atopaxar was consistently abrogating the effect of both 
PAR1 agonists, this concentration was used for further analyses.   
3.4.4 AT-MSCs secrete IL-6 and IL-8 
Given the stimulation of mRNA expression of IL-6, IL-8 and MCP-1 by PAR1 stimulation in AT-MSCs 
(Figure 3-15), it appeared plausible that this should also lead to enhanced protein synthesis, and thus 
the secretion of these cytokines into the surrounding culture medium. This was already indicated by 
the preliminary analysis with the proteome arrays (Figure 3-14). Therefore, we followed up the analysis 
using commercially available ELISA systems that allow a multitude of assays at a reasonable price. Such 
ELISA systems were only readily available for IL-6 and IL-8, and therefore, the analyses were limited to 
these cytokines.  
The AT-MSCs for the following assays were cultured in 6-well plates, starved for 24 h, and conditioned 
in the presence of thrombin or PAR1-AP over the following 24 h. Inhibitors and antagonists were pre-
incubated prior to conditioning.   
3.4.4.1 AT-MSCs secrete IL-6 and IL-8 in larger amounts than Hep3B cells 
In order to grasp the basal amount of secreted IL-6 and IL-8 by AT-MSCs, we examined the secretion 
of these cytokines via specific ELISA arrays and referred them to the amount of total cell protein that 
was present during the time of secretion.  
The AT-MSCs of two analyzed donors secreted approx. 1.5 pg IL-6/µg protein, and 2 pg IL-8/µg protein 
over 24 h (Figure 3-16). Since MSCs are under investigation for targeted cellular therapy of various 
diseases including malformations of the liver, cells from the HCC cell line Hep3B served as a reference 
in order to comprehend the secreted amounts of IL-6 and IL-8. As further seen in Figure 3-16, the 
Hep3B cells hardly secreted any IL-6 and approx. only one-third of the amount of IL-8 as the AT-MSCs.  
As a consequence, MSCs would presumably contribute larger amounts of IL-6 and IL-8 to an HCC 
microenvironment than Hep3B cells themselves. 
 
 
Figure 3-16: Absolute secretion of IL-6 and IL-8 by AT-MSC and Hep3B cells over 24 h 
AT-MSCs (donors #6 and 8) and Hep3B cells were cultured in 6-well plates and grown up to 
approx. 50 % confluence, followed by 24 h starvation. Medium was replaced with fresh, FCS-
free culture medium and left on the cells for 24 h. The concentrations of IL-6 and IL-8 in the 
supernatant were analyzed by specific ELISAs and the cell protein concentrations of respective 
wells were determined. Bars depict mean values ± SD of technical duplicates from two to four 
separate experiments, showing absolute secretion of IL-6 and IL-8 per amount of total cell 
protein.   
AT-MSCs secreted larger amounts of IL-6 and IL-8, compared to Hep3B cells. 
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3.4.4.2 PAR1 mediates increase in IL-6 and IL-8 secretion by AT-MSCs 
Our experiments showed that PAR1 activation led to an increase in mRNA expression of IL-6 and IL-8 in 
AT-MSCs (Figure 3-15). Furthermore, we showed that AT-MSCs actually secreted those cytokines and 
that PAR1 stimulation in AT-MSCs possibly affected their secretion (Figure 3-14 and Figure 3-16). 
Building up on these data, we performed further assays to verify the initial secretion data.  
 
The AT-MSCs were cultured in the 
presence of increasing concentrations of 
thrombin and PAR1-AP. In addition, we 
included increasing concentrations of the 
PAR1 antagonist Atopaxar. Initial data 
was collected for IL-6 only since PAR1 
stimulation in AT-MSCs led to a strong 
upregulation of its mRNA up to 25-fold. 
Hence, we assumed a stronger impact of 
PAR1-stimulation on IL-6 secretion than 
on IL-8, thereby making it presumably a 
better system to assess agonists and 
antagonist concentrations in initial 
experiments. As seen in Figure 3-17, 
thrombin and PAR1-AP enhanced the 
secretion of IL-6 in a concentration-
dependent manner, while pre-treatment with Atopaxar seemed to hamper this effect in frequent 
cases. Considering the results of Figure 3-15 and Figure 3-17 together, a thrombin activity of 
1 NIH U/ml and a PAR1-AP concentration of 260 µM were assumed most effective for these 
experiments and were applied in further assays. Additionally, 0.01 µM Atopaxar seemed to antagonize 
the PAR1-mediated increase in IL-6 secretion sufficiently. 1 µM Atopaxar exerted adverse effects in 
more frequent cases in the assays. 
 
The stimulation of PAR1 with thrombin or PAR1-AP in AT-MSCs was shown to stimulate mRNA 
expression and secretion of IL-6 and IL-8 (Figure 3-15, Figure 3-17). Moreover, these agonists triggered 
a PAR1-mediated increase in [Ca2+]i (Figure 3-3, Figure 3-4). In order to assess the importance of the 
PAR1-stimulated Ca2+ pathway on the cytokine secretion by AT-MSCs, we treated the cells with the 
PAR1 antagonist Atopaxar and the Ca2+ chelator BAPTA-AM prior to conditioning of the culture 
medium, which have been shown to attenuate PAR1-triggered Ca2+ release in AT-MSCs in our Ca2+ 
 
 
Figure 3-17: Influence of Atopaxar on the relative secretion of IL-6 by 
AT-MSCs upon PAR1 activation 
AT-MSCs (donors #3, 6 and 8) were cultured in 6-well plates and grown up to 
approx. 50 % confluence, followed by 24 h starvation. Medium was replaced 
with fresh EM6F and left on the cells for 24 h. 40 min of incubation with several 
concentrations of Atopaxar (Ato) were carried out prior to stimulation with 
different concentrations of thrombin and PAR1-AP. IL-6 content of supernatant 
was measured with specific ELISAs and plotted in relation to control samples 
of each experiment. Bars depict mean values ± SD of technical duplicates from 
two to five separate experiments.   
Stimulation of AT-MSCs with thrombin and PAR1-AP caused increased 
concentrations of secreted IL-6 in AT-MSC supernatants (black bars). Pre-
treatment with PAR1 antagonist Atopaxar seemed to prevent observed 
enhanced secretion in frequent cases (gray bars).  
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assays (Figure 3-5, Figure 3-6).  Moreover, Ca2+ affects the central Ca2+-dependent downstream 
effector protein kinase C (PKC), which is involved in the regulation of expression and secretion (Hilfiker 
& Augustine 1999; Kang 2014). PKC was inhibited by prior treatment with BIM-1. The results are 
presented in Figure 3-18. 
 
 
 
Figure 3-18: Influence of Atopaxar, BAPTA-AM and BIM-1 on the relative secretion of IL-6 or IL-8 by AT-MSCs upon PAR1 
activation 
AT-MSCs (donors #3, 6 and 8) were cultured in 6-well plates and grown up to approx. 50 % confluence, followed by starvation for 24 h. 
Subsequently, the culture medium was replaced with fresh EM6F. Prior to stimulation with thrombin or PAR1-AP, 40 min of incubation with 
Atopaxar (Ato) and several concentrations of BAPTA-AM and BIM-1 were carried out. The conditioned medium was collected after 24 h. The 
IL-6 and IL-8 content of the supernatant were measured with specific ELISAs. Bars depict mean values ± SD of technical duplicates of two to 
eleven assays in relation to unstimulated control of respective assays. ***/°°°p-value ≤ 0.001, °°p-value ≤ 0.01, °p-value ≤ 0.05 versus 
untreated control (stars) or respective stimulations without antagonist (circles). 
Stimulation of AT-MSCs with thrombin and PAR1-AP caused a significant enhancement of IL-6 and IL-8 concentrations in AT-MSC supernatants 
versus unstimulated control (black bars). Pre-treatment with PAR1 antagonist Atopaxar, Ca2+ chelator BAPTA-AM and PKC inhibitor BIM-1 
attenuated the observed enhanced secretion in a concentration-dependent manner.  
 
The stimulation of AT-MSCs with thrombin or PAR1-AP led to a significant enhancement of IL-6 
secretion by up to 1.5- till 3.5-fold. While the PAR1 antagonist Atopaxar showed no effect on basal 
secretion rate, it significantly attenuated the stimulation by both activating agents. 
The Ca2+-chelating agent BAPTA-AM and the PKC inhibitor BIM-1 reduced basal IL-6 secretion as well 
as the elevated IL-6 secretion in response to the PAR1 agonists in a concentration-dependent manner. 
The secretion pattern of IL-8 was found to be quite similar to the one of IL-6. While thrombin and 
PAR1-AP generated an up to a four-fold enhancement of IL-8 secretion compared to basal levels, this 
effect was completely abolished by Atopaxar. BAPTA-AM as well as BIM-1 caused a concentration-
dependent attenuation of PAR1-stimulated secretion of IL-8. 
 
Although the impact of PAR1-stimulation on the mRNA expression of IL-6 and IL-8 in AT-MSCs was 
already assessed in paragraph 3.4.3 (page 56), we conducted further expression analyses to correlate 
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Figure 3-19: Effect of PAR1 activation on IL-6 
and IL-8 mRNA levels in AT-MSCs 
The AT-MSCs (donors #6 and 8) from the ELISAs 
(Figure 3-18) were analyzed for fold changes in IL-6 
and IL-8 mRNA expression using qPCR. Bars depict 
mean values ± SD of technical triplicates of eight 
assays in relation to unstimulated control of 
respective assays. ***p-value ≤ 0.001, **/°°p-value 
≤ 0.01, °p-value ≤ 0.05 versus untreated control 
(stars) or respective stimulations without 
antagonist (circles). 
Stimulation with thrombin or PAR1-AP caused a 
significantly increased expression of IL-6 mRNA in 
AT-MSCs, while pre-treatment with Atopaxar 
attenuated this effect significantly. No significant 
change was observed for the IL-8 expression. 
However, the trend was similar to IL-6.  
directly the secretion data shown in Figure 3-18 with the expression of the respective cytokines in 
AT-MSCs. Figure 3-19 shows the mRNA expression analyses of samples from the ELISA analyses in 
Figure 3-18. 
 
 
 
 
 
As seen in Figure 3-19, PAR1 stimulation with thrombin or PAR1-AP significantly increased the IL-6 
mRNA expression, which in turn was significantly attenuated by Atopaxar. However, thrombin exerted 
an increase in expression of up to six-fold, while PAR1-AP exerted an increase of up to three-fold only. 
The data for IL-8 were rather inconsistent and not significant for the analyzed number of samples, but 
the trend appeared to be similar to IL-6.  
3.5 Assessment of the interaction of AT-MSCs and Hep3B cells at in vivo 
conditions and impact of PAR1 
MSCs provide a valuable source for a cell-based therapy of damaged and cirrhosis-affected liver 
parenchyma. Though MSCs tend to support the curation of liver failure and cirrhotic liver through their 
paracrine activity, which favors limitation of inflammation and support of self-renewal and 
proliferation (Zhang & Wang 2013), their impact on cancerous cells remains unclear. Our experiments 
pointed out a biological relevance of PAR1 activation for biologic features of AT-MSCs, including the 
enhanced expression and secretion of regulatory cytokines. This paracrine activity could potentially 
support tumor progression. Hence, we employed a murine in vivo xenotransplantation model in order 
to assess the impact of AT-MSCs on cells from the HCC cell line Hep3B. Moreover, we generated a PAR1 
knockdown in AT-MSCs to analyze PAR1’s impact on the xenograft tumor growth. 
3.5.1 Generation of a PAR1 gene knockdown in AT-MSCs 
For additional assessment of PAR1’s relevance for the biological features of AT-MSCs, we applied 
shRNA technology to deplete the cells of PAR1. Since we used primary MSCs, it was an open question 
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if the required lentiviral delivery of shRNA and selection of depleted cell pools would be possible with 
the concomitant maintenance of MSC properties. 
The knockdown protocol was carried out according to paragraph 2.4.4 (page 33), including the 
treatment with PAR1-shRNA mounted lentiviruses and following the selection of successfully 
transduced AT-MSCs with puromycin over 48 h. Figure 3-20 A shows the effects of five out of nine 
available PAR1-shRNA clones provided by Sigma that were tested for their PAR1 knockdown efficiency 
in AT-MSCs. Compared to non-target shRNA, clone number 5 (Clone ID: NM_001992.x-2152s1c1) 
yielded the best knockdown levels, with a remaining PAR1 expression of 17 %. 
 
 
 
The lentivirus-mediated transduction had no apparent negative effect on the AT-MSCs. Furthermore, 
approx. 50-80 % of the cells survived the selection with puromycin, thus being successfully transduced. 
In the following period of culture expansion, the AT-MSC proliferation occurred slower than before the 
selection process. In addition, the general cell size of adherent AT-MSC-nt and AT-MSC-PAR1KD was 
larger than AT-MSC-wt (not shown). Therefore, a proportion of the cells was analyzed with flow 
Figure 3-20: mRNA and flow cytometry scatter analyses of genetically modified AT-MSC-nt and AT-MSC-PAR1KD 
A: AT-MSCs were lentivirally transduced with different plasmids containing shRNA to knockdown PAR1. Remaining PAR1 levels were 
quantified with qPCR and compared to AT-MSCs that were transduced with control shRNA (non-target, nt). The bars represent mean values 
± SD of technical triplicates from one assay. The knockdown for clone #5 is representative for two separate assays. 
The best stable knockdown of PAR1 in AT-MSCs was achieved with Sigma’s PAR1 shRNA clone number 5 (clone ID: NM_001992.x-2152s1c1).  
B: Suspended AT-MSCs were analyzed with flow cytometry to acquire scatter data that correlate with relative-size (forward scatter, FSC) and 
cell complexity (side scatter, SSC) of the cells. Data for AT-MSC-wild type (wt), AT-MSC-non-target (nt) and AT-MSC-PAR1knockdown (KD) 
were plotted as histograms (B) and dot plots (C). 
The FSC of AT-MSC-nt and AT-MSC-PAR1KD did not change during the transduction protocol compared to AT-MSC-wt, thus showing no 
apparent change in cell volume/size. However, SSC, which hints on granularity, showed increases compared to AT-MSC-wt. 
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cytometry analyses before they were employed for the in vivo xenotransplantation studies (paragraph 
3.5.2).   
The flow cytometry technique is based on suspended cells that pass through a laser beam. The beam 
gets refracted by passing cells, which causes light diffusion at small and large angles. The magnitude 
of diffused light depends on cell properties and is detected and grouped as forward scatter (FSC, small 
angle scatter) and side scatter (SSC, large angle scatter). SSC hints on complex structures inside the 
cells, like granules. The FSC is a sign for the relative size of the cells. Both are proportional to the 
particular cell characteristics (Picot et al. 2012). Figure 3-20 B clarifies that the FSC remained 
unchanged for the transduced AT-MSCs, but the whole cell populations of the modified cells showed 
slightly increased SSCs, compared to wild type AT-MSCs. Therefore, the size of the modified cells, in 
terms of volume, was apparently not changed. Moreover, the overall cell distributions in the scatter 
plots showed a similar pattern for all three AT-MSC-entities (Figure 3-20 C).  
3.5.2 Co-injection of AT-MSCs and Hep3B cells enhances tumor formation in a 
subcutaneous xenograft SCID mouse model – PAR1 gene knockdown in 
AT-MSCs has no significant effect on tumor formation 
The treatment of cirrhosis- or HCC-affected patients comprises various techniques with good prognosis 
at early tumor stages and poor prognosis at late stages. MSCs may provide an alternative tool to cure 
completely late-stage liver diseases like cirrhosis. But, the development of HCC might occur 
simultaneously and beneath the limits of detection. Moreover, the impact of MSCs on tumor cells is 
uncertain and cancer-inhibiting as well as cancer-promoting effects through the paracrine activity of 
MSCs were described.    
Our goal was to assess the interaction of AT-MSCs and cells from the HCC cell line Hep3B under in vivo 
conditions. Since we found the enhanced paracrine activity of AT-MSCs after PAR1 stimulation, the 
second question was whether PAR1 in AT-MSCs contributes to the stimulation of Hep3B cell 
proliferation.  
The HCC cell line Hep3B readily generates tumors upon xenotransplantation into severe combined 
immunodeficiency (SCID) mice. To test the effect of potential MSC-HCC cell interactions, Hep3B cells 
were subcutaneously co-injected with AT-MSCs into SCID mice, and the tumor formation was 
monitored. Genetically modified AT-MSCs bearing the PAR1 knockdown, as described in paragraph 
2.4.4 (page 33), were also included to assay the possible influence of PAR1. 
 
Figure 3-21 presents all the in vivo results of tumor growth experiments done in SCID mice. The display 
comprises (1) the effect of AT-MSCs on Hep3B tumor growth in general, (2) the fate of the AT-MSCs 
during the onset of tumor formation, and (3) the influence of a PAR1KD in AT-MSC on Hep3B cell tumor 
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growth compared to a non-target (nt) control. The adjacent graphs show the mean volumes of each 
experimental group, which were calculated on the basis of obtained computed tomography (CT)-scans.  
 
(1) As seen in the tumor overview (Figure 3-21, A-D), Hep3B cells were occasionally able to 
generate tumors under the chosen conditions. Four out of nine injections of Hep3B cells 
caused the formation of tumors, which remained small, less than 10 mm³, and did not grow to 
a much larger size even when left longer inside the mice. 
The injection of AT-MSCs alone caused no formation of visible aberrant tissue. 
The co-injection of both cell types together resulted in each of the 13 cases in tumor growth. 
The tumor sizes did not seem to correlate with the duration of the experiment. After 16 days, 
the experiment B yielded the largest tumors of up to 150 mm³, while experiment D yielded 
tumors of comparable sizes, but after 24 days. 
 
Hep3B cells and AT-MSCs together caused large tumors. Even genetically modified AT-MSCs that had 
been treated with the transduction/knockdown protocol and were cultured in vitro for a total duration 
of four weeks were able to cause similar Hep3B cell tumor formations: 
 
(2) AT-MSCs labeled with a green fluorescent protein (GFP) vector resulted in all three cases in a 
tumor of similar size compared to tumors induced by injection of Hep3B cells and AT-MSC-wt 
cells (Figure 3-21, D).  
 
(3) The co-injection of Hep3B cells with AT-MSCs-nt caused tumor formation in eight out of twelve 
assayed mice, while Hep3B cells with AT-MSCs-PAR1KD caused tumor formation in nine out of 
twelve mice (Figure 3-21, C-E). Both co-injections caused small tumors as well as large tumors 
of similar sizes like the co-injections of Hep3B cells and AT-MSC-wt. Hence, the PAR1 
knockdown in AT-MSCs had no significant impact on the caused tumor volume, compared to 
non-target control. 
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Figure 3-21: Overview of all 
obtained tumors after subcutane-
ous injection of Hep3B cells and 
AT-MSCs into SCID mice 
100,000 Hep3B cells or/and 500,000 
AT-MSCs (donors #1, 6 and 7) were 
subcutaneously (co-)injected into the 
flank of male SCID mice. After 11-24 
days (d) the tumor formation was 
stopped and evaluated. White squares 
represent mice with no tumor 
formation. The charts on the right 
display the mean tumor volumes ± SD 
of the single groups of each 
experiment. 
The injection of Hep3B cells under the 
skin of SCID mice caused occasional 
small tumors in approx. half of the 
cases, otherwise no tumors. AT-MSCs 
alone caused no tumors. Both cell types 
together caused large tumors in all 
cases. The co-injection of Hep3B cells 
with modified AT-MSCs caused in 
frequent cases tumors of comparable 
sizes like the ones with wild type AT-
MSCs. However, not all injected mice 
grew tumors. The PAR1-KD did not 
seem to affect the tumor formation or 
progression, compared to non-target 
control.  
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The caused tumors of the Hep3B and AT-MSC xenotransplantation were further characterized by 
histologic analyses. The tumors were fixed and embedded in paraffin, sliced and analyzed with 
hematoxylin/eosin stain and specific antibodies for cytokeratins, alpha-smooth muscle actin (α-SMA) 
and Ki-67. The slides were digitalized and evaluated.  
 
The following panels show representative images of representative tumors for the groups (1) Hep3B 
and Hep3B + AT-MSC (Figure 3-22), (2) Hep3B + AT-MSC-GFP (Figure 3-23), and (3) Hep3B + AT-MSC-nt 
and Hep3B + AT-MSC-PAR1KD (Figure 3-24). In general, all of the obtained tumors showed similar 
patterns for all assayed stainings. Moreover, the tumors displayed typical features of the HCC. 
 
 
Figure 3-22: Tumor formation 24 days after subcutaneous injection of Hep3B cells or Hep3B cells + AT-MSCs into the flank 
of SCID mice 
100,000 Hep3B cells and 500,000 AT-MSCs were injected under the skin of SCID mice alone or in combination. After 24 days, the formed 
tumors were imaged with a CT scan, the affected skin was removed, and the tumors were isolated (top row of each panel, left to right). 
Afterward, they were sliced and histologically stained with HE stain, and primary antibodies for detection of cytokeratin, α-SMA and Ki-67 
(cross sections and magnified areas). Representative tumors and images are shown.  
Hep3B cells occasionally caused small tumors. AT-MSCs caused no tumors (not shown). The co-injection of Hep3B cells and AT-MSCs caused 
tumors in all cases. All tumors resembled HCC tissue with vesicular tumor cells in a macro-trabecular arrangement (HE). The cells were of 
epithelial origin (cytokeratin), showed mitotic activity (Ki-67) and intense vascularization (macroscopic and α-SMA). Note the formation of 
typical intratumoral necrosis (black arrows).  
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(1) , (2) and (3) Before the tumors were removed from the murine skin, the angiogenesis was 
evaluated. Almost all of the tumors showed major angiogenic activity. As seen on the 
macroscopic pictures of Figure 3-22, Figure 3-23 and Figure 3-24, the tumors were surrounded 
by one to three clearly visible vessels. The unaffected murine skin was of pale reddish-white 
color with no highlighted red vessels.  
The HE stainings showed tumor cells that were arranged in a macro-trabecular structure. In 
the normal liver, hepatocytes form single-cell-thick plates/trabeculas, which are separated by 
fenestrated capillaries (sinusoids). HCC forms characteristic micro- and macro-trabecula with 
two to ten and more cell layers. The trabecular pattern is more clearly visible in the cytokeratin 
staining images. Further HCC characteristics that were frequently found in the tumors 
comprised large vesicular nuclei and accented nucleoli, a general pathologic nucleus-plasma 
ratio, basophilic tumor plasma, and mitotic figures. These features indicate open phase nuclei 
with prominent DNA synthesis and gene expression that are characteristic for highly 
proliferative cells. (Bavle 2014; Paradis 2013; Pathpedia e-Atlas 2015). 
Especially the larger tumors and some of the smaller ones showed central necrotic areas with 
infiltrated granulocytes and cell debris.  
The staining with a cytokeratin-targeted antibody resulted in strong stainings throughout the 
tumor. Cytokeratins are expressed by hepatocytes, like all other epithelial cells (Karantza 
2011), thus proving the epithelial origin of the tumor cells and highlighting the macro-
trabecula. The observed staining differences of the large tumors on the right of Figure 3-22 
and Figure 3-24 resulted from uneven stainings. The brighter areas still showed positive 
cytokeratin staining. 
Α-SMA is a marker for myoepithelial cells, smooth muscle cells and myofibroblasts and is used 
for the detection of vessels (Skalli et al. 1989). Although MSCs express α-SMA at low levels and 
only in the minority of cells in an MSC population (Hung et al. 2006; Tamama, Sen, & Wells 
2008), our stainings were strongly α-SMA-positive throughout the tumors. Therefore, it implies 
a network of cells with a strong α-SMA expression that originate from surrounding tissue, since 
the tumor margins show stronger stainings, hence showing the presence of a multitude of 
capillary vessels throughout the tumor tissue. 
Ki-67 is a protein that is specifically found in mitotic cells and is a validated marker for 
proliferative cells (Scholzen & Gerdes 2000). All obtained tumors showed positive Ki-67 
stainings throughout the viable tumor tissue. Note that the necrotic areas showed no staining 
with this marker. 
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(2) As already mentioned, all tumors were highly proliferative and resembled HCC tissue by 
showing characteristic HCC-like features and epithelial origin (Figure 3-23). In order to 
determine the fate of the co-injected AT-MSCs, we performed co-injections of Hep3B cells with 
GFP-labeled AT-MSCs. Though tumor formation and histological stainings were similar to the 
other tumors with wild type AT-MSCs, essentially, no GFP-labeled AT-MSCs were found in the 
tumor tissues after 24 days (not shown). This implies that the GFP-labeled AT-MSCs were no 
longer present in the formed tumor tissue. Therefore, the underlying growing cells were 
presumably cells of the HCC cell line Hep3B. 
 
 
 
 
 
 
 
 
Figure 3-23: Tumor formation 24 days after 
subcutaneous injection of Hep3B cells + AT-MSC-GFP 
into flank of SCID mice 
AT-MSCs were transduced with GFP (AT-MSC-GFP). 100,000 
Hep3B cells and 500,000 AT-MSC-GFP were injected under 
the skin of SCID mice and caused formation of tumors. After 
24 days, the formed tumors were imaged with a CT scan, the 
affected skin was removed and the tumors were isolated 
(top row of each panel, left to right). Afterward, they were 
sliced and histologically stained with HE stain, and primary 
antibodies for detection of cytokeratin, α-SMA and Ki-67 
(cross sections and magnified areas). Representative tumors 
and images are shown. 
The co-injection of Hep3B cells with AT-MSC-GFP caused 
tumors that resembled HCC tissue with vesicular tumor cells 
in a macro-trabecular arrangement (HE). The cells were of 
epithelial origin (cytokeratin), showed mitotic activity (Ki-67) 
and intense vascularization (macroscopic and α-SMA). Note 
the formation of typical intra-tumoral necrosis (black 
arrows).  
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(3) The co-injection of Hep3B cells with either AT-MSC-nt or AT-MSC-PAR1KD led to frequent 
formations of tumors with no apparent impact of the PAR1 knockdown in AT-MSCs on the 
tumor volume. The histological stainings showed similar features and staining patterns 
throughout the tumor tissues for Hep3B + AT-MSC-nt and Hep3B + AT-MSC-PAR1KD and were 
similar to Hep3B and Hep3B + AT-MSC-wt tumors (Figure 3-24). As described before, all 
stainings resembled HCC-like features. Thus, there was presumably no impact of AT-MSC’s 
PAR1 on the overall Hep3B tumor formation on neither tumor volume nor histological features. 
 
 
 
Figure 3-24: Tumor formation 24 days after subcutaneous co-injection of Hep3B cells + AT-MSC-nt or Hep3B cells + AT-
MSC-PAR1KD into the flank of SCID mice 
AT-MSCs were transduced with a non-targeting control (AT-MSC-nt) or PAR1 knockdown shRNA (AT-MSC-PAR1KD). 100,000 Hep3B cells 
and 500,000 AT-MSCs of either transduction were injected under the skin of SCID mice and caused tumors in frequent cases. After 24 days, 
the formed tumors were imaged with a CT scan, the affected skin was removed and the tumors were isolated (top row of each panel, left 
to right). Afterward, they were sliced and histologically stained with HE stain, and primary antibodies for detection of cytokeratin, α-SMA 
and Ki-67 (cross sections and magnified areas). Representative tumors and images are shown. 
The co-injection of Hep3B cells with AT-MSC-nt or AT-MSC-PAR1KD caused tumors in frequent cases, but with rather inconsistent sizes 
among each group. All tumors resembled HCC tissue with vesicular tumor cells in a macro-trabecular arrangement (HE). The cells were of 
epithelial origin (cytokeratin), showed mitotic activity (Ki-67) and intense vascularization (macroscopic and α-SMA). Note the formation of 
typical intra-tumoral necrosis (black arrows). No correlation of the PAR1 knockdown in AT-MSCs with tumor formation was observed in the 
applied co-injection mouse model. 
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4 Discussion 
Mesenchymal stem cells (MSCs) secrete a variety of growth factors, angiogenic and immunoregulatory 
proteins that make them potentially suitable for the curative treatment of tissue diseases. Clinical 
research includes liver diseases as one target for MSC-guided cellular therapy, but liver diseases like 
hepatitis or cirrhosis may potentially lead to the formation of hepatocellular carcinoma (HCC). The 
progression of HCC has been shown to be promoted by proteinase-activated receptors (PARs) 
(Kaufmann et al. 2007, 2009; Mußbach et al. 2014). Moreover, liver diseases like cholangiocarcinoma 
and liver fibrosis were shown to be promoted by PARs, too (refer to paragraph 1.3.3, page 14). In 
conclusion, PARs might exert impacts on other liver cell entities as well, like liver stem cells and 
exogenously inoculated MSCs. MSCs as means of therapy would add a locally large amount of 
exogenous cells to diseased microenvironments harboring a variety of PAR-activating proteinases from 
various sources (Mason & Joyce 2011). However, the expression of PARs in MSCs and the influence of 
PAR activation on the biological features of MSCs and paracrine effects on surrounding cell entities, 
especially tumor cells, have not been characterized yet and were of keen interest to our research. 
4.1 PAR1 is the predominantly expressed PAR subtype in human AT-MSCs 
The expression of PARs in MSCs has not been part of detailed investigations in the literature so far. 
Rasmussen et al. showed in a semiquantitative analysis the expression of PAR2 in adipose tissue-
derived MSCs (AT-MSCs) of three different donors and its localization on the plasma membrane using 
immune fluorescence (Rasmussen et al. 2012). Chen et al. demonstrated PAR1 and less PAR2 expression 
in bone marrow-derived MSCs (BM-MSCs) from two donors using semiquantitative PCR, while PAR3 
and PAR4 were not detected (Chen et al. 2014b).  
Using AT-MSCs of eight different donors, we could show in qPCR-based analyses that PAR1 was 
predominantly expressed while PAR2 was expressed at lower levels (Figure 3-2 A, page 38). Though the 
PAR3 expression was low, it was apparently still higher than the expression of PAR2. PAR4 was only 
detected in marginal amounts. The PAR1 levels seemed to vary among the analyzed donors over a wide 
range, but there were no obvious correlations between these variations and age or gender. 
Nevertheless, further analyses of additional donors are necessary to assess correlations of PAR1 levels 
with donor gender and age.  
Although PAR1’s expression seemed to vary among the analyzed donors, the expression ratio of the 
receptor subtypes remained constant for each donor, when plotted in relation to respective controls 
(Figure 3-2 B, page 38). To exclude that this ratio was simply based on unequal efficiencies of the 
applied subtype-specific primer pairs, they were verified in qPCRs of a dilution series of cDNA that was 
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pooled from several cell entities. The used primers performed with sufficient linear efficiencies of more 
than 90 % (Figure 3-1, page 37).  
 
The differential PAR subtypes expression was further assessed by Ca2+ assays. The stimulation of PARs 
causes an increase in the intracellular free Ca2+ concentration, hence giving feedback on their presence 
and functionality in the cells. The PAR subtypes were stimulated with their canonical activating 
proteinases thrombin (PAR1, PAR3 and PAR4) and trypsin (PAR2). Subtype-specific activating peptides 
(APs) were employed to distinguish between the particular receptors. 
As presented in Figure 3-3 (page 39), thrombin exerted an activation of the AT-MSCs resulting in a 
strong Ca2+ release inside the cells, seen as an increase in Ca2+-binding fluorophore Fluo-4-AM. The 
PAR1-AP resulted in a similar Ca2+ signal over time. The PAR4-AP was unable to trigger a Ca2+ effect in 
the cells, consistent with the very low expression detected by qPCR. No additional PAR3 experiments 
were carried out since available PAR3 subtype-specific activating peptides cross-activate PAR1 and PAR2 
(Hansen, Saifeddine, & Hollenberg 2004). Since our expression data showed that PAR4 was minimally 
expressed by AT-MSCs and PAR1 was expressed in significantly larger amounts than PAR3, thrombin 
presumably exerted the majority of its impact via PAR1.   
Trypsin as a major PAR2 activator exerted a weaker Ca2+ effect than thrombin, and the cells were not 
responding at once but rather in short peaks, distributed over a long time until all cells responded. The 
PAR2-AP peptide also triggered a short increase in the intracellular free Ca2+ concentration, but only in 
a few cells, while the majority did not respond at all. The weak Ca2+ signals caused by stimulation with 
trypsin and PAR2-AP might be due to PAR2’s low expression, which we described above. However, 
trypsin triggered a weak but overall stronger effect than the PAR2-AP. This effect might be due to 
trypsin’s potential to act via PAR1 as well. PAR1 can be activated by pancreatic trypsin isoforms at low 
rates (Grishina et al. 2005; Knecht et al. 2007; Salameh & Radisky 2013). The applied trypsin in our 
experiments derived from bovine pancreas (Sigma, cat. no. T1426) and resembled a cocktail of trypsin 
isoforms. 
In order to distinguish thrombin’s actions more thoroughly, we conducted further Ca2+ analyses and 
applied subsequent PAR activations and the PAR1-specific antagonist Atopaxar. The subsequent 
stimulation makes use of that PARs get internalized after their activation (Ramachandran & Hollenberg 
2008; Soh et al. 2010). Therefore, subtype-specific PAR1 activation would deplete the plasma 
membrane of PAR1 and thus leaving behind the other subtypes.  
As seen in Figure 3-4 (page, 40) PAR1-AP was able to cause a Ca2+ signal in AT-MSCs. The subsequent 
stimulation with thrombin was unable to cause another major Ca2+ signal. In other words, the 
stimulation with PAR1-AP caused a depletion of PAR1 on the plasma membrane of the AT-MSCs. The 
4 Discussion 
71 
subsequent stimulation with thrombin had almost no effect, supporting the data of the absence or low 
expression of other thrombin targets. 
These findings were supported by assays including the pre-treatment with Atopaxar (Figure 3-5, page 
42). Atopaxar was able to abolish obtained Ca2+ mobilizations for PAR1-AP and thrombin in a 
concentration-dependent manner. Under the premise of Atopaxar’s specificity for PAR1, this would 
underscore PAR1’s sole responsibility for Ca2+ mobilization upon activation by thrombin in AT-MSCs. 
Currently, general extensive in vitro research on Atopaxar is lacking, and it was reported that it exerts 
minor off-target effects by weakly inhibiting ADP- and collagen-induced platelet activation (Serebruany 
et al. 2009). Hence, Atopaxar might not exclusively target PAR1. However, Atopaxar showed strong 
abolishing effects on PAR1-AP’s actions, and thus provides a valuable antagonist for characterizing 
PAR1’s actions in vitro.  
 
Taken together, our expression and functional analyses of the PAR subtypes indicate that PAR1 is the 
predominantly expressed PAR subtype in AT-MSCs and that it is the major subtype to cause an 
intracellular Ca2+ signal in AT-MSCs upon treatment with thrombin.  
 
 
In order to verify PAR1’s presence on the protein level, we performed immunoblots and the freeze-
fracture replica immunolabeling technology with the PAR1-specific primary antibodies WEDE15 
(Beckman Coulter) and ATAP2 (Santa Cruz Biotechnology). 
The application of the PAR1 antibody WEDE15 was described in several publications by the Trejo group 
(Lin & Trejo 2013; Soto et al. 2015) and revealed a molecular weight of glycosylated PAR1 at approx. 
70 kDa, and 38 kDa for deglycosylated PAR1 (Soto & Trejo 2010). Their immunoblots were obtained 
from PAR1-enriched eluates of lysates of cells overexpressing PAR1. We employed whole cell lysates of 
AT-MSCs and detected bands with molecular weights at approx. 38, 48 (and 60) kDa on the 
immunoblots (Figure 3-8, page 48). The life science companies Santa Cruz Biotechnology and Cell 
Signaling Technology claim a molecular weight of 47 kDa for unglycosylated PAR1 (Phosphosite.org 
2015) and 66 kDa for glycosylated PAR1. Our PAR1 immunoblots highlighted major bands at approx. 
48 kDa. Therefore, it is possible that the detected AT-MSC’s PAR1 has a lesser state of glycosylation as 
the model in the publications by the Trejo group. Intriguingly, their experiments with a PAR1 mutant, 
which lacked glycosylation at the extracellular loop two, showed a molecular weight of approx. 48 kDa. 
This mutant also exhibited increased Gαq-signaling compared to wild type/highly glycosylated PAR1. 
These findings might hint on an increased PAR1 signaling via the Gαq pathway and lesser signaling via 
Gα12/13 in AT-MSCs. 
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The ATAP2 antibody decorated more unexpected bands on PAR1 immunoblots and the expected one 
at 47 kDa was less pronounced compared to the other bands. Also, the WEDE15 antibody recognizes 
the WEDE sequence in the PAR1 N-terminal region, as depicted by Brass et al. (Brass et al. 1994), and 
is unaffected by receptor cleavage. Hence, we chose the WEDE15 antibody for detection of PAR1 on 
freeze-fracture replicas of AT-MSCs.  
The obtained electron microscopic images (Figure 3-9, page 49) of WEDE15-labeled freeze-fracture 
replicas of AT-MSCs showed single and grouped black dots on the exoplasmic face. The black dots were 
caused by gold particles, which obstruct the electron beam of the electron microscope. The gold 
particles were bound to secondary antibodies, which in turn detected the WEDE15 antibody. The 
control without WEDE15 caused no black dots. Therefore, the black dots are likely to represent the 
location of PAR1 on the AT-MSCs’ plasma membrane. The multiple dots might imply PAR1 homodimers 
as PAR1 is able to form receptor homodimers (Lin et al. 2013b).  
Our group has earlier shown PAR1 localization on the plasma membrane of HCC cells using the freeze-
fracture immunolabeling technique (Kaufmann et al. 2007). Moreover, PAR1’s plasma membrane 
localization and trafficking upon stimulation have been shown by fluorescence imaging by the Trejo 
group (Lin & Trejo 2013). 
4.2 PAR1 signaling in MSCs – AT-MSCs show high basal ERK phosphorylation 
As discussed above, our data clearly indicated that PAR1 is presumably the major PAR subtype in 
AT-MSCs to respond to the activation by proteinases. In general, PAR1 is described to signal mainly 
through Gαq and Gα12/13, and thus acts via Ca2+ signals and the activation of various kinases like 
extracellular-signal regulated kinase (ERK), Akt or Ras homolog gene family member A (RhoA) kinase 
(McLaughlin et al. 2005; Zhao, Metcalf, & Bunnett 2014). In order to characterize PAR1’s signaling in 
AT-MSCs, we conducted measurements of intracellular free Ca2+ elevation and immunoblot assays for 
activation of signaling proteins. 
As discussed in paragraph 4.1 (page 70), PAR1 agonists thrombin and PAR1-AP were able to enhance 
intracellular free Ca2+ levels, which was abolished by pre-treatment with the PAR1 antagonist Atopaxar. 
The PAR1-specific immediate and strong elevation of the intracellular free Ca2+ concentration could 
activate the MAPK pathway, which is a central signaling pathway for proliferation, apoptosis, 
differentiation and migration (Dhillon et al. 2007). Also, it could be demonstrated that PAR1 activation 
led to the activation of ERK via the Gαq protein subunit, which causes an increase in intracellular free 
Ca2+ levels and formation of diacylglycerol (DAG). Subsequent DAG and/or Ca2+-dependent protein 
kinase C (PKC)-mediated activation of rapidly accelerated fibrosarcoma kinase (Raf), proline-rich 
tyrosine kinase 2 (Pyk2) or transactivation of receptor tyrosine kinases like epidermal growth factor 
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receptor (EGFR) may ultimately lead to ERK activation (Gieseler et al. 2013; Wang & Reiser 2003; Wang 
et al. 2002). 
Therefore, we approached this complex issue by performing initial immunoblot assays of 
phosphorylated ERK (pERK). These experiments showed a strong phosphorylation of ERK upon PAR1 
activation with thrombin or PAR1-AP. However, repetitions of the assays revealed that the pERK signals 
in unstimulated controls were rather inconsistent in intensity by ranging from low to medium and 
frequently high pERK levels (Figure 3-10, page 50). Even though we attempted to optimize the 
experimental setup as much as possible, e.g. by usage of HEPES-buffered starvation/activation 
medium, the addition of stimulating agents in a larger volume to minimize stirring stress, and usage of 
a heating plate during the stimulation, the basal pERK level did not stabilize and seemed not to 
correlate with any of these factors. Even unstimulated controls from the same experiment differed 
without any obvious correlation while just standing on the heating plate for 1/5/10/20 min (not 
shown).  
There is one publication that described high basal ERK phosphorylation levels in human embryonal 
stem cells (ESC) and that high levels of pERK were important for keeping self-renewing characteristics. 
Moreover, this seemed to contrast with features of murine ESCs, which possessed low basal pERK 
levels (Li et al. 2007). According to our findings, it may be possible that the ERK signaling status is 
similarly high in human AT-MSCs as described for human ESCs. However, Chen et al. reported strong 
activation of ERK in human BM-MSCs upon stimulation with thrombin and mentioned no technical 
issues as encountered in the current study (Chen et al. 2014b). 
Hence, we cannot draw a firm conclusion on the ERK phosphorylation caused by PAR1 stimulation in 
the AT-MSCs. 
4.3 PAR1 mediates reduced migration rate of AT-MSCs but has no impact on 
their proliferation 
We showed that the activation of PAR1 in AT-MSCs exerted a strong transient elevation of intracellular 
free Ca2+ levels. Though we faced technical problems in addressing the PAR1 signaling in more detail 
(discussed in paragraph 4.2, page 72), the PAR1 activation was likely to result in biological responses of 
the AT-MSCs, eventually. Two major effects, which are of relevance for the MSC-guided cellular 
treatment of diseases, include migration and proliferation. MSCs were described to migrate towards 
inflamed tissues and cancers. Furthermore, when reaching the proximity of a diseased 
microenvironment, they might get stimulated to proliferate in order to repopulate the tissue.  
     
PAR1 activation was described to cause rearrangements of the cytoskeleton via the Gα12/13 pathway 
(Siehler 2009; Soh et al. 2010), and our group was able to demonstrate that PAR1 activation caused a 
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promotion of migration of colon carcinoma and HCC cells (Heider et al. 2004; Mußbach et al. 2014). 
Since we found PAR1 to be predominantly expressed in AT-MSCs, PAR1 might also affect the migratory 
behavior of AT-MSCs. In general, systemically administered MSCs seem to possess a high potential for 
homing to inflamed tissue sites like wounds and cancers along gradients of inflammatory mediators 
(Reagan & Kaplan 2011; Rustad & Gurtner 2012). Cancers are a source of activated coagulation 
proteins, and might, therefore, affect the PARs of MSCs and thus their local migration (ten Cate & 
Falanga 2008).  
To address the migration of AT-MSCs in response to PAR1-stimulating agents, the cells were seeded 
into reusable migration chambers and were allowed to migrate for 16 h. After that, they were fixed 
and counted. Our experiments affirmed the strong general ability of MSCs to migrate. As shown in 
Figure 3-11 (page 51), up to 30 % of initially seeded AT-MSCs were migrating through a polycarbonate 
membrane at serum-free control conditions. In comparison, only 0.1 % of a population of the HCC cell 
line Hep3B were migrating in a similar set up as previously published by our group (Mußbach et al. 
2014). As further shown in Figure 3-11, the stimulation of PAR1 in AT-MSCs led to a significantly 
reduced migration rate of AT-MSCs towards both thrombin and PAR1-AP. These findings might add to 
the understanding of MSC’s homing to cancer tissues. When MSCs approach tumors, they might get 
activated via PAR1. Chen et al. showed that PAR1 activation caused an increase in expression and 
secretion of fibronectin and enhanced the MSC’s adhesion in vitro (Chen et al. 2014b). The enhanced 
adhesion might explain the reduced rate of migration that we observed. These PAR1-mediated effects 
might limit the migration of MSCs towards various factors, which were shown to attract and activate 
MSCs and to stimulate their settlement at tumor sites. (Sun, Wang, & Zhao 2014). 
Unfortunately, we were not able to verify the reduction of migration by stimulation of PAR1 with 
AT-MSCs from another donor. The AT-MSCs’ basal rate of migration (not shown) differed between the 
donors, thus making it difficult to apply the protocol on another batch without prior extensive 
adjustment and optimization of seeded cell counts. Furthermore, the amount of migrated cells of one 
donor differed between the single assays. These issues might be resolved by further verification of the 
observed reduced migration via other versions of the Neuroprobe chamber or scratch/barrier assays. 
 
 
The proliferation rate of AT-MSCs upon stimulation with PAR1-activating compounds was assessed with 
a variety of experimental conditions. Control experiments ensured that alterations in proliferation 
could be reliably detected by the used assays. However, no or only a minor enhancement of the 
AT-MSCs’ proliferation rate was observed when several concentrations of thrombin and PAR1-AP were 
applied (Figure 3-12, page 52). The authors of a recent publication (in Chinese) claimed in their English 
abstract that thrombin enhanced the proliferation of BM-MSCs in vitro, especially at higher thrombin 
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concentrations with a maximum at 8 U/ml. They observed an enhanced proliferation at a minimum of 
0.5 U/ml (Chen et al. 2014a). We, however, applied concentrations of 1 NIH U/ml and also a maximum 
of 5 NIH U/ml (not shown), but no significant effects of PAR1 activation on AT-MSCs were observed. 
Although Chen et al.’s and our employed proliferation assays were both based on the metabolic activity 
of viable cells, a repetition with more sensitive proliferation assays measuring DNA synthesis may 
verify these findings. 
4.4 PAR1 activation in AT-MSCs stimulates the secretion of pro-angiogenic 
factors 
Apart from their multipotent character, MSCs possess the pre-eminent property to secrete a plethora 
of proteins with substantial effects on surrounding tissues. The secretion of various growth factors, 
immunoregulatory proteins, extracellular matrix-related proteins and proteinases, and angiogenesis-
related proteins make MSCs and other stem cell entities potentially a valuable resource for therapeutic 
purposes. However, the amount and variety of secreted proteins may differ between stem cells from 
different origins and different interacting tissue microenvironments, which they may encounter by 
means of migration or direct injection at the site of interest. (Hass & Otte 2012; Laird, von Andrian, & 
Wagers 2008; Liang et al. 2014).  
Therefore, we assessed the secretion properties of the AT-MSCs from our experiments and further 
characterized the impact of PAR1 on the expression and secretion of AT-MSC-derived proteins. 
 
To get an overview of the proteins and factors that were secreted by primary human AT-MSCs, 
immunoblot-based arrays were performed using culture supernatant of AT-MSCs. One-third of the 
potentially array-traceable proteins was detected in 24 h-conditioned media (Table 3-1, page 54). 
Among others, multiple proteins that are known for their direct or indirect angiogenic, mitogenic or 
migration-promoting properties were detected: angiogenin, angiopoietin 1, angiopoietin 2, 
hepatocyte growth factor (HGF), Interleukin 6 (IL-6), IL-8, monocyte chemotactic protein 1 (MCP-1) 
and vascular endothelial growth factor (VEGF).  
Though we were able to analyze only one batch of cells for the complete panel of proteins detectable 
by the array, our data supports previously published data from other groups, which used human 
BM-MSCs from several donors. Park et al. showed in a similar approach that IL-6, IL-8, MCP-1 and VEGF 
were secreted in larger amounts, also tracing tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) 
and HGF. However, they did not mention the timespan of medium conditioning (Park et al. 2009). 
Schinköthe and colleagues did not detect IL-6, but also showed the presence of angiopoietin 2, MCP-1, 
IL-8, HGF, TIMP-1 and VEGF. Their protocol included a conditioning over three days (Schinköthe, Bloch, 
& Schmidt 2008). Hsiao et al. compared BM-MSCs with AT-MSCs and also found IL-6, IL-8, MCP-1, 
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angiogenin and VEGF in the media with no distinct differences for those proteins among the two 
entities. However, they also conditioned the culture media over three days and additionally 
concentrated the media by 50-fold (Hsiao et al. 2012). 
Apart from the protocols of conditioning, the covered proteins, and the MSCs’ origin, these data 
collectively show that AT-MSCs are a source of IL-6, IL-8, MCP-1, VEGF, HGF and probably 
angiopoietins. However, our data and the published data from the mentioned groups were 
quantifications of immunoblot-based methods. The comparison of the resulting intensities with each 
other implies that certain proteins were secreted in larger proportions than others. But, the 
specificities and detection sensitivity of underlying primary antibodies for over hundreds of proteins 
are most likely not similar, and data from Table 3-1 (page 54) and discussed literature should only serve 
as an incentive for further detailed analyses. 
 
It was beyond the scope of this dissertation to discuss the possible biological relevance of all the 
detected proteins, which were secreted by AT-MSCs. However, a few, which caused particularly strong 
signals on the proteome arrays, implying extensive secretion by the AT-MSCs, shall be highlighted. 
These include Serpin E1, matrix metalloproteinase 2 (MMP-2) and MMP-1. These proteins could serve 
as interesting targets in further MSC/tumor research since they were described to favor thrombosis, 
intravasation, and metastasis of tumors. Serpin E1 (also known as plasminogen activator inhibitor 1, 
PAI-1) is an inhibitor of fibrinolysis and promotes thrombosis and scarring (Ghosh & Vaughan 2012). 
MMP-2 degrades basement membranes and provides a basis for angiogenesis, and has been shown to 
be elevated in various cancers leading to poor prognosis (Bauvois 2012; Nussenbaum et al. 2010). 
MMP-1 is involved in extracellular matrix degradation and is an activator of PAR1, which might support 
PAR1’s actions on MSCs and promote tumor metastasis (Arakaki, Marques, & Santos 2009; Juncker-
Jensen et al. 2013). 
In the following sections, we will focus on proteins whose secretion was affected by PAR1 stimulation. 
 
Among those detected proteins we sought to identify the ones that are affected by stimulation of PAR1. 
To this end, we stimulated AT-MSCs with thrombin and PAR1-AP over 24 h. The conditioned 
supernatant was then compared to medium from untreated AT-MSCs. As displayed in Figure 3-14 
(page 55), especially IL-6, IL-8 and MCP-1 showed a putative influence of PAR1 activation on their 
secretion since they were secreted in larger amounts by AT-MSCs in the presence of thrombin and 
PAR1.  
As a consequence, our first goal was to analyze the impact of PAR1 activation on the mRNA expression 
of IL-6, IL-8 and MCP-1, which would presumably result in their enhanced secretion. Hence, we 
performed qPCRs of multiple AT-MSC batches that were cultured in the presence of thrombin or 
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PAR1-AP for 24 h. The mRNA expression analyses revealed that IL-6, IL-8 and MCP-1 were indeed 
strongly influenced by PAR1 activation (Figure 3-15, page 56). In general, thrombin significantly 
elevated their expression by up to five to 20-fold. PAR1-AP enhanced the mRNA expression of IL-6, IL-8 
and MCP-1 by 1.5- to 4-fold. The pre-treatment with PAR1 antagonist Atopaxar caused an attenuation 
of PAR1-mediated elevation of mRNA expression. Though PAR1 activation seemed to cause constantly 
the elevation of mRNA expression for these proteins, we obtained, however, quite large standard 
deviations. In some assays, responses to PAR1 activation were only weak, which might have been 
caused by too late time points of analysis for the particular cell batch, and therefore perhaps already 
declined PAR1 effects. The kinetics of the PAR1-mediated stimulation of IL-6, IL-8 and MCP-1 mRNA 
expression needs further characterization in future research.  
A link between PAR1 activation and the upregulation of cytokine expression was previously reported 
for several other cell entities by other researchers. The results for IL-6 and IL-8 will be discussed in the 
subsequent paragraphs. An increased expression of MCP-1 upon thrombin and PAR1-AP stimulation 
was shown for monocytes, vascular smooth muscle cells and human umbilical vein epithelial cells 
(Brandes et al. 2001; Colotta et al. 1994; Marin et al. 2001). Kawawani et al. showed an increased 
MCP-1 secretion and the involvement of RhoA kinase in this response, thus implying a Gα12/13-
dependent thrombin-PAR1 signaling (Kawanami et al. 2011). Furthermore, MCP-1 was found to 
increase the migration of murine and human BM-MSCs (Boomsma & Geenen 2012; Dwyer et al. 2007).  
Taken together, our results suggest that the thrombin-PAR1 axis might play an important role for 
AT-MSCs in thrombotic microenvironments, by triggering enhanced MCP-1 expression and presumably 
enhanced secretion. MCP-1, in turn, could lure even more MSCs and other monocytes to the affected 
tissue.  
 
PAR1 mediates the elevation of IL-6 and IL-8 protein amounts in AT-MSC supernatants 
Prompted by the results of the antibody arrays and the mRNA expression assays, we performed further 
experiments to assess the production and secretion of IL-6 and IL-8 with specific ELISAs. Unfortunately, 
we were not able to include MCP-1 in further analyses, since there were no suitable ELISAs available 
at this time.  
 
As already discussed above, the stimulation of PAR1 in AT-MSCs caused an enhanced expression of IL-6 
and IL-8 mRNA. The upregulation of cytokine expression was expected to result in an increased 
secretion, thus causing elevated concentrations in AT-MSC supernatants. Indeed, the stimulation of 
AT-MSCs with thrombin or PAR1-AP for 24 h led to elevated concentrations of IL-6 and IL-8 in their 
supernatant growth medium (Figure 3-17, page 58; Figure 3-18, page 59). As seen in Figure 3-18, 
thrombin exerted a significant up to four-fold and PAR1-AP a significant up to three-fold increase in the 
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IL-6 or IL-8 concentration in the supernatant growth medium of AT-MSCs after 24 h. For both cytokines, 
the elevation was attenuated by PAR1 antagonist Atopaxar, the Ca2+ chelator BAPTA-AM and the PKC 
inhibitor BIM-1. Therefore, our data suggest a major impact of PAR1 on the secretion of IL-6 and IL-8 
by AT-MSCs. Furthermore, intracellular free Ca2+ and Ca2+-dependent PKC seem to be involved in 
conveying PAR1’s signals onto elevated secretory actions.  
As will be discussed in the following paragraphs, recent publications described multiple PAR1 
downstream effectors of several signaling pathways that were found to contribute to the PAR1-
mediated IL-6 and IL-8 expression and secretion events. We applied MAPK/ERK kinase (MEK), 
phosphatidylinositide 3-kinase (PI3K), EGFR and platelet-derived growth factor receptor (PDGFR) 
inhibitors (not shown), but with no obvious correlations on cytokine secretion after two assays. As the 
results tended to vary between every assay, additional experiments might point out contributions of 
these proteins for the underlying signaling.   
 
Furthermore, we analyzed the IL-6 and IL-8 expression in the underlying AT-MSCs of these ELISAs, in 
order to draw conclusions about the correlation of the secretion data and mRNA expression. As seen 
in Figure 3-19 (page 60), IL-6 showed a significant enhancement of expression of about six-fold for 
thrombin and three-fold for PAR1-AP mediated PAR1 activation. In the presence of Atopaxar, these 
effects were significantly attenuated. Though the expression data for IL-8 were not significant, the 
PAR1 stimulation caused an enhanced IL-8 expression in most of the cases with a change of up to six-
fold for thrombin or three-fold for PAR1-AP, and again Atopaxar attenuated the expression elevation. 
Hence, these data imply that the PAR1 activation-caused enhanced expression and presumably de novo 
synthesis of IL-6 and IL-8 contributes to the elevated concentrations in the culture supernatant. 
Regarding the literature, it is known that thrombin and PAR1-APs upregulate the expression and 
secretion of IL-8 in macrophages, fibroblasts and epithelial cell lines in a concentration-dependent 
manner. Involved are PKC, RhoA and PI3K pathways to activate nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB)- and activator protein (AP-1)-mediated transcription of IL-8 (Lin 
et al. 2013a; Ludwicka-Bradley et al. 2000; Scholz et al. 2004; Zheng & Martins-Green 2007). Studies 
with MSCs reported the secretion of IL-8 by human umbilical cord-derived MSCs and AT-MSCs with an 
autocrine enhancement of proliferation and IL-8 secretion (Jeon et al. 2013), and a paracrine 
promotion of IL-8 secretion and migration and metastasis of breast cancer cells (Ma et al. 2015). In 
addition, Hou et al. have shown the autocrine stimulation of VEGF secretion by IL-8 in BM-MSCs (Hou 
et al. 2014).  
Similar results were published for IL-6. Thrombin, and if applied, PAR1-APs too, triggered increased IL-6 
expression and secretion in MSCs (De Luca et al. 2012; Ma et al. 2015), fibroblasts (Shin et al. 1999; 
Tanaka et al. 2004), epithelial cells (Marin et al. 2001; Scholz et al. 2004), vascular smooth muscle cells 
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(Tokunou et al. 2001), osteoblasts (Kozawa et al. 1997), mast cells (Gordon et al. 2000) and T cells (Li 
& He 2006). Some of these studies identified mediating signaling molecules including PKC, p38, ERK, 
RhoA, PI3K, NF-κB, cAMP response element-binding protein (CREB) and the transactivation of EGFR as 
downstream effectors of thrombin-induced activation (Kozawa et al. 1997; Scholz et al. 2004; Shin et 
al. 1999; Tanaka et al. 2004; Tokunou et al. 2001). In addition, these studies revealed that IL-6 was 
elevated in co-cultures of MSCs and cancer cell lines (So et al. 2015), IL-6 exerted a promotion of 
migration and metastasis of breast cancer cells (Ma et al. 2015), and IL-6 enhanced VEGF secretion by 
BM-MSCs (Herrmann et al. 2011). 
Tanaka et al. pointed out that the enhanced secretion of IL-6 upon PAR1 activation seems rather due 
to enhanced de novo synthesis than the initial release of internally stored IL-6. They also claimed that 
BAPTA-AM had no effect on the secretion profile of IL-6 after 24 h, which stands in contrast to our 
assays. However, they removed the BAPTA-AM-containing medium after pre-treatment for 1 h, while 
it was present throughout the whole assay in our cases. BAPTA-AM is able to permeate into the cells, 
and one could imagine that present BAPTA-AM molecules are saturated after the initial thrombin-
induced activation and might not attenuate the Ca2+ signal over longer time. Another group that 
analyzed the involvement of PKC and Ca2+ were Kozawa et al. They reported that TMB-8, a PKC inhibitor 
and Ca2+ antagonist, was able to reduce secreted IL-6 upon thrombin stimulation (Kozawa et al. 1997). 
These observations imply a general Ca2+ dependency and thus PAR1’s actions via Gαq. Our Ca2+ assays 
displayed almost no elevation of the intracellular free Ca2+ concentration upon PAR1 activation at the 
highest applied concentration of BAPTA-AM (Figure 3-6, page 45), but a minor enhancement of 
cytokine secretion was still achieved in the ELISAs (Figure 3-18, page 59). As shown by McLaughlin et 
al., abrogation of intracellular Ca2+ signaling by BAPTA-AM was not affecting PAR1’s actions via Gα12/13 
(McLaughlin et al. 2005). Therefore, a minor contribution via Gα12/13 to the PAR1-stimulated cytokine 
secretion may be possible. 
 
All these observations point out an autocrine and paracrine activity of MSCs via IL-6 and IL-8, which 
are likely to contribute to favorable conditions for cancer cells. The treatment of diseased tissues with 
MSCs would bring the stem cells in proximity of active inflammation, coagulation and tissue 
remodeling, thus presumably causing PAR1 activation in MSCs. As discussed above, this would cause 
enhanced expression and secretion of IL-6 and IL-8 by MSCs. The impact of these potent cytokines 
might cause beneficial or adverse effects on selected cell populations and processes and might favor 
curing diseased tissue. Cancerous cells that might occur in the liver during the progression of hepatitis, 
alcoholic liver diseases, cirrhosis and others can lead to the formation of HCC. Adding MSCs to these 
aberrant microenvironments would contribute an additional source of IL-6 and IL-8, and might cause 
unforeseeable effects on the HCC cells and the affected microenvironments.  
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In order to fathom the amounts of secreted cytokines that originate from MSCs, we correlated the 
concentrations of IL-6 and IL-8 from AT-MSC supernatants with the amount of total cellular protein, 
which was present during the conditioning of the medium, and compared the results to the values of 
cells from the HCC line Hep3B. As displayed in Figure 3-16 (page 57), we could show that AT-MSCs 
secreted a basal amount of about 1-2 pg IL-6 or IL-8 per µg of cells. Hep3B cells themselves hardly 
secreted IL-6 and approx. one-third of the IL-8 as the same amount of AT-MSCs.  
So what would this larger amount of cytokines deriving from MSCs mean for Hep3B cells? Effects of 
IL-8 and IL-6 on Hep3B cells and other HCC cell lines were reported in several publications. Both 
cytokines have been shown to decrease sensitivity to potent anti-cancer drugs like doxorubicin. The 
expression of IL-8 and its receptor in HCC cells was shown to be increased by those drugs. Also, the 
knockdown of IL-8 showed a reduced proliferation in vitro and in vivo, as well as reduced expression 
and secretion of VEGF, EGF and HGF. Conditioned media of HCC cells with an IL-8 knockdown also 
exerted reduced potency to cause angiogenesis of human umbilical vein endothelial cells. (Choi et al. 
2014; Liu et al. 2010; Park et al. 2009). 
 
In conclusion, HCC cell lines are already generating self-stimulating microenvironments to favor their 
proliferation and survival, also by supporting surrounding angiogenesis. Adding MSCs into this context 
might increase the pool of angiogenic and anti-apoptotic cytokines that in turn will be promoted by 
the present coagulate microenvironment. 
4.5 AT-MSCs promote Hep3B cell tumor formation at initial stages without 
the involvement of PAR1 in a subcutaneous xenotransplantation SCID 
mouse model  
The characterization of PAR1 in AT-MSCs revealed that the stimulation of PAR1 had a strong impact on 
the expression and secretion of IL-8 and especially IL-6. MCP-1 and other regulatory proteins might 
also be affected, although this has not been further investigated apart from initial overview analyses 
with antibody arrays. As discussed in paragraph 4.4 (page 78), IL-8 and IL-6 were reported to exert 
crucial impacts on HCC cell lines by favoring survival through pro-angiogenic and anti-apoptotic 
processes. Since clinicians intend to use MSCs as means of cellular therapy of e.g. diseased liver tissue, 
a direct or indirect interaction of MSCs and HCC cells may occur. Basal and stimulated secretion of a 
plethora of proteins by MSCs may provide complex stimuli and promote tumor growth. Hence, we 
assessed this complex issue with a xenograft tumor model in severe combined immunodeficiency 
(SCID) mice. 
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Immunodeficient mice were injected with the HCC cell line Hep3B or AT-MSCs alone, or with both cell 
types together. The cells were subcutaneously injected into the flank of the mice and tumor growth 
was analyzed after 11-26 days. The assays (Figure 3-21, page 64) revealed (I) a weak potency of 100,000 
Hep3B cells to occasionally form tumors, (II) no potency of 500,000 AT-MSCs to form tumors, and that 
(III) the co-injection of Hep3B cells and AT-MSCs caused a strong formation of tumors in all assayed 
mice. 
 
In this model that we employed for our investigations, the overall ability of Hep3B cells to form tumors 
was rather weak. Four out of nine mice showed tumor formation, and there was only a small difference 
in size between the tumors after eleven or after 26 days. Hep3B cells were frequently applied in 
xenograft tumor studies previously, but in most of the studies 5-10 Mio cells were injected, that is 50-
100 times more cells than we applied in our experiments (Ryan et al. 2004; Tang et al. 2010; Tian et al. 
2014; Zhao et al. 2013). However, these kinds of studies were intended to test conditions for reducing 
tumor formation. For our experiments, the small amount of Hep3B cells, which displayed a weak tumor 
formation ability, was well-suited in the combination with AT-MSCs. The presence of AT-MSCs 
increased the tumor formation ability of Hep3B cells drastically. All co-injections caused tumors with a 
much larger volume than the injections of Hep3B cells alone. The injections of AT-MSCs alone were 
not able to form tumors. 
Histologically the ‘Hep3B cell-AT-MSC tumors’ resembled the structures of the Hep3B cell tumors. They 
showed typical features of HCC tissue, e.g. macro-trabecular structures, vesicular nuclei and 
pronounced nucleoli, mitotic figures, basophilic cytoplasm, and intratumoral necrotic areas. Also, the 
tumors showed positive Ki-67 stainings, which revealed a high proliferative character of the tumors. 
The tumors were also positive for cytokeratins, which are secreted by epithelial cells. Hep3B cells 
derive from aberrant hepatocytes, which are, unlike MSCs, epithelial cells. In addition, the tumors 
showed vessel formation on the inner mouse skin towards the tumor, and the tumor tissue was highly 
positive for alpha-smooth muscle actin (α-SMA), especially at the tumor margins. Α-SMA is a marker 
for myoepithelial cells, smooth muscle cells and myofibroblasts and thus hints at the presence of 
vessels (Skalli et al. 1989). Though there is some literature data on the α-SMA expression in MSCs, they 
reported only low expression levels of α-SMA and only approx. 15 % of an MSC population were 
positive for α-SMA in immunocytochemical stainings (Hung et al. 2006; Tamama, Sen, & Wells 2008). 
Therefore, it seems unlikely that the α-SMA stainings of our experiments represented the AT-MSCs 
since we were not able to detect them in the tumors of assays with green fluorescent protein (GFP)-
labeled MSCs, which will be discussed later. Also, the higher distribution of α-SMA-positive cells at the 
tumor margins implies increasing protrusion/formation of new vessels from the surrounding 
microenvironment into the tumor. 
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At least under the applied conditions of the co-injection of 100,000 Hep3B cells and 500,000 AT-MSCs, 
the AT-MSCs seemed to favor the formation of a Hep3B cell tumor.  
 
Since MSCs are capable of differentiating into a variety of cell lineages, it generates the question of 
whether they contributed to the Hep3B cell tumor formation in some way. The injection of MSCs alone 
revealed no growth of a tumor beneath the murine skin after 11-26 days. Hence, it seems that the 
AT-MSCs did not survive the in vivo assay or got incorporated into the murine tissue without a trace. 
Also, incorporation or fusion with surrounding Hep3B cells could occur in the co-injection model, 
including taking over of epithelial characteristics. MSCs were demonstrated to fuse with liver tissue in 
transplantation models and Ferrand et al. showed that BM-MSCs took over epithelial characteristics 
of gastrointestinal epithelial cells in a co-culture model (Ferrand et al. 2011; Vassilopoulos, Wang, & 
Russell 2003; Wang et al. 2003). However, engraftment of locally administered MSCs into host tissue 
was reported to make up 3.5 % of the total administered cells (Rustad & Gurtner 2012). Therefore, it 
is doubtful that most of the AT-MSCs would persist in the tumor in an either singular or fused state. 
Moreover, the complete trans-differentiation of the AT-MSCs into hepatocytes seems also doubtful, 
since direct co-cultures of Hep3B cells and AT-MSCs gave no rise to changes of the stem cells 
(unpublished data from the group of Prof. B. Christ, University Hospital Leipzig, Germany). 
The AT-MSCs’ contribution to the tumor via aberrations might be another potential source of tumor 
cells. There have been reports of spontaneous chromosomal aberrations of ex vivo cultured MSCs that 
led to stem cell-derived tumors in vivo. However, the observed events led to sarcoma formation in 
proximity to vascular smooth muscle cells or were mainly due to long-term cultured MSCs 
(Hatzistergos et al. 2011; Jeong et al. 2011). In our case, as will be discussed later, long-term-cultured 
and transduction protocol-exposed AT-MSCs led to a reduced tumor formation in the applied 
xenotransplantation model. 
 
The observed tumor formations raised the question of how AT-MSCs promoted Hep3B cells’ survival 
and proliferation. The Hep3B cells might have been favored by the presence of AT-MSCs in several 
ways. Both cell types were mixed and injected as a homogenous suspension underneath the skin of 
mice. Since the ratio was 5:1 AT-MSCs to Hep3B cells, it is imaginable that most of the Hep3B cells 
were surrounded by AT-MSCs. Most likely, this larger batch of cells prevented scattering of single 
Hep3B cells at the point of inoculation and might have kept the tumor cells closer together. This close 
contact with each other presumably favors the actions of the secreted factors from AT-MSCs and 
tumor cells, respectively. Though a direct action of conditioned AT-MSC media on Hep3B cells could 
not be shown at in vitro conditions (Winkler et al. 2015), secreted growth factors might still promote 
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Hep3B cell proliferation in vivo. The strong vascularization towards and inside the tumors indicated a 
well-organized angiogenesis in the tumor microenvironment.  
The AT-MSCs were shown to secrete a variety of angiogenesis-promoting and immunoregulatory 
factors like angiopoietin 1, VEGF, IL-8, IL-6 and MCP-1. As introduced in paragraph 1.2.3 (page 7) and 
discussed in paragraph 4.4 (page 78), these factors were frequently reported to promote autocrine 
and paracrine stimulations of HCC-cells and MSCs, as well as the induction of angiogenesis. Single 
tumor cells will need time and effort to overcome the initial lag phase to reach a stable tumor mass 
with sufficient oxygen supply. At this stage, the presence of MSCs might promote the Hep3B cells 
greatly by stimulating surrounding angiogenesis, limiting inflammation and supplying a variety of 
growth factors, extracellular matrix proteins and proteinases to establish a niche for tumor-initiating 
cells (Plaks, Kong, & Werb 2015). 
 
Summing up, it is worth to note that, under conditions of the employed in vivo mouse model, small 
numbers of Hep3B tumor cells were proliferating much better when surrounded by AT-MSCs. Events 
like this might occur when MSCs get inoculated into HCC-affected tissue as means of cellular therapy. 
Locally the ratio of MSCs and HCC cells will tend towards the MSCs, and few HCC cells might benefit 
from their new neighbors.  
We are the first to show these promoting effects of AT-MSCs on the in vivo proliferation of cells from 
the HCC cell line Hep3B. In a similar approach, Han et al. employed the subcutaneous co-injection of 
MSCs and the HCC cell line SMMC-7721 into mice. They observed minor contributions of MSCs to the 
HCC tumor growth but observed major contribution if the MSCs were pretreated with 
proinflammatory interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α). However, they did not 
mention the tissue origin of the MSCs and they employed twice as many MSCs and 60 times as many 
tumors cells. Hence, the number of tumor cells was five times larger than the number of MSCs, thus 
making it difficult to compare the results to our model due to significant differences in cell counts (Han 
et al. 2014). 
Yang et al. showed similar data for MSCs and gastric cancer cells. Their project was dedicated to 
investigating the interaction of macrophages and umbilical cord-derived MSCs and their impact on 
gastric cancer cells. They showed that the co-culture of MSCs with macrophages enhanced the 
expression and secretion of IL-6, IL-8, MCP-1, VEGF and others by MSCs, which we also detected in 
supernatants of AT-MSCs. Those macrophage-activated MSCs were able to promote tumor growth of 
gastric cancer cell and proliferation and migration of gastric epithelial cells. Unstimulated control MSCs 
were also able to increase tumor proliferation in vivo, but with less impact (Yang et al. 2014).  
Therefore, the attraction of monocytes to the tumor might be enhanced by MSCs, and the cytokine 
crosstalk between them and the tumor cells may contribute to the observed enhancement of tumor 
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growth in the presence of MSCs. This notion is supported by our data showing that MCP-1 was secreted 
by AT-MSCs (Figure 3-14, page 55) and that its expression was enhanced by PAR1 stimulation (Figure 
3-15, page 56). MCP-1 is a potent monocyte/macrophage attractor and will attract them to 
inflammation or tumor sites (Deshmane et al. 2009).  
 
AT-MSCs promote initial Hep3B cell tumor formation 
The subcutaneous co-injection of Hep3B cells and AT-MSCs into the flank of SCID mice caused a strong 
formation of tumors. The histologic stainings revealed the epithelial origin and HCC-like polygonal cells 
in a macro-trabecular pattern, thus implying a Hep3B cell-derived tumor mass. However, one question 
remained: What happens to the AT-MSCs during tumor formation? Unfortunately, stem cells do not 
bear single stem cell-specific markers to detect them specifically. Therefore, we labeled the AT-MSCs 
with green fluorescent protein (GFP) to trace their fate during tumor formation. Some publications 
stated that stem cells engraft into the liver tissue by cell fusion (Vassilopoulos, Wang, & Russell 2003; 
Wang et al. 2003). Hence, in the case of persisting AT-MSCs or fused AT-MSC-Hep3B cells, we should 
detect GFP in the sliced tumors. However, we did not detect green fluorescing cells in the otherwise 
well-formed tumors. Though this was only one approach, a similar xenotransplantation model was 
carried out by our collaborators from Leipzig, with no detection of GFP inside the tumor slices, apart 
from single green fluorescing fragments. Furthermore, our collaborators showed using in vitro co-
cultures that the Hep3B cells easily outgrow the AT-MSCs after a few days and limit their space for 
proliferation (Winkler et al. 2015). Therefore, it seemed plausible that the percentage of AT-MSCs 
would decrease over time in the arising tumor and perhaps proliferating Hep3B cells would limit the 
proliferation of the AT-MSCs, too. 
Based on the tumor volume and the hematoxylin and eosin staining of the presented tumor in Figure 
3-23 (page 67), we estimated how many AT-MSCs we could expect in a magnified area (0.1 mm²) like 
in the tumor panel if their count would stagnate and persist throughout the formation of the tumor. 
The particular tumor of Figure 3-23 had an average of approx. 18 nuclei/cells per 200 µm segment, 
which equals 5832 cells per 0.008 mm³ and approx. 48 Mio cells for the total tumor volume 
(66.16 mm³). If the 500,000 initially injected stem cells would have persisted until the day of the tumor 
removal, it would have meant that every 96th cell should be an AT-MSC within the displayed images. 
The area of the tumor cross-section was 5.6 mm² large, thus comprising approx. 45,360 cells in total, 
including 473 potential AT-MSCs. A magnified area (0.1 mm²) should, therefore, comprise around 8.5 
stem cells. 
Hence, for the case that the injected AT-MSCs were proliferating or, at least, surviving, we could expect 
some GFP signal. Perhaps, fixation issues might have caused damage to the GFP and its fluorescence 
emitting properties, thus leaving the cells invisible under the fluorescence microscope. The 
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immunohistochemical staining of the tumor slices with a GFP-targeting antibody could shed more light 
on this hypothesis. However, it might also be plausible that the AT-MSCs did not survive the tumor 
formation over 24 d. Therefore, the promotion of tumor formation might have been due to initial 
stimuli on the Hep3B cells and surrounding murine tissue, thus promoting angiogenesis and the 
formation of a favorable tumor niche and survival of the tumor cells. 
 
PAR1 gene knockdown in AT-MSCs has no significant effect on Hep3B cell tumor formation  
The enhanced Hep3B cell tumor formation under the presence of AT-MSCs may depend on paracrine 
stem cell-derived stimuli that affect the Hep3B cells and surrounding tissue. As discussed in the 
previous paragraphs, we were able to show for the first time that PAR1 activation in AT-MSCs caused 
an upregulation of MCP-1, IL-8 and IL-6 expression and secretion of especially the latter two. These 
cytokines are known to exert crucial impacts on in vivo tumor formations, hence making the effects of 
PAR1 activation in AT-MSCs potential tumor contributors.  
For the purpose of assessing the impact of PAR1 in AT-MSCs on the size of resulting Hep3B cell tumors 
at in vivo conditions, a protocol for knocking down PAR1 in AT-MSCs was established. The PAR1 
knockdown cells were then subcutaneously co-injected with Hep3B cells into the flank of SCID mice. 
Tumor formation was compared to co-injections with Hep3B cells and AT-MSCs, which were 
transduced with control non-target shRNA. 
The knockdown protocol included one passage and about two weeks of cell culture. No obvious 
aberrations and cell changes were observed during this process. As seen in Figure 3-20 (page 61), PAR1 
was knocked down to a remaining presence of approx. 17 % in AT-MSCs. For the purpose of generating 
a sufficient amount of cells for the in vivo studies, the total knockdown and expansion process required 
two passages and four weeks of culture. Over that time, the stem cells appeared larger, and the rate 
of proliferation decreased. We tested the cells with flow cytometry and the scatter data revealed that 
the relative cell volume of the transduced AT-MSCs did not change compared to wild type AT-MSCs. 
Apparently, the transduced cells were attaching and spreading more than their wild type counterparts. 
Nevertheless, the AT-MSC-PAR1KD (knockdown) and AT-MSC-nt (non-target) showed a shifted side 
scatter in the flow cytometry parameter, thus implying increased granularity or complexity of the cells. 
All of these observations could indicate the onset of cellular senescence (Muñoz-Espín & Serrano 
2014).  
The co-injection of Hep3B cells with AT-MSCs of either PAR1 knockdown or non-target control caused 
the formation of large, medium and small tumors of comparable sizes in most assayed mice. Some did 
not show any tumor formation. However, compared to the constant tumor formation obtained by the 
injection of Hep3B cells with wild type AT-MSCs, the lentivirally-guided modified AT-MSCs appeared to 
have a diminished ability to form tumors in general. These observations implied that the AT-MSCs 
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might have succumbed to the long in vitro transduction protocol, thus having a reduced impact on the 
tumor formation, and presumably did not contribute to the tumor by own aberrations as discussed 
earlier (page 82). Still, their potential was sufficient to promote Hep3B cell tumor formation with HCC-
like histologic characteristics in most of the assayed mice.  
After all, the obtained tumor volumes of this xenotransplant approach did not show a significant 
impact of the PAR1 knockdown in AT-MSCs on the Hep3B cell tumor formation, compared to the 
control group with the non-target control vector. However, this technique might not take into 
consideration that the non-target control AT-MSCs had a diminished impact on the tumor formation 
themselves, compared to the more consistent impacts of wild type AT-MSCs, which could overshadow 
minor impacts of PAR1. 
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5 Conclusions & Outlook 
Mesenchymal stem cells (MSCs) provide a valuable resource for the treatment of diseased tissues like 
chronic wounds or especially liver cirrhosis. However, inflammation- and coagulation-affected tissues 
produce proteinases that activate proteinase-activated receptors (PARs), which are insufficiently 
characterized in MSCs. In this context, we characterized the PAR family in adipose tissue-derived (AT)-
MSCs. Our results pointed out that PAR1 was the predominating PAR subtype in AT-MSCs. While PAR2 
and PAR3 were present and mediated weak responses in the cells, PAR4 was barely detected and might 
have no major impact on the AT-MSC’s biology. 
 
We showed that PAR1 played a crucial role in the 
upregulation of expression and secretion of interleukins 
(IL) 6 and 8 in AT-MSCs. Our data suggests a major 
dependence of the PAR1-elicited elevation on the 
intracellular free Ca2+ level and the Ca2+-dependent 
protein kinase C (PKC) for cytokine production and 
secretion. However, further detailed investigations are 
required to unveil the involved signaling cascades and to 
clarify to what extent the observed enhanced expression 
contributes to the elevated secretion of cytokines (Figure 
5-1).  
 
In consideration of employing MSCs as means of cell-
based therapy of hepatic diseases, we assessed the in 
vivo interaction of AT-MSCs with cells from the 
hepatocellular carcinoma (HCC) cell line Hep3B. We 
observed a strong promotion of tumor formation of 
Hep3B cells if they were subcutaneously co-injected with 
AT-MSCs into immunodeficient mice. The tumors 
resembled HCC characteristics and showed no signs of 
persisting AT-MSCs, thus hinting on a promotion of the tumor formation during early stages. Additional 
investigations with other HCC cell lines and variations of inoculated cell numbers of the two cell types 
may shed further light on the controversial issue of MSCs’ impact on tumor cells. Nevertheless, we 
found a plethora of potentially tumor-promoting factors in the supernatants of AT-MSCs. Since PAR1 
was found to promote the secretion of several factors, we hypothesized an influence of PAR1 in 
 
Figure 5-1: Schematic overview of PAR1’s actions 
in AT-MSCs 
The image summarizes the results of our PAR1 assays in 
AT-MSCs. Dashed lines represent hypothesized and 
elsewhere described signaling and may present 
interesting research targets for the future. 
PAR1 was found to represent the predominantly 
expressed PAR subtype in AT-MSCs. Stimulation with 
thrombin or PAR1-AP caused a strong elevation of the 
intracellular free Ca2+ concentration ([Ca2+]i), an elevated 
secretion of IL-6 and IL-8 into the supernatant growth 
medium, and an enhanced expression of IL-6, IL-8 and 
MCP-1. Those observations were attenuated by pre-
treatment with the PAR1 antagonist Atopaxar. Pre-
treatment with the Ca2+ chelator BAPTA-AM or the PKC 
inhibitor BIM-1 attenuated the amounts of secreted IL-6 
and IL-8.  
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AT-MSCs on the tumor formation model. However, the lentivirally-guided transduction of shRNA to 
knockdown PAR1 in AT-MSCs had no significant effect on the final tumor volume, compared to non-
target shRNA transduced cells. The transduction protocol might have caused detrimental effects on 
the AT-MSCs’ survival since both groups showed reduced abilities to form tumors. Hence, different 
approaches should be considered to verify the data. 
 
In conclusion, we provide data that may help to understand better the curative effects of MSCs for 
cirrhosis and liver failure. However, chronic liver diseases bear the chance of resulting in the formation 
of HCC beneath the level of detection at initial medical diagnosis. At these conditions, few tumor cells 
may benefit greatly from a larger amount of neighboring exogenous stem cells. Additionally, the 
activation of MSCs inside the tumor microenvironment might increase the secretion of potential tumor 
promoting factors, as described in the thesis and other publications. PAR1 might be one of the factors 
to contribute to the impact of MSCs on diseased tissue. 
6 Acknowledgements 
89 
6 Acknowledgements 
The time has come to thank all the authorities, minds, helping hands, and restless supporters that 
contributed to this work… 
 
My deep gratitude goes to the Deutsche Forschungsgemeinschaft (DFG) and Prof. U. Settmacher for 
supporting this research project and giving me the opportunity to work on it. 
No words mean to express my gratitude to Dr. R. Kaufmann and Prof. F. Böhmer, my guiding beacons 
of knowledge and wisdom, who always had a helping idea or soothing sense of humor when things 
went wrong or didn’t work out the way we expected.  
Thanks to the patients and the hospital in Leipzig that contributed the endless stem cells for making 
this research possible. Thank you, Prof. B. Christ, for the generous collaboration and courier services 
and for opening up this intriguing stem cell topic to our group and me. Thank you, Madlen and Sandra, 
for the continuous preparation of the cells, medium and information that I required, and the kind 
support in times of late and urgent requests. 
Thank you, Jörg and Annette for technical and theoretical support along the bench and lab work and 
for bringing so much culture, joy and activities into my life. 
Thanks to all the people that helped me realize the specialized assays: electron microscopy, Dr. 
Westermann, Beate; mice assays, Dr. Günther, Yvonne, Elke, Kathrin. You were amazing, and I couldn’t 
ask for any better support! Thank you, Prof. R. Heller, and her group for the continuous support, the 
opportunity for the side activity as a tutor and for drawing my attention to the vacant PhD position. 
Another big thank you goes to the ones making life easy in the lab, thank you Dorith, Manu and Ute 
for providing reliable and clean material.  
 
Thank you to all my fellow students and lab mates for making this period a time of scientific, cultural, 
culinary and humorous exchange. This time has been amazing!  
Franzi, my dearest colleague and courier between our labs, you were always there when I needed 
specific information and more material from the other lab at short notice. Your restless support, 
candor and sincerity made this project much easier and saved me lots of time and trouble. 
Thank you to my beloved friends and family for supporting me in all conditions of life, mood and 
matters. I couldn’t have done it without you!         
 
Thank you, धवाद, faleminderit, ευχαριστώ, merci, grazie, und einfach nur vielen Dank für die schöne 
Zeit ☺ 
 
Thank you for the cookies! 
7 List of figures 
90 
7 List of figures 
Figure 1-1: Basic concept of PAR1 signaling and research tools ....................................................................................................................... 12 
Figure 1-2: Hypothesis of the PAR-mediated impact of MSCs on the HCC microenvironment ........................................................................ 15 
Figure 3-1: Efficiency of primers used for PAR expression analyses ................................................................................................................. 37 
Figure 3-2: Expression levels of PARs in AT-MSCs ............................................................................................................................................ 38 
Figure 3-3: Intracellular Ca2+ response to stimulation of PARs in AT-MSCs ...................................................................................................... 39 
Figure 3-4: Subsequent stimulation of AT-MSCs with PAR1-AP and thrombin ................................................................................................. 40 
Figure 3-5: PAR1 antagonist Atopaxar reduces Ca2+ mobilization in AT-MSCs upon PAR1 activation with thrombin or PAR1-AP ..................... 43 
Figure 3-6: Intracellular Ca2+ response to PAR stimulation in AT-MSCs in presence of the Ca2+ chelator BAPTA-AM ...................................... 45 
Figure 3-7: Ca2+ chelator BAPTA-AM causes multiple internal changes in AT-MSCs’ morphology at a concentration of 10 µM ...................... 47 
Figure 3-8: Test of PAR1-specific antibodies ATAP2 and WEDE15 on AT-MSC lysates ...................................................................................... 48 
Figure 3-9: PAR1-immunolabeled freeze-fracture replica of the exoplasmic fracture face (EF) of AT-MSCs .................................................... 49 
Figure 3-10: AT-MSCs show inconsistent ERK phosphorylation upon PAR1 stimulation, probably due to high basal pERK levels ................... 50 
Figure 3-11: Stimulation of PAR1 reduces the migration rate of AT-MSCs ....................................................................................................... 51 
Figure 3-12: PAR1 stimulation has no significant effect on AT-MSC proliferation ............................................................................................ 52 
Figure 3-13: AT-MSCs secrete various proteins with potential effects on tumor microenvironments ............................................................ 55 
Figure 3-14: Overview of cytokines and growth factors secreted by AT-MSCs under the influence of PAR1 activation over 24 h ................... 55 
Figure 3-15: Effect of 24 h PAR1 activation on the fold change of IL-6, IL-8 and MCP-1 mRNA expression in AT-MSCs ................................... 56 
Figure 3-16: Absolute secretion of IL-6 and IL-8 by AT-MSC and Hep3B cells over 24 h .................................................................................. 57 
Figure 3-17: Influence of Atopaxar on the relative secretion of IL-6 by AT-MSCs upon PAR1 activation .......................................................... 58 
Figure 3-18: Influence of Atopaxar, BAPTA-AM and BIM-1 on the relative secretion of IL-6 or IL-8 by AT-MSCs upon PAR1 activation .......... 59 
Figure 3-19: Effect of PAR1 activation on IL-6 and IL-8 mRNA levels in AT-MSCs ............................................................................................. 60 
Figure 3-20: mRNA and flow cytometry scatter analyses of genetically modified AT-MSC-nt and AT-MSC-PAR1KD ....................................... 61 
Figure 3-21: Overview of all obtained tumors after subcutaneous injection of Hep3B cells and AT-MSCs into SCID mice .............................. 64 
Figure 3-22: Tumor formation 24 days after subcutaneous injection of Hep3B cells or Hep3B cells + AT-MSCs into the flank of SCID mice .. 65 
Figure 3-23: Tumor formation 24 days after subcutaneous injection of Hep3B cells + AT-MSC-GFP into flank of SCID mice .......................... 67 
Figure 3-24: Tumor formation 24 days after subcutaneous co-injection of Hep3B cells + AT-MSC-nt or Hep3B cells + AT-MSC-PAR1KD into 
the flank of SCID mice ...................................................................................................................................................................................... 68 
Figure 5-1: Schematic overview of PAR1’s actions in AT-MSCs ......................................................................................................................... 87 
8 List of tables 
91 
8 List of tables 
Table 2-1: Human AT-MSC batches .................................................................................................................................................................. 16 
Table 2-2: Analyzed characteristics of AT-MSCs ............................................................................................................................................... 16 
Table 2-3: Composition of AT-MSC growth medium EM6F .............................................................................................................................. 17 
Table 2-4: Protocol for cDNA synthesis ............................................................................................................................................................ 19 
Table 2-5: List of used primers for qPCR .......................................................................................................................................................... 20 
Table 2-6: Protocol for qPCR analyses.............................................................................................................................................................. 20 
Table 2-7: Reagents for calcium assays ............................................................................................................................................................ 21 
Table 2-8: Agents used for the investigation of PAR-mediated effects on intracellular calcium ...................................................................... 22 
Table 2-9: Lysis buffer composition ................................................................................................................................................................. 26 
Table 2-10: Buffers used for SDS-PAGE ............................................................................................................................................................ 26 
Table 2-11: Buffers used for immunoblotting .................................................................................................................................................. 27 
Table 2-12: Antibodies used for Immunoblotting ............................................................................................................................................ 28 
Table 2-13: Substrate solution for ELISAs......................................................................................................................................................... 30 
Table 2-14: Number of cells for Injection ......................................................................................................................................................... 31 
Table 2-15: F2R MISSION® shRNA bacterial glycerol stocks used for PAR1 knockdown ................................................................................... 33 
Table 2-16: Material for plasmid purification, transfection and transduction ................................................................................................. 33 
Table 2-17: Vectors used for transfection of HEK293T cells ............................................................................................................................. 35 
Table 2-18: Ratios of DNA for preparation of transfection .............................................................................................................................. 35 
Table 3-1: Proteins secreted by AT-MSCs into supernatant growth medium over 24 h................................................................................... 54 
 
9 References 
92 
9 References 
Adams DH, & Hubscher SG. (2006). Systemic Viral Infections and 
Collateral Damage in the Liver. The American Journal of 
Pathology, 168(4), 1057–1059. 
Adams MN, Ramachandran R, Yau M-K, Suen JY, Fairlie DP, 
Hollenberg MD, & Hooper JD. (2011). Structure, function 
and pathophysiology of protease activated receptors. 
Pharmacology & Therapeutics, 130(3), 248–282. 
Aden DP, Fogel A, Plotkin S, Damjanov I, & Knowles BB. (1979). 
Controlled synthesis of HBsAg in a differentiated human 
liver carcinoma-derived cell line. Nature, 282(5739), 615–
616. 
Ahmed M. (2015). Non-alcoholic fatty liver disease in 2015. World 
Journal of Hepatology, 7(11), 1450–1459. 
Ali SH, & DeCaprio JA. (2001). Cellular transformation by SV40 large 
T antigen: interaction with host proteins. Seminars in 
Cancer Biology, 11(1), 15–23. 
Al-Khafaji K, Mutyala M, Al-Khafaji N, Harper Y, Ismail I, Hakim H, 
& Arora RR. (2015). Protease-Activated Receptor 1 
Inhibitors: Novel Antiplatelet Drugs in Prevention of 
Atherothrombosis. American Journal of Therapeutics. 
Arakaki PA, Marques MR, & Santos MCLG. (2009). MMP-1 
polymorphism and its relationship to pathological 
processes. Journal of Biosciences, 34(2), 313–320. 
Aravalli RN. (2010). Progress in stem cell-derived technologies for 
hepatocellular carcinoma. Stem Cells and Cloning : 
Advances and Applications, 3, 81–92. 
Attwa MH, & El-Etreby SA. (2015). Guide for diagnosis and 
treatment of hepatocellular carcinoma. World Journal of 
Hepatology, 7(12), 1632–1651. 
Aurich I, Mueller LP, Aurich H, Luetzkendorf J, Tisljar K, Dollinger 
MM, … Christ B. (2007). Functional integration of 
hepatocytes derived from human mesenchymal stem 
cells into mouse livers. Gut, 56(3), 405–415. 
Baer PC, & Geiger H. (2012). Adipose-derived mesenchymal 
stromal/stem cells: tissue localization, characterization, 
and heterogeneity. Stem Cells International, 2012, 
812693. 
Bauvois B. (2012). New facets of matrix metalloproteinases MMP-2 
and MMP-9 as cell surface transducers: Outside-in 
signaling and relationship to tumor progression. 
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 
1825(1), 29–36. 
Bavle RM. (2014). Eosinophilic nucleoli. Journal of Oral and 
Maxillofacial Pathology : JOMFP, 18(2), 152–154. 
Bayo J, Marrodán M, Aquino JB, Silva M, García MG, & Mazzolini 
G. (2013). The therapeutic potential of bone marrow-
derived mesenchymal stromal cells on hepatocellular 
carcinoma. Liver International: Official Journal of the 
International Association for the Study of the Liver. 
Boomsma RA, & Geenen DL. (2012). Mesenchymal Stem Cells 
Secrete Multiple Cytokines That Promote Angiogenesis 
and Have Contrasting Effects on Chemotaxis and 
Apoptosis. PLoS ONE, 7(4). 
Borensztajn K, Von Der Thüsen JH, Peppelenbosch MP, & Spek CA. 
(2010). The coagulation factor Xa/protease activated 
receptor-2 axis in the progression of liver fibrosis: a 
multifaceted paradigm. Journal of Cellular and Molecular 
Medicine, 14(1-2), 143–153. 
Brandes RP, Viedt C, Nguyen K, Beer S, Kreuzer J, Busse R, & 
Görlach A. (2001). Thrombin-induced MCP-1 Expression 
Involves Activation of the p22phox-containing NADPH 
Oxidase in Human Vascular Smooth Muscle Cells. Thromb 
Haemost, 85(6), 1104–1110. 
Brass LF, Pizarro S, Ahuja M, Belmonte E, Blanchard N, Stadel JM, 
& Hoxie JA. (1994). Changes in the structure and function 
of the human thrombin receptor during receptor 
activation, internalization, and recycling. Journal of 
Biological Chemistry, 269(4), 2943–2952. 
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, 
… Wittwer CT. (2009). The MIQE Guidelines: Minimum 
Information for Publication of Quantitative Real-Time 
PCR Experiments. Clinical Chemistry, 55(4), 611–622. 
Chan JKC. (2014). The Wonderful Colors of the Hematoxylin–Eosin 
Stain in Diagnostic Surgical Pathology. International 
Journal of Surgical Pathology, 22(1), 12–32. 
Chan SL, & Yeo W. (2012). Targeted therapy of hepatocellular 
carcinoma: Present and future. Journal of 
Gastroenterology and Hepatology, 27(5), 862–872. 
Charles River. (2015). Fox Chase SCID® Mouse. Retrieved July 11, 
2015, from http://www.criver.com/products-
services/basic-research/find-a-model/fox-chase-scid-
mouse 
Chen J, Ma Y-J, Wang Z, Lin S-S, Xiao F-J, Wang H, Wang L-S, & Guo 
Z-K. (2014a). [Promoting effect of thrombin on 
proliferation of bone marrow-derived mesenchymal stem 
cells and its mechanisms]. Zhongguo Shi Yan Xue Ye Xue 
Za Zhi / Zhongguo Bing Li Sheng Li Xue Hui = Journal of 
Experimental Hematology / Chinese Association of 
Pathophysiology, 22(2), 485–490. 
Chen J, Ma Y, Wang Z, Wang H, Wang L, Xiao F, Wang H, Tan J, & 
Guo Z. (2014b). Thrombin promotes fibronectin secretion 
by bone marrow mesenchymal stem cells via the 
protease-activated receptor mediated signalling 
pathways. Stem Cell Research & Therapy, 5(2), 36. 
Chen M, Suzuki A, Borlak J, Andrade RJ, & Lucena MI. (2015a). Drug-
induced liver injury: Interactions between drug properties 
and host factors. Journal of Hepatology, 63(2), 503–514. 
Chen Y-X, Zeng Z-C, Sun J, Zeng H-Y, Huang Y-, & Zhang Z-Y. (2015b). 
Mesenchymal stem cell–conditioned medium prevents 
radiation-induced liver injury by inhibiting inflammation 
and protecting sinusoidal endothelial cells. Journal of 
Radiation Research, 56(4), 700–708. 
Choi SH, Kwon O-J, Park JY, Kim DY, Ahn SH, Kim SU, … Han K-H. 
(2014). Inhibition of tumour angiogenesis and growth by 
small hairpin HIF-1α and IL-8 in hepatocellular 
carcinoma. Liver International: Official Journal of the 
International Association for the Study of the Liver, 34(4), 
632–642. 
Christ B, Brückner S, & Stock P. (2011). Hepatic transplantation of 
mesenchymal stem cells in rodent animal models. 
Methods in Molecular Biology (Clifton, N.J.), 698, 315–
330. 
Christ B, & Pelz S. (2013). Implication of hepatic stem cells in 
functional liver repopulation. Cytometry. Part A: The 
Journal of the International Society for Analytical 
Cytology, 83(1), 90–102. 
Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, & Mantovani A. 
(1994). Expression of monocyte chemotactic protein-1 by 
9 References 
93 
monocytes and endothelial cells exposed to thrombin. 
The American Journal of Pathology, 144(5), 975–985. 
Coughlin SR. (2000). Thrombin signalling and protease-activated 
receptors. Nature, 407(6801), 258–264. 
Coughlin SR, & Camerer E. (2003). PARticipation in inflammation. 
The Journal of Clinical Investigation, 111(1), 25–27. 
Cui H, Tan W, Shi J, & Xia Y. (2012). Recent Development in Thrombin 
Receptor Antagonist as Novel Antithrombotic Agent. 
Open Journal of Medicinal Chemistry, 2(4), 112–118. 
Cunningham CC, & Van Horn CG. (2003). Energy availability and 
alcohol-related liver pathology. Alcohol Research & 
Health: The Journal of the National Institute on Alcohol 
Abuse and Alcoholism, 27(4), 291–299. 
Dagouassat M, Suffee N, Hlawaty H, Haddad O, Charni F, Laguillier 
C, … Charnaux N. (2010). Monocyte chemoattractant 
protein-1 (MCP-1)/CCL2 secreted by hepatic 
myofibroblasts promotes migration and invasion of 
human hepatoma cells. International Journal of Cancer, 
126(5), 1095–1108. 
Davis HE, Morgan JR, & Yarmush ML. (2002). Polybrene increases 
retrovirus gene transfer efficiency by enhancing receptor-
independent virus adsorption on target cell membranes. 
Biophysical Chemistry, 97(2–3), 159–172. 
Davis HE, Rosinski M, Morgan JR, & Yarmush ML. (2004). Charged 
Polymers Modulate Retrovirus Transduction via 
Membrane Charge Neutralization and Virus Aggregation. 
Biophysical Journal, 86(2), 1234–1242. 
DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, & Bunnett 
NW. (2000). beta-arrestin-dependent endocytosis of 
proteinase-activated receptor 2 is required for 
intracellular targeting of activated ERK1/2. The Journal of 
Cell Biology, 148(6), 1267–1281. 
De Luca A, Lamura L, Gallo M, Maffia V, & Normanno N. (2012). 
Mesenchymal stem cell-derived interleukin-6 and 
vascular endothelial growth factor promote breast 
cancer cell migration. Journal of Cellular Biochemistry, 
113(11), 3363–3370. 
Deshmane SL, Kremlev S, Amini S, & Sawaya BE. (2009). Monocyte 
Chemoattractant Protein-1 (MCP-1): An Overview. 
Journal of Interferon & Cytokine Research, 29(6), 313–
326. 
Dhillon AS, Hagan S, Rath O, & Kolch W. (2007). MAP kinase 
signalling pathways in cancer. Oncogene, 26(22), 3279–
3290. 
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, 
Krause D, … Horwitz E. (2006). Minimal criteria for 
defining multipotent mesenchymal stromal cells. The 
International Society for Cellular Therapy position 
statement. Cytotherapy, 8(4), 315–317. 
Duplantier JG, Dubuisson L, Senant N, Freyburger G, Laurendeau I, 
Herbert J-M, Desmoulière A, & Rosenbaum J. (2004). A 
role for thrombin in liver fibrosis. Gut, 53(11), 1682–1687. 
Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy 
E, Murphy JM, Barry FP, O’Brien T, & Kerin MJ. (2007). 
Monocyte Chemotactic Protein-1 Secreted by Primary 
Breast Tumors Stimulates Migration of Mesenchymal 
Stem Cells. Clinical Cancer Research, 13(17), 5020–5027. 
El-Serag HB. (2011). Hepatocellular carcinoma. The New England 
Journal of Medicine, 365(12), 1118–1127. 
European Association for the Study of the Liver, & European 
Organisation for Research and Treatment of Cancer. 
(2012). EASL–EORTC Clinical Practice Guidelines: 
Management of hepatocellular carcinoma. Journal of 
Hepatology, 56(4), 908–943. 
Falanga A. (2011). The Cancer-Thrombosis Connection. Retrieved 
August 5, 2014, from 
http://www.hematology.org/Thehematologist/Mini-
Review/1244.aspx 
Farazi PA, & DePinho RA. (2006). Hepatocellular carcinoma 
pathogenesis: from genes to environment. Nature 
Reviews. Cancer, 6(9), 674–687. 
Ferrand J, Noël D, Lehours P, Prochazkova-Carlotti M, 
Chambonnier L, Ménard A, Mégraud F, & Varon C. 
(2011). Human Bone Marrow-Derived Stem Cells Acquire 
Epithelial Characteristics through Fusion with 
Gastrointestinal Epithelial Cells. PLoS ONE, 6(5), e19569. 
Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni 
M, … Cirino G. (2004). PAR1 antagonism protects against 
experimental liver fibrosis. Role of proteinase receptors in 
stellate cell activation. Hepatology, 39(2), 365–375. 
Forte G, Minieri M, Cossa P, Antenucci D, Sala M, Gnocchi V, … Di 
Nardo P. (2006). Hepatocyte growth factor effects on 
mesenchymal stem cells: proliferation, migration, and 
differentiation. Stem Cells (Dayton, Ohio), 24(1), 23–33. 
Friedenstein AJ, Gorskaja JF, & Kulagina NN. (1976). Fibroblast 
precursors in normal and irradiated mouse 
hematopoietic organs. Experimental Hematology, 4(5), 
267–274. 
Fujimoto K. (1995). Freeze-fracture replica electron microscopy 
combined with SDS digestion for cytochemical labeling of 
integral membrane proteins. Application to the 
immunogold labeling of intercellular junctional 
complexes. Journal of Cell Science, 108 ( Pt 11), 3443–
3449. 
Gaça MDA, Zhou X, & Benyon RC. (2002). Regulation of hepatic 
stellate cell proliferation and collagen synthesis by 
proteinase-activated receptors. Journal of Hepatology, 
36(3), 362–369. 
Gaffney PJ, & Edgell TA. (1995). The International and “NIH” units 
for thrombin--how do they compare? Thrombosis and 
Haemostasis, 74(3), 900–903. 
Garnier D, Milsom C, Magnus N, Meehan B, Weitz J, Yu J, & Rak J. 
(2010). Role of the tissue factor pathway in the biology of 
tumor initiating cells. Thrombosis Research, 125 Suppl 2, 
S44–50. 
Ghosh AK, & Vaughan DE. (2012). PAI-1 in tissue fibrosis. Journal of 
Cellular Physiology, 227(2), 493–507. 
Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, & 
Kaufmann R. (2013). Proteinase-activated receptors 
(PARs) - focus on receptor-receptor-interactions and their 
physiological and pathophysiological impact. Cell 
Communication and Signaling: CCS, 11, 86. 
Goel HL, & Mercurio AM. (2013). VEGF targets the tumour cell. 
Nature Reviews Cancer, 13(12), 871–882. 
Gordon JR, Zhang X, Stevenson K, & Cosford K. (2000). Thrombin 
Induces IL-6 but Not TNFα Secretion by Mouse Mast Cells: 
Threshold-Level Thrombin Receptor and Very Low Level 
FcϵRI Signaling Synergistically Enhance IL-6 Secretion. 
Cellular Immunology, 205(2), 128–135. 
Grishina Z, Ostrowska E, Halangk W, Sahin-Tóth M, & Reiser G. 
(2005). Activity of recombinant trypsin isoforms on 
human proteinase-activated receptors (PAR): 
mesotrypsin cannot activate epithelial PAR-1, -2, but 
weakly activates brain PAR-1. British Journal of 
Pharmacology, 146(7), 990–999. 
9 References 
94 
Hamilton JR, Cornelissen I, & Coughlin SR. (2004). Impaired 
hemostasis and protection against thrombosis in 
protease-activated receptor 4-deficient mice is due to 
lack of thrombin signaling in platelets. Journal of 
Thrombosis and Haemostasis: JTH, 2(8), 1429–1435. 
Hansen KK, Saifeddine M, & Hollenberg MD. (2004). Tethered 
ligand-derived peptides of proteinase-activated receptor 
3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells. 
Immunology, 112(2), 183–190. 
Han Z, Jing Y, Xia Y, Zhang S, Hou J, Meng Y, … Wei L. (2014). 
Mesenchymal stem cells contribute to the 
chemoresistance of hepatocellular carcinoma cells in 
inflammatory environment by inducing autophagy. Cell & 
Bioscience, 4, 22. 
Hass R, & Otte A. (2012). Mesenchymal stem cells as all-round 
supporters in a normal and neoplastic microenvironment. 
Cell Communication and Signaling: CCS, 10(1), 26. 
Hatzistergos KE, Blum A, Ince TA, Grichnik JM, & Hare JM. (2011). 
What Is the Oncologic Risk of Stem Cell Treatment for 
Heart Disease? Circulation Research, 108(11), 1300–
1303. 
Heider I, Schulze B, Oswald E, Henklein P, Scheele J, & Kaufmann R. 
(2004). PAR1-Type Thrombin Receptor Stimulates 
Migration and Matrix Adhesion of Human Colon 
Carcinoma Cells by a PKC-Dependent Mechanism. 
Oncology Research Featuring Preclinical and Clinical 
Cancer Therapeutics, 14(10), 475–482. 
Herrmann JL, Weil BR, Abarbanell AM, Wang Y, Poynter JA, 
Manukyan MC, & Meldrum DR. (2011). IL-6 and TGF-α 
Costimulate Mesenchymal Stem Cell Vascular Endothelial 
Growth Factor Production by ERK-, JNK-, and PI3K-
Mediated Mechanisms: Shock, 35(5), 512–516. 
Hilfiker S, & Augustine GJ. (1999). Regulation of synaptic vesicle 
fusion by protein kinase C. The Journal of Physiology, 
515(Pt 1), 1. 
Hou Y, Ryu CH, Jun JA, Kim SM, Jeong CH, & Jeun S-S. (2014). IL-8 
enhances the angiogenic potential of human bone 
marrow mesenchymal stem cells by increasing vascular 
endothelial growth factor. Cell Biology International, 
38(9), 1050–1059. 
Hsiao ST-F, Asgari A, Lokmic Z, Sinclair R, Dusting GJ, Lim SY, & 
Dilley RJ. (2012). Comparative analysis of paracrine 
factor expression in human adult mesenchymal stem cells 
derived from bone marrow, adipose, and dermal tissue. 
Stem Cells and Development, 21(12), 2189–2203. 
Hung S-C, Kuo P-Y, Chang C-F, Chen T-H, & Ho LL-T. (2006). Alpha-
smooth muscle actin expression and structure integrity in 
chondrogenesis of human mesenchymal stem cells. Cell 
and Tissue Research, 324(3), 457–466. 
Iavarone M, Lampertico P, Iannuzzi F, Manenti E, Donato MF, 
Arosio E, … Colombo M. (2007). Increased expression of 
vascular endothelial growth factor in small 
hepatocellular carcinoma. Journal of Viral Hepatitis, 
14(2), 133–139. 
Jansen BJH, Gilissen C, Roelofs H, Schaap-Oziemlak A, Veltman JA, 
Raymakers RAP, … Adema GJ. (2009). Functional 
Differences Between Mesenchymal Stem Cell Populations 
Are Reflected by Their Transcriptome. Stem Cells and 
Development, 19(4), 481–490. 
Jeon B-J, Yang Y, Kyung Shim S, Yang H-M, Cho D, & Ik Bang S. 
(2013). Thymosin beta-4 promotes mesenchymal stem 
cell proliferation via an interleukin-8-dependent 
mechanism. Experimental Cell Research, 319(17), 2526–
2534. 
Jeong J-O, Han JW, Kim J-M, Cho H-J, Park C, Lee N, Kim D-W, & 
Yoon Y-S. (2011). Malignant Tumor Formation After 
Transplantation of Short-Term Cultured Bone Marrow 
Mesenchymal Stem Cells in Experimental Myocardial 
Infarction and Diabetic Neuropathy. Circulation 
Research, 108(11), 1340–1347. 
Johnson C, Han Y, Hughart N, McCarra J, Alpini G, & Meng F. (2012). 
Interleukin-6 and its receptor, key players in hepatobiliary 
inflammation and cancer. Translational Gastrointestinal 
Cancer, 1(1), 58–70. 
Juncker-Jensen A, Deryugina EI, Rimann I, Zajac E, Kupriyanova TA, 
Engelholm LH, & Quigley JP. (2013). Tumor MMP-1 
Activates Endothelial PAR1 to Facilitate Vascular 
Intravasation and Metastatic Dissemination. Cancer 
Research, 73(14), 4196–4211. 
Kang J-H. (2014). Protein Kinase C (PKC) Isozymes and Cancer, 
Protein Kinase C (PKC) Isozymes and Cancer. New Journal 
of Science, New Journal of Science, 2014, 2014, e231418. 
Karantza V. (2011). Keratins in health and cancer: more than mere 
epithelial cell markers. Oncogene, 30(2), 127–138. 
Kaufmann R, Hascher A, Mußbach F, Henklein P, Katenkamp K, 
Westermann M, & Settmacher U. (2012). Proteinase-
activated receptor 2 (PAR2) in cholangiocarcinoma (CCA) 
cells: effects on signaling and cellular level. 
Histochemistry and Cell Biology, 138(6), 913–924. 
Kaufmann R, & Hollenberg MD. (2012). Proteinase-activated 
receptors (PARs) and calcium signaling in cancer. 
Advances in Experimental Medicine and Biology, 740, 
979–1000. 
Kaufmann R, Oettel C, Horn A, Halbhuber K-J, Eitner A, Krieg R, … 
Settmacher U. (2009). Met receptor tyrosine kinase 
transactivation is involved in proteinase-activated 
receptor-2-mediated hepatocellular carcinoma cell 
invasion. Carcinogenesis, 30(9), 1487–1496. 
Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, 
… Settmacher U. (2007). Thrombin-mediated 
hepatocellular carcinoma cell migration: Cooperative 
action via proteinase-activated receptors 1 and 4. Journal 
of Cellular Physiology, 211(3), 699–707. 
Kawanami D, Matoba K, Kanazawa Y, Ishizawa S, Yokota T, & 
Utsunomiya K. (2011). Thrombin induces MCP-1 
expression through Rho-kinase and subsequent 
p38MAPK/NF-κB signaling pathway activation in 
vascular endothelial cells. Biochemical and Biophysical 
Research Communications, 411(4), 798–803. 
Knecht W, Cottrell GS, Amadesi S, Mohlin J, Skåregärde A, Gedda 
K, … Bunnett NW. (2007). Trypsin IV or Mesotrypsin and 
p23 Cleave Protease-activated Receptors 1 and 2 to 
Induce Inflammation and Hyperalgesia. Journal of 
Biological Chemistry, 282(36), 26089–26100. 
Knight V, Tchongue J, Lourensz D, Tipping P, & Sievert W. (2012). 
Protease-activated receptor 2 promotes experimental 
liver fibrosis in mice and activates human hepatic stellate 
cells. Hepatology (Baltimore, Md.), 55(3), 879–887. 
Knowles BB, Howe CC, & Aden DP. (1980). Human hepatocellular 
carcinoma cell lines secrete the major plasma proteins 
and hepatitis B surface antigen. Science (New York, N.Y.), 
209(4455), 497–499. 
Kozawa O, Tokuda H, Kaida T, Matsuno H, & Uematsu T. (1997). 
Thrombin Regulates Interleukin-6 Synthesis through 
Phosphatidylcholine Hydrolysis by Phospholipase D in 
Osteoblasts. Archives of Biochemistry and Biophysics, 
345(1), 10–15. 
9 References 
95 
Kreso A, & Dick JE. (2014). Evolution of the Cancer Stem Cell Model. 
Cell Stem Cell, 14(3), 275–291. 
Kuo TK, Hung S-P, Chuang C-H, Chen C-T, Shih Y-RV, Fang S-CY, Yang 
VW, & Lee OK. (2008). Stem cell therapy for liver disease: 
parameters governing the success of using bone marrow 
mesenchymal stem cells. Gastroenterology, 134(7), 
2111–2121, 2121.e1–3. 
Laird DJ, von Andrian UH, & Wagers AJ. (2008). Stem cell trafficking 
in tissue development, growth, and disease. Cell, 132(4), 
612–630. 
Liang X, Ding Y, Zhang Y, Tse H-F, & Lian Q. (2014). Paracrine 
Mechanisms of Mesenchymal Stem Cell-Based Therapy: 
Current Status and Perspectives. Cell Transplantation, 
23(9), 1045–1059. 
Licari LG, & Kovacic JP. (2009). Thrombin physiology and 
pathophysiology. Journal of Veterinary Emergency and 
Critical Care, 19(1), 11–22. 
Li J, Wang G, Wang C, Zhao Y, Zhang H, Tan Z, Song Z, Ding M, & 
Deng H. (2007). MEK/ERK signaling contributes to the 
maintenance of human embryonic stem cell self-renewal. 
Differentiation, 75(4), 299–307. 
Lin C-H, Yu M-C, Chiang C-C, Bien M-Y, Chien M-H, & Chen B-C. 
(2013a). Thrombin-induced NF-κB activation and IL-
8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-
1, and ERK pathways in lung epithelial cells. Cellular 
Signalling, 25(5), 1166–1175. 
Lin H, Liu AP, Smith TH, & Trejo J. (2013b). Cofactoring and 
Dimerization of Proteinase-Activated Receptors. 
Pharmacological Reviews, 65(4), 1198–1213. 
Lin H, & Trejo J. (2013). Transactivation of the PAR1-PAR2 
heterodimer by thrombin elicits β-arrestin-mediated 
endosomal signaling. The Journal of Biological Chemistry, 
288(16), 11203–11215. 
Li T, & He S. (2006). Induction of IL-6 release from human T cells by 
PAR-1 and PAR-2 agonists. Immunology and Cell Biology, 
84(5), 461–466. 
Liu Y, Li P-K, Li C, & Lin J. (2010). Inhibition of STAT3 Signaling Blocks 
the Anti-apoptotic Activity of IL-6 in Human Liver Cancer 
Cells. Journal of Biological Chemistry, 285(35), 27429–
27439. 
Lopez AM, & Hendrickson RG. (2014). Toxin-Induced Hepatic Injury. 
Emergency Medicine Clinics of North America, 32(1), 
103–125. 
Ludwicka-Bradley A, Tourkina E, Suzuki S, Tyson E, Bonner M, 
Fenton JW, Hoffman S, & Silver RM. (2000). Thrombin 
Upregulates Interleukin-8 in Lung Fibroblasts via 
Cleavage of Proteolytically Activated Receptor-I and 
Protein Kinase C-γ Activation. American Journal of 
Respiratory Cell and Molecular Biology, 22(2), 235–243. 
Lu J, Chen B, Li S, & Sun Q. (2014). Tryptase inhibitor APC 366 
prevents hepatic fibrosis by inhibiting collagen synthesis 
induced by tryptase/protease-activated receptor 2 
interactions in hepatic stellate cells. International 
Immunopharmacology, 20(2), 352–357. 
Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, & Plevin R. (2001). 
Proteinase-activated receptors. Pharmacological 
Reviews, 53(2), 245–282. 
Madhusudhan T, Kerlin BA, & Isermann B. (2015). The emerging 
role of coagulation proteases in kidney disease. Nature 
Reviews Nephrology, advance online publication. 
Ma F, Chen D, Chen F, Chi Y, Han Z, Feng X, Li X, & Han Z. (2015). 
Human Umbilical Cord Mesenchymal Stem Cells Promote 
Breast Cancer Metastasis by Interleukin-8 and 
Interleukin-6 Dependent Induction of CD44(+)/CD24(-) 
Cells. Cell Transplantation. 
Malik N, & Rao MS. (2013). A Review of the Methods for Human iPSC 
Derivation. Methods in Molecular Biology (Clifton, N.J.), 
997, 23–33. 
Marin V, Montero-Julian FA, Grès S, Boulay V, Bongrand P, 
Farnarier C, & Kaplanski G. (2001). The IL-6-Soluble IL-
6Rα Autocrine Loop of Endothelial Activation as an 
Intermediate Between Acute and Chronic Inflammation: 
an Experimental Model Involving Thrombin. The Journal 
of Immunology, 167(6), 3435–3442. 
Marquardt JU, Andersen JB, & Thorgeirsson SS. (2015). Functional 
and genetic deconstruction of the cellular origin in liver 
cancer. Nature Reviews Cancer, 15(11), 653–667. 
Martello G, & Smith A. (2014). The Nature of Embryonic Stem Cells. 
Annual Review of Cell and Developmental Biology, 30(1), 
647–675. 
Mason SD, & Joyce JA. (2011). Proteolytic Networks in Cancer. 
Trends in Cell Biology, 21(4). 
Ma S, Xie N, Li W, Yuan B, Shi Y, & Wang Y. (2014). Immunobiology 
of mesenchymal stem cells. Cell Death & Differentiation, 
21(2), 216–225. 
Matsuoka T, Kogushi M, Kawata T, Kimura A, Chiba K, Musha T, … 
Hishinuma I. (2004). 1102-48 Inhibitory effect of E5555, 
an orally active thrombin receptor antagonist, on intimal 
hyperplasia following balloon injury. Journal of the 
American College of Cardiology, 43(5, Supplement 1), 
A68. 
Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, & LeRoux 
MA. (2012). Concise Review: Role of Mesenchymal Stem 
Cells in Wound Repair. Stem Cells Translational Medicine, 
1(2), 142–149. 
McLaughlin JN, Shen L, Holinstat M, Brooks JD, DiBenedetto E, & 
Hamm HE. (2005). Functional Selectivity of G Protein 
Signaling by Agonist Peptides and Thrombin for the 
Protease-activated Receptor-1. Journal of Biological 
Chemistry, 280(26), 25048–25059. 
Mercer PF, & Chambers RC. (2013). Coagulation and coagulation 
signalling in fibrosis. Biochimica et Biophysica Acta (BBA) 
- Molecular Basis of Disease, 1832(7), 1018–1027. 
Mihara M, Hashizume M, Yoshida H, Suzuki M, & Shiina M. (2012). 
IL-6/IL-6 receptor system and its role in physiological and 
pathological conditions. Clinical Science, 122(4), 143–
159. 
Morgan AJ, & Jacob R. (1994). Ionomycin enhances Ca2+ influx by 
stimulating store-regulated cation entry and not by a 
direct action at the plasma membrane. Biochemical 
Journal, 300(Pt 3), 665–672. 
Moschonas IC, Goudevenos JA, & Tselepis AD. (2015). Protease-
activated receptor-1 antagonists in long-term 
antiplatelet therapy. Current state of evidence and future 
perspectives. International Journal of Cardiology, 185, 9–
18. 
Muñoz-Espín D, & Serrano M. (2014). Cellular senescence: from 
physiology to pathology. Nature Reviews Molecular Cell 
Biology, 15(7), 482–496. 
Mußbach F, Henklein P, Westermann M, Settmacher U, Böhmer F-
D, & Kaufmann R. (2014). Proteinase-activated receptor 
1- and 4-promoted migration of Hep3B hepatocellular 
carcinoma cells depends on ROS formation and RTK 
transactivation. Journal of Cancer Research and Clinical 
Oncology, 141(5), 813–825. 
9 References 
96 
Nakamura T, Sakai K, Nakamura T, & Matsumoto K. (2011). 
Hepatocyte growth factor twenty years on: Much more 
than a growth factor. Journal of Gastroenterology and 
Hepatology, 26 Suppl 1, 188–202. 
Nakanuma S, Tajima H, Okamoto K, Hayashi H, Nakagawara H, 
Onishi I, … Harada S. (2010). Tumor-derived trypsin 
enhances proliferation of intrahepatic 
cholangiocarcinoma cells by activating protease-
activated receptor-2. International Journal of Oncology, 
36(4), 793–800. 
National Institutes of Health. (2015). Stem Cell Basics. Retrieved 
October 27, 2015, from 
http://stemcells.nih.gov/info/basics/pages/basics1.aspx 
Neuss S, Becher E, Wöltje M, Tietze L, & Jahnen-Dechent W. (2004). 
Functional Expression of HGF and HGF Receptor/c-met in 
Adult Human Mesenchymal Stem Cells Suggests a Role in 
Cell Mobilization, Tissue Repair, and Wound Healing. 
STEM CELLS, 22(3), 405–414. 
Niess H, Bao Q, Conrad C, Zischek C, Notohamiprodjo M, Schwab F, 
… Bruns CJ. (2011). Selective targeting of genetically 
engineered mesenchymal stem cells to tumor stroma 
microenvironments using tissue-specific suicide gene 
expression suppresses growth of hepatocellular 
carcinoma. Annals of Surgery, 254(5), 767–774; 
discussion 774–775. 
Nussenbaum F, Herman IM, Nussenbaum F, & Herman IM. (2010). 
Tumor Angiogenesis: Insights and Innovations, Tumor 
Angiogenesis: Insights and Innovations. Journal of 
Oncology, Journal of Oncology, 2010, 2010, e132641. 
O’Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, 
Woulfe DS, & Brass LF. (2000). Thrombin responses in 
human endothelial cells. Contributions from receptors 
other than PAR1 include the transactivation of PAR2 by 
thrombin-cleaved PAR1. The Journal of Biological 
Chemistry, 275(18), 13502–13509. 
O’Shea RS, Dasarathy S, & McCullough AJ. (2009). Alcoholic Liver 
Disease. The American Journal of Gastroenterology, 
105(1), 14–32. 
Paradis V. (2013). Histopathology of hepatocellular carcinoma. 
Recent Results in Cancer Research. Fortschritte Der 
Krebsforschung. Progrès Dans Les Recherches Sur Le 
Cancer, 190, 21–32. 
Park CW, Kim K-S, Bae S, Son HK, Myung P-K, Hong HJ, & Kim H. 
(2009). Cytokine Secretion Profiling of Human 
Mesenchymal Stem Cells by Antibody Array. International 
Journal of Stem Cells, 2(1), 59–68. 
Pathpedia e-Atlas. (2015). Histopathology images of Hepatocellular 
carcinoma. Retrieved October 3, 2015, from 
http://www.pathpedia.com/education/eatlas/histopath
ology/liver_and_bile_ducts/hepatocellular_carcinoma.a
spx 
Phosphosite.org. (2015). PAR1 (human). Retrieved August 12, 2015, 
from 
http://www.phosphosite.org/proteinAction.do?id=4882
&showAllSites=true 
Picot J, Guerin CL, Le Van Kim C, & Boulanger CM. (2012). Flow 
cytometry: retrospective, fundamentals and recent 
instrumentation. Cytotechnology, 64(2), 109–130. 
Plaks V, Kong N, & Werb Z. (2015). The Cancer Stem Cell Niche: How 
Essential Is the Niche in Regulating Stemness of Tumor 
Cells? Cell Stem Cell, 16(3), 225–238. 
Ramachandran R. (2012). Developing PAR1 antagonists: minding 
the endothelial gap. Discovery Medicine, 13(73), 425–
431. 
Ramachandran R, & Hollenberg MD. (2008). Proteinases and 
signalling: pathophysiological and therapeutic 
implications via PARs and more. British Journal of 
Pharmacology, 153 Suppl 1, S263–282. 
Ramachandran R, Noorbakhsh F, Defea K, & Hollenberg MD. 
(2012). Targeting proteinase-activated receptors: 
therapeutic potential and challenges. Nature Reviews. 
Drug Discovery, 11(1), 69–86. 
Rasmussen JG, Riis SE, Frøbert O, Yang S, Kastrup J, Zachar V, 
Simonsen U, & Fink T. (2012). Activation of protease-
activated receptor 2 induces VEGF independently of HIF-
1. PloS One, 7(9), e46087. 
Reagan MR, & Kaplan DL. (2011). Concise Review: Mesenchymal 
Stem Cell Tumor-Homing: Detection Methods in Disease 
Model Systems. STEM CELLS, 29(6), 920–927. 
Regad T. (2015). Targeting RTK Signaling Pathways in Cancer. 
Cancers, 7(3), 1758–1784. 
Rehermann B, & Nascimbeni M. (2005). Immunology of hepatitis B 
virus and hepatitis C virus infection. Nature Reviews 
Immunology, 5(3), 215–229. 
Ren Y, Poon RT-P, Tsui H-T, Chen W-H, Li Z, Lau C, Yu W-C, & Fan S-
T. (2003). Interleukin-8 serum levels in patients with 
hepatocellular carcinoma: correlations with 
clinicopathological features and prognosis. Clinical 
Cancer Research: An Official Journal of the American 
Association for Cancer Research, 9(16 Pt 1), 5996–6001. 
Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, & Minor L. 
(2004). Cell Viability Assays. In G. S. Sittampalam, N. P. 
Coussens, H. Nelson, M. Arkin, D. Auld, C. Austin, … J. 
Weidner (Eds.), Assay Guidance Manual. Bethesda (MD): 
Eli Lilly & Company and the National Center for 
Advancing Translational Sciences. Retrieved from 
http://www.ncbi.nlm.nih.gov/books/NBK144065/ 
Romano M, De Francesco F, Pirozzi G, Gringeri E, Boetto R, Di 
Domenico M, Zavan B, Ferraro GA, & Cillo U. (2015). 
Expression of cancer stem cell biomarkers as a tool for a 
correct therapeutic approach to hepatocellular 
carcinoma. Oncoscience, 2(5), 443–456. 
Rustad KC, & Gurtner GC. (2012). Mesenchymal Stem Cells Home to 
Sites of Injury and Inflammation. Advances in Wound 
Care, 1(4), 147–152. 
Ryan PC, Jakubczak JL, Stewart DA, Hawkins LK, Cheng C, Clarke 
LM, … Hallenbeck PL. (2004). Antitumor efficacy and 
tumor-selective replication with a single intravenous 
injection of OAS403, an oncolytic adenovirus dependent 
on two prevalent alterations in human cancer. Cancer 
Gene Therapy, 11(8), 555–569. 
Salameh MA, & Radisky ES. (2013). Biochemical and structural 
insights into mesotrypsin: an unusual human trypsin. 
International Journal of Biochemistry and Molecular 
Biology, 4(3), 129–139. 
Schinköthe T, Bloch W, & Schmidt A. (2008). In vitro secreting profile 
of human mesenchymal stem cells. Stem Cells and 
Development, 17(1), 199–206. 
Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, & Cabrera R. 
(2015). Current and future treatments for hepatocellular 
carcinoma. World Journal of Gastroenterology: WJG, 
21(28), 8478–8491. 
Scholzen T, & Gerdes J. (2000). The Ki-67 protein: From the known 
and the unknown. Journal of Cellular Physiology, 182(3), 
311–322. 
Scholz M, Vogel J-U, Höver G, Kotchetkov R, Cinatl J, Doerr H, & 
Cinatl J. (2004). Thrombin stimulates IL-6 and IL-8 
9 References 
97 
expression in cytomegalovirus-infected human retinal 
pigment epithelial cells. International Journal of 
Molecular Medicine. 
Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, & Bhatt DL. 
(2009). The in-vitro effects of E5555, a protease-activated 
receptor (PAR)-1 antagonist, on platelet biomarkers in 
healthy volunteers and patients with coronary artery 
disease. Thrombosis and Haemostasis, 102(1), 111–119. 
Severs NJ. (2007). Freeze-fracture electron microscopy. Nature 
Protocols, 2(3), 547–576. 
Shein HM, & Enders JF. (1962). Transformation Induced By Simian 
Virus 40 In Human Renal Cell Cultures, I. Morphology And 
Growth Characteristics. Proceedings of the National 
Academy of Sciences of the United States of America, 
48(7), 1164–1172. 
Shin H, Kitajima I, Nakajima T, Shao Q, Tokioka T, Takasaki I, Hanyu 
N, Kubo T, & Maruyama I. (1999). Thrombin receptor 
mediated signals induce expressions of interleukin 6 and 
granulocyte colony stimulating factor via NF-κB 
activation in synovial fibroblasts. Annals of the 
Rheumatic Diseases, 58(1), 55–60. 
Siehler S. (2009). Regulation of RhoGEF proteins by G12/13-coupled 
receptors. British Journal of Pharmacology, 158(1), 41–
49. 
Skalli O, Pelte MF, Peclet MC, Gabbiani G, Gugliotta P, Bussolati G, 
Ravazzola M, & Orci L. (1989). Alpha-smooth muscle 
actin, a differentiation marker of smooth muscle cells, is 
present in microfilamentous bundles of pericytes. Journal 
of Histochemistry & Cytochemistry, 37(3), 315–321. 
Soh UJ, Dores MR, Chen B, & Trejo J. (2010). Signal transduction by 
protease-activated receptors. British Journal of 
Pharmacology, 160(2), 191–203. 
So KA, Min KJ, Hong JH, & Lee J-K. (2015). Interleukin-6 expression 
by interactions between gynecologic cancer cells and 
human mesenchymal stem cells promotes epithelial-
mesenchymal transition. International Journal of 
Oncology. 
Sonawane ND, Szoka FC, & Verkman AS. (2003). Chloride 
Accumulation and Swelling in Endosomes Enhances DNA 
Transfer by Polyamine-DNA Polyplexes. Journal of 
Biological Chemistry, 278(45), 44826–44831. 
Soto AG, Smith TH, Chen B, Bhattacharya S, Cordova IC, Kenakin T, 
Vaidehi N, & Trejo J. (2015). N-linked glycosylation of 
protease-activated receptor-1 at extracellular loop 2 
regulates G-protein signaling bias. Proceedings of the 
National Academy of Sciences, 112(27), E3600–E3608. 
Soto AG, & Trejo J. (2010). N-linked glycosylation of protease-
activated receptor-1 second extracellular loop: a critical 
determinant for ligand-induced receptor activation and 
internalization. The Journal of Biological Chemistry, 
285(24), 18781–18793. 
Stock P, Brückner S, Ebensing S, Hempel M, Dollinger MM, & Christ 
B. (2010). The generation of hepatocytes from 
mesenchymal stem cells and engraftment into murine 
liver. Nature Protocols, 5(4), 617–627. 
Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, & 
Andreeff M. (2002). Bone Marrow-derived Mesenchymal 
Stem Cells as Vehicles for Interferon-β Delivery into 
Tumors. Cancer Research, 62(13), 3603–3608. 
Sun Z, Wang S, & Zhao RC. (2014). The roles of mesenchymal stem 
cells in tumor inflammatory microenvironment. Journal 
of Hematology & Oncology, 7, 14. 
Tamama K, Sen CK, & Wells A. (2008). Differentiation of Bone 
Marrow Mesenchymal Stem Cells into the Smooth Muscle 
Lineage by Blocking ERK/MAPK Signaling Pathway. Stem 
Cells and Development, 17(5), 897–908. 
Tanaka N, Morita T, Nezu A, Tanimura A, Mizoguchi I, & Tojyo Y. 
(2004). Signaling Mechanisms Involved in Protease-
Activated Receptor-1-Mediated Interleukin-6 Production 
by Human Gingival Fibroblasts. Journal of Pharmacology 
and Experimental Therapeutics, 311(2), 778–786. 
Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, & 
Kerbel RS. (2010). Development of a Resistance-like 
Phenotype to Sorafenib by Human Hepatocellular 
Carcinoma Cells Is Reversible and Can Be Delayed by 
Metronomic UFT Chemotherapy. Neoplasia (New York, 
N.Y.), 12(11), 928–940. 
Taub R. (2004). Liver regeneration: from myth to mechanism. Nature 
Reviews Molecular Cell Biology, 5(10), 836–847. 
Tello-Montoliu A, Tomasello SD, Ueno M, & Angiolillo DJ. (2011). 
Antiplatelet therapy: thrombin receptor antagonists. 
British Journal of Clinical Pharmacology, 72(4), 658–671. 
ten Cate H, & Falanga A. (2008). Overview of the postulated 
mechanisms linking cancer and thrombosis. 
Pathophysiology of Haemostasis and Thrombosis, 36(3-
4), 122–130. 
Tian S, Hui X, Fan Z, Li Q, Zhang J, Yang X, … Chen H. (2014). 
Suppression of hepatocellular carcinoma proliferation 
and hepatitis B surface antigen secretion with interferon-
λ1 or PEG-interferon-λ1. The FASEB Journal, 28(8), 3528–
3539. 
Tokunou T, Ichiki T, Takeda K, Funakoshi Y, Iino N, Shimokawa H, 
Egashira K, & Takeshita A. (2001). Thrombin Induces 
Interleukin-6 Expression Through the cAMP Response 
Element in Vascular Smooth Muscle Cells. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 
21(11), 1759–1763. 
Tsochatzis EA, Bosch J, & Burroughs AK. (2014). Liver cirrhosis. The 
Lancet, 383(9930), 1749–1761. 
Ulvik RJ. (2015). The liver in haemochromatosis. Journal of Trace 
Elements in Medicine and Biology, 31, 219–224. 
Vassilopoulos G, Wang P-R, & Russell DW. (2003). Transplanted 
bone marrow regenerates liver by cell fusion. Nature, 
422(6934), 901–904. 
Vu TK, Hung DT, Wheaton VI, & Coughlin SR. (1991). Molecular 
cloning of a functional thrombin receptor reveals a novel 
proteolytic mechanism of receptor activation. Cell, 64(6), 
1057–1068. 
Wang H, & Reiser G. (2003). The role of the Ca2+-sensitive tyrosine 
kinase Pyk2 and Src in thrombin signalling in rat 
astrocytes. Journal of Neurochemistry, 84(6), 1349–
1357. 
Wang H, Ubl JJ, Stricker R, & Reiser G. (2002). Thrombin (PAR-1)-
induced proliferation in astrocytes via MAPK involves 
multiple signaling pathways. American Journal of 
Physiology - Cell Physiology, 283(5), C1351–C1364. 
Wang W-W, Ang SF, Kumar R, Heah C, Utama A, Tania NP, … Toh 
HC. (2013). Identification of Serum Monocyte 
Chemoattractant Protein-1 and Prolactin as Potential 
Tumor Markers in Hepatocellular Carcinoma. PLoS ONE, 
8(7). 
Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy 
M, … Grompe M. (2003). Cell fusion is the principal source 
of bone-marrow-derived hepatocytes. Nature, 
422(6934), 897–901. 
9 References 
98 
Waugh DJJ, & Wilson C. (2008). The interleukin-8 pathway in cancer. 
Clinical Cancer Research: An Official Journal of the 
American Association for Cancer Research, 14(21), 6735–
6741. 
Winkler S, Schmidt L, Leibiger K, Hempel M, Ditze M, Böhmer F, 
Müller J, Kaufmann R, & Christ B. (2015). Indirekte 
Wechselwirkungen zwischen HCC (Hep3B) und humanen 
mesenchymalen Stammzellen in vitro und in vivo. 
Zeitschrift für Gastroenterologie, 53(01). 
Wu F, Wang J, Pu C, Qiao L, & Jiang C. (2015). Wilson’s Disease: A 
Comprehensive Review of the Molecular Mechanisms. 
International Journal of Molecular Sciences, 16(3), 6419–
6431. 
Wurster T, & May AE. (2012). Atopaxar. A novel player in 
antiplatelet therapy? Hämostaseologie, 32(3), 228–233. 
Xiu P, Dong X-F, Li X-P, & Li J. (2015). Clusterin: Review of research 
progress and looking ahead to direction in hepatocellular 
carcinoma. World Journal of Gastroenterology : WJG, 
21(27), 8262–8270. 
Xue Y-H, Zhang X-F, Dong Q-Z, Sun J, Dai C, Zhou H-J, … Qin L-X. 
(2010). Thrombin is a therapeutic target for metastatic 
osteopontin-positive hepatocellular carcinoma. 
Hepatology, 52(6), 2012–2022. 
Yagi H, & Kitagawa Y. (2013). The role of mesenchymal stem cells in 
cancer development. Frontiers in Genetics, 4, 261. 
Yang T, Zhang X, Wang M, Zhang J, Huang F, Cai J, … Xu W. (2014). 
Activation of Mesenchymal Stem Cells by Macrophages 
Prompts Human Gastric Cancer Growth through NF-κB 
Pathway. PLoS ONE, 9(5), e97569. 
Yang ZF, & Poon RTP. (2008). Vascular changes in hepatocellular 
carcinoma. Anatomical Record (Hoboken, N.J.: 2007), 
291(6), 721–734. 
Zacharski LR, Hommann M, & Kaufmann R. (2004). Rationale for 
clinical trials of coagulation: reactive drugs in 
hepatocellular carcinoma. Expert Review of 
Cardiovascular Therapy, 2(5), 777–784. 
Zhang Z, & Wang F-S. (2013). Stem cell therapies for liver failure and 
cirrhosis. Journal of Hepatology, 59(1), 183–185. 
Zhao P, Metcalf M, & Bunnett NW. (2014). Biased signaling of 
protease-activated receptors. Molecular and Structural 
Endocrinology, 5, 67. 
Zhao P, Yang X, Qi S, Liu H, Jiang H, Hoppmann S, … Cheng Z. (2013). 
Molecular Imaging of Hepatocellular Carcinoma 
Xenografts with Epidermal Growth Factor Receptor 
Targeted Affibody Probes, Molecular Imaging of 
Hepatocellular Carcinoma Xenografts with Epidermal 
Growth Factor Receptor Targeted Affibody Probes. 
BioMed Research International, BioMed Research 
International, 2013, 2013, e759057. 
Zheng L, & Martins-Green M. (2007). Molecular mechanisms of 
thrombin-induced interleukin-8 (IL-8/CXCL8) expression 
in THP-1-derived and primary human macrophages. 
Journal of Leukocyte Biology, 82(3), 619–629. 
Zipori D. (2004). The nature of stem cells: state rather than entity. 
Nature Reviews Genetics, 5(11), 873–878. 
 
 
 
Ehrenwörtliche Erklärung 
IX 
Ehrenwörtliche Erklärung 
Hiermit versichere ich,  
(1) dass mir die Promotionsordnung der Biologisch-Pharmazeutischen Fakultät bekannt ist, 
(2) dass ich die vorliegende Dissertation selbständig angefertigt habe, und alle verwendeten 
Quellen, Hilfsmittel und persönlichen Informationen als solche gekennzeichnet habe, 
(3) dass mich Prof. Dr. F.-D. Böhmer sowie Dr. R. Kaufmann bei der Auswahl und Anfertigung des 
Materials sowie Manuskriptes unterstützt haben, 
(4) dass ich weder die Hilfe eines Promotionsberaters in Anspruch genommen habe, noch andere 
Personen unmittelbare oder mittelbare geldwerte Leistungen von mir erhalten haben, die im 
Zusammenhang mit dem Inhalt der vorgelegten Dissertation stehen, 
(5) dass ich die Dissertation noch nicht als Prüfungsarbeit für eine staatliche oder andere 
wissenschaftliche Prüfung eingereicht habe, 
(6) dass ich zu keinem Zeitpunkt die gleiche, eine in wesentlichen Teilen ähnliche oder eine andere 
Abhandlung als Dissertation an einer anderen Hochschule eingereicht habe.  
 
 
 
Jena, März 2017 
